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ABSTRACT 
 
Current synthetic vascular grafts have high failure rates in small-diameter (<6 
mm) applications due to inadequate cell-material interactions and poor matching of 
arterial biomechanical properties. To address this, we have developed a multilayer 
vascular graft design with a non-thrombogenic inner layer that promotes endothelial cell 
(EC) interactions and a reinforcing layer with tunable biomechanical properties.  
 The blood-contacting layer of the graft is based on a Streptococcal collagen-like 
protein (Scl2-1). Scl2-1 has the triple helical structure of collagen, but it is a non-
thrombogenic protein that can be modified to have selective cell adhesion. For this 
application, Scl2-2 has been modified from Scl2-1 to contain integrin binding sites that 
promote EC adhesion. We have developed the methodology to incorporate Scl2 proteins 
into a poly(ethylene glycol) (PEG) hydrogel matrix. PEG-Scl2 hydrogels facilitate 
optimization of both bioactivity and substrate modulus to offer unique control over graft 
endothelialization. However, scaffold properties that promote endothelialization may not 
be consistent with the mechanical properties necessary to withstand physiological 
loading. To address this issue, we have reinforced PEG-Scl2-2 hydrogels with an 
electrospun polyurethane mesh. This multilayer vascular graft design decouples requisite 
mechanical properties from endothelialization processes and permits optimization of 
both design goals.  
We have confirmed the thromboresistance of PEG-Scl2-2 hydrogels in a series of 
whole blood tests in vitro as well as in a porcine carotid artery model. Additionally, we 
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have shown that the electrospun mesh biomechanical properties can be tuned over a 
wide range to achieve comparable properties to current autologous grafts. Traditional 
acrylate-derivatized PEG (PEGDA) hydrogels were replaced with PEG diacrylamide 
hydrogels with similar properties to increase biostability for long-term implantation. 
These findings indicate that this multilayer design shows promise for vascular graft 
applications. 
As vascular graft endothelialization can significantly improve success rates, the 
ability to alter cell-material interactions through manipulations in PEG-Scl2-2 hydrogel 
properties was studied extensively. By reducing Scl2-2 functionalization density and 
utilizing a biostable PEG functionalization linker, Acrylamide-PEG-I, significantly 
improved initial EC adhesion was achieved that was maintained over 6 weeks of 
swelling in vitro. Additionally, increases in Scl2-2 concentration and in hydrogel 
modulus provided increased EC interactions. It was found that PEG-Scl2-2 hydrogels 
promoted enhanced EC proliferation over 1 week compared to PEG-collagen gels.  
In summary, we have developed a vascular graft with a biostable, non-
thrombogenic intimal layer that promotes EC adhesion and migration while providing 
biomechanical properties comparable to current autologous grafts. This design 
demonstrates great potential as an off-the-shelf graft for small diameter arterial 
prostheses that improves upon current clinically available options.   
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NOMENCLATURE 
 
 
4-arm PEG-Acr 4-arm poly(ethylene glycol) acrylate 
 
Aam-PEG-I Acrylamide-poly(ethylene glycol)-isocyanate 
Acr-PEG-NHS Acrylate-poly(ethylene glycol)-N-hydroxysuccinimide 
ADP Adenosine diphosphate 
BAOEC Bovine aortic endothelial cell 
CAD Coronary artery disease 
CBQCA 3-(4-carboxy-benzoyl)-2-quinoline-carboxaldehyde 
CVD Cardiovascular disease 
DCM Dichloromethane  
DMAC Dimethylacetamide 
DMEM Dulbecco’s Modified Eagle Medium 
DMSO Dimethylsulfoxide 
EC Endothelial cell 
ECM Extracellular matrix 
EPC Endothelial progenitor cell 
ePTFE Expanded poly(ethylene tetrafuron) 
FBGC Foreign body giant cell 
FBS Fetal bovine serum 
FTIR Fourier transform infrared 
LDH Lactate dehydrogenase 
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MFI Mean fluorescence intensity 
MSC Mesenchymal stem cell 
NHS N-hydroxysuccinimide 
NMR Nuclear magnetic resonance 
NO Nitrous oxide 
PAD Peripheral artery disease  
PBS Phosphate buffered saline 
PEG Poly(ethylene glycol) 
PEGDA Poly(ethylene glycol) diacrylate 
PEGDAA Poly(ethylene glycol) diacrylamide 
PEGDI Poly(ethylene glycol) diisocyanate 
PET Poly(ethylene terephthalate) 
PGA Poly(glycolic acid) 
RO Reverse osmosis 
Scl2 Streptococcal collagen-like protein 
SEM Scanning electron microscopy 
SIS  Small intestinal submucosa 
SMC Smooth muscle cell 
SPU Segmented polyurethane 
TCPS Tissue culture polystyrene 
TEA Triethylamine 
TEGDA Tri(ethylene glycol) diacrylate 
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CHAPTER I  
INTRODUCTION 
 
1.1  Clinical Need:  Cardiovascular Disease 
For over a century, cardiovascular disease (CVD) has been the leading cause of 
death in the United States each year. One-third of American adults are affected by CVD 
with approximatly 25 million coronary artery and peripheral artery disease (CAD, PAD) 
cases annually. 
1
 Both CAD and PAD are characterized by atherosclerosis that arises 
from smooth muscle cell hyperproliferation and thrombus formation. 
2
 Atherosclerosis is 
a progressive narrowing and occlusion of arteries that eventually results in a loss of 
blood flow to specific areas of the body. The coronary, iliac, and carotid arteries, 
abdominal aorta, and vascular bifurcations are especially susceptible to atherosclerosis, 
and occlusion of these vessels can have serious clinical consequences such as heart 
attack or stroke. 
3
 Ideally, CAD and PAD are treated with lifestyle changes or 
medications. Failing this, non-invasive options, such as angioplasty and stenting, are 
available to physically open the lumen of the occluded vessel. In the most severe cases, 
bypass procedures are required in which blood flow is rerouted around the occluded 
vessels. Currently, over 500,000 bypass surguries are performed each year in the U.S. 
1
  
 
 
1.2 Native Vasculature Structure 
1.2.1 The Intima While native vasculature was initially considered to be a 
relatively simple tissue, it has proven very difficult to replicate the structure and function 
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of blood vessels in the design of viable vascular grafts. Veins and arteries are comprised 
of three distinct layers, each of which have a specific role in maintaining healthy 
vasculature. The innermost intimal layer is an endothelial cell (EC) lining. Vascular ECs 
actively promote vessel thromboresistance, and it has been shown that a quiescent, 
luminal endothelial layer inhibits both platelet aggregation and smooth muscle cell 
proliferation. 
4-5
 Thus, generation of a stable endothelium can greatly improve vascular 
graft success. However, the vascular endothelium is one of the few areas of the body that 
can survive the continual application of high pressures, which makes it difficult to 
produce a pre-endothelialized graft that remains stable following implantation. 
6
 Injury 
of the intimal layer causes EC activation, during which cytokines are released and 
proteins are expressed that promote inflammatory reactions and thrombosis. In a healthy 
system, this results in regeneration of a healthy, non-thrombogenic lumen, but CVD can 
affect this remodeling process. 
7
 The basement membrane, an extracellular matrix 
(ECM) composed primarily of type IV collagen, laminin, and heparan sulphate 
proteoglycans, surrounds the endothelium and bridges the intimal and medial layers. 
8
  
1.2.2 The Media The media is made up of vascular smooth muscle cells (SMCs) 
surrounded by an interstitial matrix of collagen, elastin, and fibronectin. 
9
 SMCs are 
responsible for contraction and distention of blood vessels in response to the variable 
pressures of blood flow. 
6
 The collagen in this layer provides the outer limit of 
distensibility of vessels and contributes to the stiffness and high burst pressure of 
vasculature. The elastin imparts vessel compliance and elasticity. 
6
 This interstitial 
matrix is responsible for the incredible biomechanical properties of arteries which are 
 3 
 
very difficult to replicate. In addition to its mechanical roles, the media also plays a part 
in maintaining patent vessels in healthy vasculature. Medial SMCs of adult arteries 
exhibit very low rates of proliferation or death; however, they retain the ability to 
migrate and divide rapidly in response to problems such as hypertension, vascular injury, 
and atherosclerosis. 
9-10
 This is accompanied by a shift in the production of ECM 
molecules, wherein basement membrane proteins are downregulated and interstitial 
matrix components increase. 
11
 This provides a matrix wherein SMCs can proliferate and 
ultimately results in intimal thickening and vessel occlusion. 
9
 
1.2.3 The Adventitia The outermost adventitial layer of vasculature is comprised 
of fibroblasts in a loose connective tissue that contains blood vessels and fat. 
9
 The 
adventitia is important for preventing vessel dilation and rupture. Additionally, it is 
responsible for defining a vessel’s territory and in providing boundaries to maintain 
vessel seperation and prevent arteriovenous fistula formation. 
6
 Together, the intimal, 
medial, and adventitial layers make up the highly organized veins and arteries that do 
much more than simply sustain blood flow through the body. These unique properties 
have proven to be very difficult to replicate in the development of small-diameter 
vascular grafts, but researchers have made significant progress in providing improved 
designs over current graft options.  
 
 
1.3  Current Vascular Graft Options 
1.3.1 Autologous Vessels Due to their relatively high patency rates and reduced 
chances of infection, the current “gold standard” for bypass grafts is to use autologous 
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vessels from the patients’ own body. This procedure involves removal of a vessel, such 
as the saphenous vein or mammary artery, and implanting it into the bypass location. 
12
 
The matched structural and biomechanical properties of autologous bypass grafts to 
native arteries in the bypass location results in significantly improved patency over other 
graft options. 
13
 However, due to disease, trauma, and anatomic abnormalities, 
autologous vessels are unavailable in up to 20% of bypass patients. 
14-15
 In these cases, 
synthetic vascular grafts are required. 
1.3.2 Synthetic Grafts Current options for synthetic grafts include Dacron® 
(poly(ethylene terephthalate), PET) and GORE-TEX® (expanded 
poly(tetrafluroethylene), ePTFE). Synthetic grafts are not limited by availability and 
have relatively high patency rates in large diameter applications (> 6mm). However, 
thrombosis and low compliance cause occlusion in smaller vessels.
16-17
 Even in large 
diameter applications, grafts made of PET and ePTFE must be accompanied by 
anticoagulant medications such as heparin that help to reduce the risk of thrombosis and 
intimal hyperplasia.
18
 Thus, there is a growing clinical need for a synthetic, small-
diameter vascular graft that improves on current options. 
 
 
1.4  In Vivo Characterization of Vascular Grafts 
1.4.1 Basic Host Response to Biomaterial Implants Acute inflammation is part 
of the body’s innate immune response and is the immediate response to tissue injury, 
such as that which occurs upon implantation of a synthetic biomaterial. The effects of 
acute inflammation are limited to the first hours to days of injury and can therefore be 
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distinguished from chronic inflammation that persists over weeks to months. Briefly, 
following injury, nearby blood vessels dilate, resulting in redness and heating. Nearby 
capillaries experience an increase in permeability to allow leakage of fluid into the 
surrounding space. This fluid contains blood proteins, such as fibrinogen, that encourage 
clotting in order to create a barrier to invading organisms. Other soluble factors in the 
fluid attract granulocytes and monocytes that release degradative agents and 
phagocytose foreign oranisms that are visible microscopically, Figure 1.1.
19-22
  
 
 
 
Figure 1.1. Acute host response. Scanning electron micrograph of attached monocytes 
on an implanted polyurethane surface at 0 days as part of the acute host response. [taken 
from Ref. 22]  
 
 
 
In the case of a biostable implant, acute inflammation would ideally end with 
fibrous encapsulation, which begins with the formation of granulation tissue. 
Approximately 24 hours after implantation, macrophages and other inflammatory cells 
release chemoattractive signals that promote fibroblast and vascular EC migration into 
the area. Granulation tissue can be viewed microscopically within three to five days. 
Histologically, it is characterized by a pebbly, granular appearance that is a result of 
vascular bud formation that occurs in angiogenesis, Figure 1.2A.
23
 Additionally, 
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granulation tissue is rich in fibroblasts, which serve to create an ECM of collagen and 
proteoglycans. Some fibroblasts in wound healing differentiate into smooth muscle cell-
like myofibroblasts that are responsible for wound contraction to reduce defect size and 
promote healing. After appoximately four weeks, the granulation tissue matures to form 
a fibrous capsule. Maturation involves formation of larger blood vessels and alignment 
of collagen fibers as they respond to local mechanical stimuli, Figure 1.2B. 
19,22,24-25
 
 
 
 
Figure 1.2. Biomaterial host response. (A) Hematoxylin and eosin stained biomaterial at 
14 days post-implantation demonstrating granulation tissue (g) separating the polymeric 
implant (p) from the spleen (s). Arrows point to blood vessel-like areas at the leading 
edge of the granulation tissue. [taken from Ref. 23] (B) Safranin O/von Kossa stained 
polymer explant 12 weeks post-implantation demonstrating fibrous encapsulation (Ft). 
Aligned collagen fibrils can be seen between the polymer sample and surrounding 
muscle tissue (Mc). [taken from Ref. 24] (C) Toluidine blue stained dextran hydrogel (h) 
5 days post-implantation demonstrating chronic inflammation. Macrophages (black 
arrow) are attached to surface and surrounded by lymphocytes (white arrow). [taken 
from Ref. 26] (D) Scanning electron micrograph of foreign body giant cells attached to 
polyurethane surface 14 days post-implantation, demonstrating chronic inflammation. 
[taken from Ref. 22]  
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Chronic inflammation is similar to actute inflammation except that it persists for 
weeks and months, rather than hours to days and it is less uniform histologically. It is 
characterized by the presence of mononuclear cells, such as lyphocytes and plasma cells, 
Figure 1.2C.
26
 Chronic inflammation can also include granulomas, which are made up 
of a layer of foreign body giant cells (FBGCs) surrounding a particle that cannot be 
phagocytosed. FBGCs are contained within a group of epitheloid cells, which are 
derived from macrophages. The epitheliod cells are surrounded by lymphocytes, Figure 
1.2D.
19,22,25
  
1.4.2 Thrombosis and Intimal Hyperplasia Thrombosis is the process of blood 
coagulation that occurs within injured vessels. Thrombosis is mediated by platelets, non-
nucleated fragments of megakaryocytes. Platelets serve to reduce bleeding after injury 
through the creation of a platelet plug and subsequent activation of the blood coagulation 
cascade to stabilize the plug. Collagen and von Willebrand factor are platelet activators 
that commonly adsorb to synthetic biomaterial surfaces and cause thrombosis.
27
 Graft 
patency (% closure), platelet deposition, and thrombus coverage are common indicators 
utilized to measure in vivo thrombogencity. Patency is typically measured with Doppler 
ultrasonography or angiography to visualize blood flow through the graft, or it can be 
measured post-implantation with histology or scanning electron microscopy (SEM).
28-29
 
One method for quantifying platelet attachment in vivo involves injection of 
radiolabelled platelets. Detectors can be utilized outside of the body to measure 
radioactivity inside of grafts relative to healthy vessels.
28,30-31
 Qualitative assessment of 
platelet deposition and thrombus coverage can be made using SEM on explanted 
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specimens, Figure 1.3A.
28
 Current synthetic graft materials (PET and ePTFE) support 
adsorption of platelet activators and successive platelet adhesion and activation and thus 
have high failure rates due, in part, to thrombosis.
32-33
 Thrombosis can be prevented in 
vascular grafts through the use of materials that do not promote platelet interactions 
and/or through the formation of a stable, quiescent EC layer. 
 
 
 
Figure 1.3. Thrombosis and intimal hyperplasia. (A) Scanning electron micrograph 
demonstrating platelet, erythrocyte, and leukocyte deposition to the inner layer of a 
Dacron® vascular graft 12 weeks post-implantation in a dog model. [taken from Ref. 28] 
(B) Longitudinal histological section (7.5X) of a distal anastomosis of a GORE-TEX® 
vascular graft after 12 weeks in a dog model. [White star denotes native artery; black 
star denotes synthetic graft; arrows identify regions of neointimal hyperplasia. Flow is 
from left to right] [taken from Ref. 38]  
 
 
 
Intimal hyperplasia is characterized as a chronic structural change that occurs at 
vascular graft distal anastomoses wherein a thickened fibrocellular layer forms between 
the endothelium and the inner elastic lamina. This causes narrowing of the lumen and 
reduced blood flow, and it has been reported to happen to some extent in all vascular 
bypass grafts.
12,34-35
 The development of intimal hyperplasia at vascular graft 
anastomoses is directly related to the alterations in wall shear stresses that occur due to a 
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compliance mismatch with native vasculature.
13,36
 Namely, the transition of blood flow 
into a stiffer tube results in a flow stagnation point and creates a region of low and 
oscillating shear forces on the vascular walls.
36
 These alterations in shear forces have a 
large effect on the underlying endothelium. ECs in these regions increase their uptake of 
lipoproteins, produce leukocyte adhesion molecules on their surfaces, and secrete 
chemotactic factors that promote proliferation of nearby monocytes/macrophages (MCP-
1, VCAM-1) and underlying SMCs (Angiotensin II, PDGF, Endothelin-I).
37
 This 
process ultimately results in atherosclerosis, characterized by accumulation of lipids and 
fibrous plaques and hyperproliferation of medial smooth muscle cells into the intimal 
layer. Where thrombosis is an acute response that results in rapid graft failure, 
athersoclerosis is associated with late graft failure.
34,38
 These changes can be observed 
histologically in the graft anastomoses post-explantation as substantially thickened 
intimal layers dominated by SMCs and reduced medial layers, Figure 1.3B.
38
 A direct 
relationship exists between vascular graft patency and compliance; thus, improved 
compliance matching is an important factor in improving synthetic vascular grafts to 
prevent intimal hyperplasia.
13
  
1.4.3 Endothelialization Due to the role of ECs in providing thromboresistance 
and reducing intimal hyperplasia, endothelialization of vascular grafts has been 
identified as a key goal in improving their performance. This process can occur via EC 
migration from connecting native vasculature or through recruitment of circulating 
endothelial progenitor cells (EPCs).
39-40
 The extent to which either of these events occur 
in vivo can be determined post-explantation using histology or SEM.39-40 ECs that have 
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migrated from graft anastamoses are limited to the graft edges, whereas recruited cells 
from circulation are dispersed throughout the graft surface. Confluent and quiescent 
endothelial layers feature ECs in contact with each other and aligned in the direction of 
blood flow, Figure 1.4A.
40
 Current synthetic vascular graft endothelialization is limited 
to ECs that migrate from surrounding vasculature onto the outer graft edges, as these 
materials do not promote significant EC adhesion or migration, Figure 1.4 B and C.
41
  
 
 
 
Figure 1.4. Vascular graft endothelialization. (A) Scanning electron micrograph of 
endothelial cells on PET grafts with granulate-colony stimulating growth factor that have 
been recruited from circulating blood after 4 weeks in a dog model. [taken from ref 40] 
(B) Gross specimen and (C) map of endothelial cell-like coverage distribution in Dacron 
vascular graft at 4 weeks in a dog model. [taken from ref 41] 
 
 
1.5.  Vascular Graft Design Advances 
1.5.1 Cadaveric Allografts 
1.5.1.1 Direct Allografts Cadaveric allografts were initially considered as a 
replacement solution for the cases in which autologous vessels are unavailable and 
synthetic grafts fail. Unfortunately, these grafts have had very limited success. 
Heterografts from the bovine carotid artery and homografts from the human umbilical 
cord vein have been shown to fail in the long-term due to degradation, dilation, and 
aneurysm formation.
42
 Antigenicity of saphenous vein allografts results in immunologic 
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rejection and correspondingly low patency rates.
42-43
 Early work by Weber et al. 
indicated that cryopreservation of venous allografts in dimethylsulfoxide (DMSO) 
served to maintain graft viability and resulted in long-term patency in dogs that was 
comparable to autografts.
44
 However, Axthelm et al. showed that cryopreservation does 
not reduce the immunologic concerns of venous allografts in rats.
43
 A T cell-mediated 
response to cyropreserved saphenous vein allografts in humans has since been 
confirmed, and these grafts have shown high failure rates even when used in conjunction 
with immunosuppressants.
45-46
 This is possibly due to graft imbrittlement that occurs 
during the cryopreservation process and can cause early rupture in humans.
47  
1.5.1.2 Decellularized Allografts In efforts to reduce immunological concerns of 
venous allografts, researchers have turned towards decellularization techniques. This 
process removes cells and cellular debris while maintaining the structural ECM proteins 
of native vasculature. Although enzymatic digestion of the cellular components of 
allografts is successful in reducing antigenicitiy, it also results in thinner vessel walls 
and increased difficulty in handling.
48
 New decellularization techniques have focused on 
improving the maintenance of structural integrity and biomechanical properties.
49-50
 
While these grafts are promising alternatives and show positive results in short-term in 
vivo studies, it has been found that their luminal layer is thrombogenic and that in vivo 
endothelialization is minimal.
49,51-53
 Due to the important role that vascular ECs play in 
preventing thrombosis and intimal hyperplasia, endothelialization of the graft inner layer 
is required to maintain long-term patency.
4-5
 To address this issue, researchers have pre-
endothelialized decellularized grafts with patient cells. This results in significantly 
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improved graft patency in humans. However, approximately 3 weeks are required to 
prepare the grafts for implantation, which increases the cost of the graft and the risk of 
graft infection. Additionally, in some cases, the endothelial layer destabilizes under the 
application of vascular flow and pressures, and there are some concerns about side 
effects from use of the required in vitro growth factors used to promote 
endothelialization.
54-55
  
1.5.1.3 Small Intestine Submucosa Allografts An alternative allograft material 
that has been studied is the small intestine submucosa (SIS). These scaffolds are 
prepared by mechanically removing the mucosa and muscle from the small intestine and 
lysing native cells to obtain an acellular collagen matrix with retained angiogenic growth 
factors, such as basic fibroblast growth factor and vascular endothelial growth factor.
56-57
 
Roeder et al. measured mechanical properties of small-diameter SIS grafts and 
determined that they have compliance and burst pressure values that are suitably high for 
implantation.
58
 Badylak et al. provided one of the first reports of the use of SIS as a 
vascular graft in large diameter applications in dogs.
59
 These studies laid the groundwork 
for a novel vascular graft material, and the grafts remained patent for up to one year. 
However, there was no evidence of in vivo endothelialization, and this study utilized 
autogenous tissue in large diameter vessels. Lantz et al. implanted small diameter arterial 
SIS autografts in dogs.
60
 They observed an overall graft patency rate of 75% after up to 
82 weeks, but no surface EC growth occurred. Sandusky et al. implanted small-diameter, 
xenogenic (porcine) SIS grafts into dogs and compared them to autologous savenous 
vein grafts. They found similar patency for the two graft types and no cases of aneurysm, 
 13 
 
infection, or rupture occurred. Additionally, both SIS and saphenous vein grafts had 
smooth muscle medial layers and endothelial intimal layers at 90 and 180 days post-
implantation. Similar patency rates and remodeling were seen in a study comparing 
xenogenic SIS grafts to ePTFE grafts in dogs, wherein the ePTFE grafts demonstrated a 
75% occlusion rate.
61
 However, it has since been shown that canine animal models will 
spontaneously endothelialize natural vascular graft materials whereas humans do not.
62
 
Robotin-Johnson et al. evaluated autogenic SIS grafts with bound heparin as growing 
vascular grafts in piglets over 90 days.
63
 The grafts showed to be non-thrombogenic and 
were patent with evidence of endothelialization and remodeling. Additionally, the graft 
dimensions increased throughout the implant time as the piglets grew. Some concerns 
have arisen concerning the risks associated with remnant porcine DNA in SIS scaffolds. 
To address this, SIS could be obtained as an autograft from the patient to circumvent 
these issues; however, this would require a second surgical site that increases patient 
risk, and autologous tissue is limited in availability.
64-65  
1.5.2 Synthetic Graft Modification 
1.5.2.1 Surgical Approach Due to the decreased cost and time of getting a new 
graft material to the market, many researchers have attempted to modify existing 
synthetic vascular grafts to improve their patency in small diameter applications.
66
 The 
most simple of these techniques is to alter the surgical approach, which has been utilized 
to reduce the compliance mismatch between the synthetic graft and native vasculature. 
These include the use of vein cuffs, vein patches, vein boots, and arteriovenous fistulas 
at the distal anastomosis.
67-71
 While some of these techniques have shown significant 
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improvements compared to unmodified grafts, these have been limited to large diameter 
(6 mm) grafts, and overall patency rates remain below 71%.
68,70-71
  
1.5.2.2 Thromboresistant Coatings An alternate approach is to apply coatings to 
smaller diameter ePTFE and PET grafts to reduce thrombosis. Poly(propylene sulfide)-
poly(ethylene glycol) coatings on ePTFE grafts showed decreased thrombogenicity 
following nine minutes of perfusion in an extracorporeal porcine arteriovenous graft 
when used with heparin.
72
 In an alternate approach, an acrylate phosopholipid was 
utilized as a membrane-mimetic film on the luminal surface of a 4 mm ePTFE grafts. 
These grafts demonstrated thromboresistance following one hour in a baboon 
arteriovenous shunt model.
73
 Similarly, hydrophilic acrylic coatings on PET grafts that 
release salicylic acid showed decreased thrombogenicity in an ex vivo canine circuit.74 
While these techniques show some potential for improving synthetic graft 
thromboresistance, there is little data indicating their long-term effectiveness. 
Drug coatings have also been investigated as a potential method for improving 
synthetic grafts. Poly(ethylene glycol) (PEG) was used as a delivery system for hirudin, 
an anticoagulant, and iloprost, a vasodilation promoter, in 4 mm ePTFE grafts. This 
resulted in 100% patency in a porcine model with reduced intimal hyperplasia compared 
to the ePTFE control after 6 weeks.
75
 While this is promising data, the long-term 
effectivness of this delivery method is yet to be established. Greisler et al. pretreated 
ePTFE grafts with a mixture of fibroblast growth factor-1, fibrin glue, and heparin to 
induce endothelialization through capillary ingrowth.
76
 Although this resulted in 
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improved endothelialization in a canine model after 28 days, no discussion of thrombosis 
or intimal hyperplasia was included.  
1.5.2.3 Pre-endothelialization Due to the importance of a stable endothelium in 
reducing thrombosis and intimal hyperplasia, researchers have attempted to improve 
synthetic graft patency by seeding them with ECs prior to implantation. Laube et al. 
cultured patient ECs and seeded them onto 4 mm ePTFE grafts for coronary artery 
bypass procedures.
77
 This resulted in a 91% patency rate after 28 months. Similar studies 
have been conducted with EPCs isolated from patient peripheral blood or bone marrow 
with improved patency seen in animal models.
78-79
 While these results are promising, 
culture of patient cells introduces a delay prior to implantation and is associated with the 
same concerns that are dicsussed above with pre-endothelialized allografts.
54
 To address 
this, Rotmans et al. coated ePTFE grafts with anti-CD43 antibodies to recruit EPCs in 
vivo. This enhanced graft endothelialization in a porcine model at 72 hours.80 However, 
the technique did not reduce intimal hyperplasia in the distal anastomosis, and there is 
still some controversy as to whether EPCs function as true endogenous ECs following 
seeding and implantation. 
1.5.2.4 Nitric Oxide The incorporation of nitric oxide (NO) is another method 
that has been employed to improve synthetic graft patency. NO is produced by quiescent 
ECs and has been found to play a role in regulating vascular tone, preventing platelet 
aggregation, and inhibiting vascular smooth muscle cell migration and proliferation.
81
 
The presence of NO helps to maintian healthy vasculature and prevent neointimal 
hyperplasia following vascular injury. The majority of NO modifications utilize one of 
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two classes of NO donors: diazeniumdiolates and S-nitrosothiols. Diazeniumdiolates are 
stable solids that can be altered to provide tunable NO release rates in aqueous 
environments.
82
 Initial attempts to use NO-releasing diazeniumdiolates to reduce 
thrombosis and intimal hyperplasia were promising, but it was found that some 
diazeniumdiolate polymers can leach out of polymer matrixes and form nitrosamines, 
which are carcinogenic.
83-85
 To avoid this problem, Batchelor et al. developed a more 
lipophilic, discrete diazeniumdiolate species that is resistant to leaching and used it to 
coat 5 mm diameter commercially available polyurethane vascular grafts. These grafts 
were patent after 21 days in a sheep arteriovenous shunt, at which point all control grafts 
had occluded.
86
 An alternate approach to prevent leaching of undesired byproducts is to 
covalently bind diaseniumdiolates to a polyurethane backbone.
87-88
 In vitro studies with 
these polyurethane films have shown initial hemocompatibility, suitable mechanical 
properties, and sustained NO production for 2 months.  
S-nitrosothiols are a biological NO transporter that are present in circulating 
blood.
89
 Bohl and West developed NO-releasing PEG-based hydrogels through 
covalently linking S-nitrosothiols within the hydrogel network.
90
 This resulted in 
reduced SMC proliferation and platelet adhesion in vitro, and these gels could be used to 
coat synthetic vascular grafts to provide controlled and localized NO delivery. While 
these methods are promising, the delivery of NO from these materials is limited to 
relatively short time frames. To address this, new materials are being developed that 
utilize the nitrosothiols and nitrates that are already present in circulating blood. Gappa-
Fahlenkamp et al. immobilized L-cysteine on Dacron and polyurethane surfaces to 
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provide a free thiol group that can undergo NO exchange reactions to release NO. This 
resulted in improved hemocompatibility in vitro and has the potential to provide 
localized NO release throughout the lifetime of the graft.
91
  
While these methods have shown some preliminary effectiveness at decreasing 
synthetic graft thrombogenicity, they do not reduce the compliance mismatch with the 
native vasculature, which is a primary cause of intimal hyperplasia in ePTFE and PET 
grafts. Thus, there is a need for new graft materials that improve on both biomechanical 
properties and hemocompatibility. 
1.5.3 Protein-Based Vascular Grafts 
1.5.3.1 Collagen To provide a more functional vascular graft, many researchers 
have incorporated native ECM proteins into graft designs. The use of biological 
scaffolding provides the potential for cell-mediated remodeling and functional 
vasoactivity over time.
92
 Collagen has been extensively studied as a vascular graft 
material due to its inherent binding sites for ECs and its presence in native vasculature.
93-
94
 Weinberg and Bell developed one of the first collagen-based vascular grafts by 
embedding vascular cells into tubular collagen gels. However, these grafts had very poor 
mechanical properties (burst pressure <10 mmHg) and required incorporation with PET 
vascular graft sleeves to support the physiological pressures of vasculature.
94
 
Researchers have attempted to improve upon these properties by culturing constructs 
with inner mandrels to promote gel contraction, varying collagen concentration, using 
magnetic prealignment of the collagen fibers during fibrillogenesis, and fabricating 
electrospun collagen scaffolds.
95-98
 While these methods have improved the mechanical 
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properties of collagen-based scaffolds, they fail to provide sufficeint strength for use as 
vascular grafts without the use of an outer stabilizing layer. Additionally, native collagen 
is thrombogenic, and collagen-based grafts must be pre-endothelialized to prevent in 
vivo occlusion.99 Small-diameter vascular grafts with pre-cultured and pre-
endothelialized collagen scaffolds that demonstrate adequate mechanical properties and 
hemocompatibility have been developed, but these techniques require increased 
preparation time and cost, and more work has turned to the development of bioactive 
grafts based on alternate ECM proteins.
100-101
  
1.5.3.2 Elastin It has been proposed that the shortcomings in the biomechanical 
properties of collagen-based scaffolds could be due to the lack of elastin in the 
scaffolds.
102
 Elastin is the ECM protein that contributes to the compliance of native 
vessels and has been investigated as a tool to provide bioactive vascular grafts with 
mechanical properties that more closely match those of the surrounding vasculature.
103
 
Additionally, studies have suggested that intact collagen and elastin networks in 
vasculature play a role in inhibiting SMC hyperproliferation.
104-105
 Many researchers 
have attempted to harness these properties through fabrication of collagen-elastin-based 
vascular grafts. Electrospinning in particular has emerged as a fabrication technique for 
these protein scaffolds.
106
 Boland et al. electrospun a collagen/elastin blend onto a 
rotating mandrel to create tubular constructs that were then crosslinked with 
glutaraldehyde.
107
 Following culture of ECs and SMCs in a bioreactor, three-layer grafts 
that mimic the architecture of native vasculature were produced. Similarly, Buttafoco et 
al. co-electrospun collagen and elastin, but utilized a non-organic solvent (10 mM 
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hydrochloric acid) and a crosslinker with improved biocompatibility over glutaraldehyde 
(N-(3-dimethylaminopropyl)-N0-ethylcarbodiimide hydrochloride (EDC), in the 
presence of N-hydroxysuccinimide (NHS)).
108
 While most of the presented data was 
proof-of-concept, this fabrication technique has the potential to provide improved 
scaffolds for vascular tissue engineering. Researchers have also investigated the 
potential of synthetic-natural polymer blends. Stitzel et al. fabricated electrospun 
vascular grafts with a blend of collagen type I, elastin, and poly(D,L-lactide-co-
glycolide).
109
 These grafts had high compliance and burst pressure, promoted SMC and 
EC growth in vitro, and induced a minimal inflammatory response when implanted 
subcutaneously into mice. However, thromboresistance was not reported, and these 
grafts would likely require in vitro endothelialization prior to implantation to prevent 
thrombus formation. Wise et al. was the first group to develop a vascular graft with 
recombinant human elastin.
110
 The authors incorporated elastin into a synthetic 
poly(caprolactone) electrospun mesh to provide thromboresistant vascular grafts with 
tunable biomechanical properties that support EC adhesion. These grafts were well-
tolerated in a rabbit carotid animal model for 1 month, but in vivo endothelialization and 
thrombosis were not assessed. In general, elastin-based scaffolds show potential in the 
development of small-diameter vascular grafts. However, this is a relatively new 
approach, and much of the research in the use of elastin in small diameter grafts is still in 
the developmental phase. 
1.5.3.3 Fibrin Fibrin, a protein involved in blood clotting, has been investigated 
as an alternative vascular graft material. Although it is not a main ECM component of 
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native vasculature, its role in wound healing can be harnessed to stimulate regeneration 
and remodeling in a variety of cell types.
111
 Autologous fibrinogen can be isolated from 
patient blood and mixed with thrombin to yield insoluble fibrin fibers.
112-114
 SMCs and 
fibroblasts cultured in fibrin gels have shown to produce greater amounts of collagen 
than those in collagen gels, and fibrin gels supported in vivo remodeling of collagen and 
elastin when implanted into sheep for 15 weeks following in vitro culture with SMCs 
and ECs.
112,114-115
 Fibrin and collagen have been co-polymerized to produce bioactive 
gels with improved mechanical properties compared to those of the pure components. 
These gels also allow manipulation of scaffold properties by varying the ratios of the 
protein components and the mechanical stimulation of the resulting gels.
116-117
  
Many of the ECM protein-based approaches to small diameter vascular grafts 
represent progress in this difficult area. However, native ECM proteins demonstrate 
significant batch-to-batch variability that makes it difficult to acheive reproducible 
mechanical properties without the use of a significant amount of pre-culture with SMCs, 
fibroblasts, and/or ECs to synthesize a network of ECM proteins prior to in vivo 
use.
96,98,101,109,112,114-125
 Additionally, most of these designs rely on in vitro 
endothelialization to prevent thrombosis and intimal hyperplasia following 
implantation.
95,100-101,109,114,118,120,125
 This not only presents a significant increase in 
treatment cost and time, but there is little evidence that pre-endothelialized grafts retain a 
quiescent endothelium under the flow conditions of native vasculature.
120,126-127
  
1.5.4 In Vitro Cultured Biological Vascular Grafts L’Heureux et al. initiated a 
new approach to vascular tissue engineering with the introduction of cell sheet-based 
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tissue engineering in which scaffolds are synthesized by cultured human cells without 
the use of an additional scaffold.
97,128
 Cells are cultured in vitro under conditions that 
induce deposition of ECM to produce a solid sheet. In this first approach, a fibroblast 
sheet was wrapped around a cylindrical support tube, matured, and dehydrated to 
provide an acellular scaffold for EC seeding. An SMC sheet was wrapped around this 
layer to provide the medial layer, and these layers were matured in a bioreactor. The 
adventitial layer was comprised of a second fibroblast sheet, and the grafts were matured 
and endothelialized following addition of this third layer. Through increasing the culture 
period of the adventitial layer to 5 weeks, burst pressures of greater than 2000 mmHg 
were acheived, which are comparable to or greater than those of human saphenous veins 
(~1700 mmHg). Additionally, the EC layer provided increased in vitro 
thromboresistance.
128
 These grafts were implanted into rats for long-term (8 months) in 
vivo characterization and into primates for 8 weeks to provide a more physiologically 
relevant model.
129
 In the rat model, the grafts had an 85% patency rate with no evidence 
of a chronic inflammatory response and remodeling into a more physiological tissue. 
The grafts in the primate study were 100% patent at explantation and showed signs of 
remodeling as well. 
Niklason et al. developed an alternative approach to biological vascular grafts by 
seeding SMCs onto tubular biodegradable polyglycolic acid (PGA) scaffolds in a 
bioreactor.
130
 The PGA scaffold degrades to less than 15% of its initial mass within 5 
weeks of culture. After 8 weeks of culture, the grafts were seeded with ECs and cultured 
for an additional 3 days. This resulted in scaffolds with burst pressures of greater than 
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2000 mmHg that remained patent in a porcine saphenous vein model for 4 weeks. Solan 
et al. utilized this same approach and investigated the effect of pulse rate during the 
culture period on collagen depostion by the SMCs.
131
 It was found that grafts grown with 
higher pulse rates had significantly higher levels of collagen than those grown under 
static conditions. This provided a tool to enhance the graft physical and mechanical 
properties and to possibly decrease culture time. Unfortunately, translation of the 
approach from swine to adult human cells failed due to the limited proliferative capacity 
of terminally differentiated SMCs.
132
 To address this issue, human telomerase (hTERT) 
was introduced into SMCs. This resulted in cells with significantly extended 
proliferation and mechanically robust human grafts which burst pressures up to 600 
mmHg.
133-134
 While this was promising, these grafts still lacked the strength necessary 
for use in vascular grafts, and there are some concerns about long-term oncogenicity of 
hTERT-infected SMCs. Thus, current work is focused on the use of human bone 
marrow-derived mesenchymal stem cells (MSCs) rather than SMCs.
135
 Gong and 
Niklason able to optimize culture conditions to drive MSC differentiation and matrix 
production to provide grafts that were histologically and molecularly similar to native 
vessels.  
While these approaches shows potential, they required a total culture time of 2-3 
months to produce viable vascular grafts. This prevents this technology from being 
applied to urgent clinical use and significantly increases the cost of the graft.
92,129
 
However, individuals who have a disease with a well-defined progession and who lack 
healthy autologous vessels for use in bypass surgery can be identified during the pre-
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operative waiting periods. In these cases, these vascular grafts could provide useful 
alternatives to current synthetic options.
136
 Additionally, it has been proposed that the 
graft maturation period could be accelerated by providing the cells with mechanical 
stimulation in a dynamic culture environment.
92
 This could reduce the time frame for 
obtaining suitable grafts, but could also increase the total cost of the constructs. 
1.5.5 Synthetic ECM Analogs 
1.5.5.1 Peptide-Based Scaffolds An alternative approach to developing bioactive 
grafts is the incorporation of ECM peptides into synthetic polymer scaffolds. While 
many researchers are interested in harnessing the control that synthetic polymers provide 
over material properties, non-specific protein adsoprtion and cell adhesion to synthetic 
materials in vivo can have detrimental effects on synthetic vascular graft success.137 To 
overcome this, a synthetic material that is highly resistant to protein adsoprtion, such as 
PEG, is used as a base for covalently attaching bioactive moities to provide synthetic 
scaffolds with controlled cell-material interactions. Arg-Gly-Asp (RGD), a cell-binding 
peptide sequence found in fibronection, fibrinogen, and vonWillebrand factor, is one of 
the most extensively used peptide sequence bases.  
RGD has been incorporated into polyurethanes to enhance EC adhesion and 
proliferation for use in vascular grafts, and alterations in RGD concentration can be used 
to easily control levels of cell adhesion.
138-139
 Additionally, RGD has been immobilized 
in electrospun fibers to provide bioactive scaffolds with mechanical properties and 
structures that could be tuned to approach those of native vasculature.
140-141
 While RGD-
based scaffolds provide tunability and a means for endothelialization, RGD sequences 
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can be recognized by platelet integrin receptors, which could result in thrombosis in 
vascular grafts.
137,142
 Thus, signalling peptides that specifically interact with ECs have 
been sought out. Specifically, Tyr-Ile-Gly-Ser-Arg (YIGSR) and Arg-Glu-Asp-Val 
(REDV) have been used to provide enhanced EC adhesion while preventing platelet 
adhesion and aggregation.
137,143
 In a different approach to create vascular grafts, Gobin 
and West incorporated the elastin-derived peptide Val-Ala-Pro-Gly (VAPG) into PEG 
hydrogels to promote SMC-specific adhesion while preventing adhesion of fibroblasts, 
ECs, and platelets.
144
 This could be used to create an SMC-rich medial layer of a 
vascular graft that mimics the architecture of native arteries. While these results are 
promising, the high cost and purity concerns associated with large scale solid-phase 
peptide synthesis limits the utility of this approach.
145-146
 Additionally, short peptide 
sequences lack the triple helical conformation of native ECM proteins, which has been 
shown to affect EC adhesion strength and endothelium remodeling processes.
147-150
  
1.5.5.2 Multilayer Vascular Grafts 
Many of the synthetic polymer-based approaches utilize either hydrogel 
scaffolds, which lack the mechanical properties to sustain the pressures of native 
vasculature, or stiff polymer scaffolds, which may not provide the optimal substrate for 
EC adhesion and growth.
151-152
 The ability to decouple cell-material interactions from 
biomechanical properties would be valuable in the development of synthetic vascular 
grafts. Many groups have created multilayer vascular grafts with electrospun 
polyurethanes supporting gelatin or collagen hydrogels to attempt this.
153-154
 Similarly, 
PEG-fibrin gels were added as an inner layer to electrospun polyurethane to provide 
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vascular grafts with suitable substrates for endothelialization and adequate mechanical 
properties.
155
 While these are promising approaches, they currently require pre-
endothelialization to reduce thrombogenicity of the luminal layer, which is associated 
with previously mentioned concerns.  
 
 
1.6  Summary 
Vascular grafts that combine the cell-material interactions of native polymers 
with the thromboresistance and tunability of synthetic polymers have the potential to 
improve upon current small diameter graft options. While endothelialization has proven 
to be very important in vascular graft success, thus far, luminal EC layers have typically 
been been obtained through in vitro cell culture and seeding. An “of-the-shelf’ vascular 
graft that does not require pre-culture with ECs would represent a significant advantage 
in terms of treatment time and cost. Thus, gaining a better understanding of how in vivo 
endothelialization can be obtained through rational design of scaffolds to promote 
desirable EC interactions is an important step forward in developing a successful off-the-
shelf, small diameter vascular graft.  
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CHAPTER II  
DEVELOPMENT AND CHARACTERIZATION OF MULTILAYER VASCULAR 
GRAFTS* 
 
2.1 Introduction 
Due to the low availability of autologous vessels and the high failure rates of 
synthetic vascular grafts, an urgent clinical need for off-the-shelf, small diameter 
vascular prostheses has prompted investigation of biomimetic grafts with properties that 
more closely match those of native blood vessels.
130-131,156-157
 For a graft to be effective 
as an off-the-shelf arterial prosthesis, it must avoid cell harvesting and construct pre-
culture, which delay treatment and increase cost.
94,128,158-159
 Thus, generation of the 
luminal endothelial cell (EC) layer critical to inhibiting platelet aggregation and smooth 
muscle cell hyperproliferation must occur following implantation, and rapid 
endothelialization has been identified as a critical element in the development of off-the-
shelf vascular prostheses to prevent small-caliber graft reocclusion.
4,158
  
A vascular graft that incorporates the potential for endothelialization of native 
collagen while circumventing thrombogenicity concerns and providing appropriate 
mechanical properties would represent a significant advance in off-the-shelf graft design.  
To this end, we have developed a novel biomaterial platform based on a collagen-
*Reprinted with permission from “Multilayer Vascular Grafts Based on Collagen-
Mimetic Proteins,” by MB Browning, D Dempsey, V. Guiza, S. Becerrea, J. Rivera, B. 
Russell, M. Höök, F. Clubb, M. Miller, T. Fossum, J-F Dong, A.L. Bergeron, M. Hahn, 
and E. Cosgriff-Hernandez, Acta Biomaterialia 2012, 8 (3), 1010-1021. Copyright (2012) 
Elsevier. 
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mimetic protein derived from group A Streptococcus, Scl2.28 (Scl2-1). Scl2-1 has 
several properties that make it desirable for cardiovascular applications. It contains the 
Gly-Xaa-Yaa (GXY) motifs that form collagen’s characteristic triple-helix but lacks 
hydroxyproline, which eliminates the need for costly post-translational modifications.
160-
161
 This enables facile recombinant expression in E. coli and eliminates the batch 
variability concerns associated with native collagen as well as the need for expensive 
solid-phase synthesis of ECM peptides.
161-162
 Perhaps the most novel aspect of these 
proteins is that they can be designed to induce selective cell adhesion and function. Scl2-
1 acts as a biological blank slate in that it resists cell adhesion even in the presence of 
serum and displays low platelet aggregation. However, specific receptor binding motifs 
can be readily inserted into the Scl2-1 sequence by site-directed mutagenesis.
162
  
In native vessels, collagen-based α1β1 and α2β1 integrin binding motifs have been 
shown to modulate EC adhesion and phenotype.
163
 We therefore inserted the GFPGER 
motif into the Scl2-1 sequence, since it has previously shown to mediate binding by α1β1 
and α2β1 integrins.
3,149
 This modified Scl2-1 (Scl2-2) maintains the triple helical 
structure and low platelet aggregation of Scl2-1 while promoting EC adhesion and 
spreading.
164
 Until recently, the use of Scl2 proteins was limited to coatings due to their 
inability to self-assemble into stable 3D structures. To address this limitation, we have 
developed a synthetic methodology to incorporate Scl2 proteins into poly(ethylene 
glycol) (PEG) based hydrogels.
164
 PEG hydrogels were selected for this application due 
to their resistance to protein adsorption, which underlies their thromboresistance and 
isolates cell-material interactions of PEG-Scl2 hydrogels to the adhesion sites introduced 
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by the Scl2 proteins.
165
 In addition, the modulus of PEG hydrogels can be broadly tuned 
by altering PEG molecular weight, concentration, or functionality.
166
 Pelham, et al. 
found that cells on flexible substrates exhibited reduced spreading and increased motility 
compared to cells on rigid substrates.
167
 Thus, the ability to control substrate modulus 
allows for further manipulation of cell adhesion, phenotype, and migration.
151-152,168
  
The tunability of both bioactivity and mechanical properties of PEG-Scl2 
hydrogels offers unique control over the endothelialization of the graft; however, 
properties that promote endothelialization may not be consistent with those that are 
sufficient to withstand physiological loading.
151-152,167-168
 To address this issue, we have 
developed a multilayered graft comprised of a luminal PEG-Scl2-2 hydrogel layer 
designed to induce rapid endothelialization and a reinforcing mesh sleeve designed to 
provide bulk strength, compliance matching, and suture retention. Thus, each component 
can be individually tuned to achieve improved outcomes without detriment to other 
design goals and then bonded together into composite grafts. In generating the 
reinforcing mesh sleeve, segmented polyurethanes (SPUs) were selected due to their 
established biocompatibility, durability, and fatigue resistance.
169
 Electrospinning was 
chosen for fabricating the SPU mesh sleeve, since this process produces fibrous, porous 
scaffolds with mechanical properties which can be broadly tailored via modification of 
electrospinning parameters.
170
 Despite having high burst pressures and suture retention 
strengths, current synthetic vascular grafts have low 2 year patency rates (40-50%) due 
to their low compliance values.
13
 The ability to tune the biomechanical properties of 
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electrospun SPUs to improve matching to those of native vasculature is important in 
preventing intimal hyperplasia and thrombosis-induced failure in small diameter grafts.  
In these studies, multilayer grafts were fabricated and characterized to assess 
their potential as off-the-shelf small-caliber vascular prostheses. The maintenance of 
graft integrity as well as biological and mechanical properties following vacuum drying 
and rehydration was evaluated to obtain an initial assessment of the capacity of the 
fabricated grafts to undergo the processing associated with long-term storage. The 
stability of the interlayer bonding and graft mechanical properties following four week 
exposure to physiological flow was then investigated.  Additionally, the capability to 
tune graft burst pressure, suture retention strength, and compliance by varying 
electrospun mesh thickness was assessed. The thromboresistance of the luminal PEG-
Scl2 hydrogels was tested through a series of in vitro, whole blood tests and in a porcine 
carotid model. Cumulatively, these studies indicate that the proposed multilayer design 
has significant potential as an off-the-shelf vascular prosthesis. 
 
 
2.2 Materials and Methods 
 
2.2.1 Materials All chemicals were used as received and purchased from Sigma 
Aldrich (St. Louis, MO) unless otherwise noted.  
2.2.2 Scl2 Functionalization The Scl2.28 sequence was amplified and purified 
as previously described.
164
 Scl2-1 served as a negative control with no binding sites for 
α1β1 or α2β1. Scl2-2 is a variant of this protein containing the sequence GFPGER that 
was generated by site directed mutagenesis as previously described.
161
 Scl2 proteins and 
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a rat tail collagen type I control were functionalized with photoreactive crosslink sites 
according to a protocol adapted from Sebra et al.
171
 Scl2 proteins include ~9% lysine 
groups that allow for bioconjugation through the established NHS-lysine Ɛ-amino group 
reaction. Briefly, the proteins were reacted with acrylate-PEG-N-hydroxysuccinimide 
(Acr-PEG-NHS, MW 3500, Jenkem Technologies USA, Allen, TX) in 50 mM sodium 
bicarbonate buffer (pH 8.5). The Acr-PEG-NHS:NH2 molar ratio was 1:1, and the 
reaction was allowed to proceed with stirring for 24 hours at room temperature. Basic 
byproducts were removed via dialysis against 0.1M hydrochloric acid for 24 hours, and 
further purification was carried out with dialysis against deionized water for 24 hours 
(MWCO = 20,000). Functionalization of the modified proteins was confirmed with 
Fourier transform infrared (FTIR) spectroscopy and sodium dodecyl sulfate poly-
acrylamide gel electrophoresis (SDS-PAGE), as previously shown.
164  
2.2.3 Preparation of Bioactive PEG-Scl2 Hydrogels Poly(ethylene glycol) 
diacrylate (PEGDA) was synthesized according to a method adapted from Hahn, et al.
172 
Briefly, 4 molar equivalents of acryloyl chloride were added dropwise to a solution of 
PEG (3.4 kDa or 6kDa; 1 molar equivalent) and triethylamine (2 molar equivalents) in 
anhydrous dichloromethane (DCM) under nitrogen. After the addition was complete, the 
reaction was stirred for 24 hours. The resulting solution was washed with 2M potassium 
bicarbonate (8 molar equivalents) and dried with anhydrous sodium sulfate. The product 
was precipitated in cold diethyl ether, filtered, and dried under vacuum. FTIR 
spectroscopy and proton nuclear magnetic resonance (
1
H-NMR) spectroscopy were used 
to confirm functionalization of PEGDA. Control and functionalized polymers were 
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solution cast directly onto KBr pellets to acquire transmission FTIR spectra using a 
Bruker TENSOR 27 spectrometer. Successful acrylation was indicated by an ester peak 
at 1730 cm
-1
 and loss of the hydroxyl peak at 3300 cm
-1
 in the spectra. Proton NMR 
spectra of control and functionalized polymers were recorded on Mercury 300 MHz 
spectrometer using a TMS/solvent signal as an internal reference. All syntheses resulted 
in percent conversions of hydroxyl to acrylate endgroups of greater than 85%. 
1
H-NMR 
(CDCl3): 3.6 ppm (m, -OCH2CH2-), 4.3 ppm (t, -CH2OCO-), 6.1 ppm (dd, -CH=CH2), 
5.8 and 6.4 ppm (dd, -CH=CH2).  
PEG, PEG-Scl2, and PEG-collagen hydrogels were prepared by dissolving 
PEGDA (10 or 20 wt%) and functionalized Scl2 or collagen (4, 6, 9, 12 or 15 mg ml
-1
) 
in deionized water. A photoinitiator solution (1 mg Irgacure 2959 per 0.1 ml 70% 
ethanol) was added at 1 vol% of precursor solution. Solutions were pipetted into a mold 
and crosslinked by 6 min exposure to long wave UV light (Intelli Ray Shuttered UV 
Flood Light, Integrated Dispensing Solutions, Inc., 365 nm, 4 mW/cm
2
).   
2.2.4 SPU Electrospinning BioSpan® (DSM-Polymer Technology Group; 
Berkeley, CA, USA) and Carbothane
®
 (Lubrizol; Wickliffe, Ohio, USA) were dissolved 
at 15 wt% in dimethylacetamide (DMAC) for electrospinning. A 4 mm diameter copper 
rod collector was dipped in a 5 wt% PEG solution in chloroform. After drying, it was 
grounded and positioned 35 cm away from the tip of a blunted 20 gauge syringe needle. 
The SPU solutions were dispensed at a rate of 1.0 ml per hour with a syringe pump 
(KDS 100, KDS Scientific) as a voltage of approximately 14 kV was applied to the 
needle tip using a high voltage source (Gamma High Voltage, Ormond Beach, FL, USA) 
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for 2 to 8 hours.
170
 After the designated time period, the copper rod with the mesh was 
placed in water overnight to dissolve the inner PEG layer, and the mesh was removed 
from the rod while submerged. High resolution images of electrospun fiber mats were 
captured using a field emission – scanning electron microscope (JSM-7500F, JEOL) 
operated at 2kV to confirm fibrous morphology (average fiber diameter = 1.6 ± 0.1 µm), 
Figure 2.1.  
 
 
 
Figure 2.1. Reinforcing electrospun mesh tube. (A) Electrospun SPU mesh tube. (B) 
Representative SEM image of fibrous SPU mesh tube. Cross-sectional views of (C) low 
thickness tube (wall thickness ≈ 0.17 mm), (D) medium thickness tube (wall thickness ≈ 
0.36 mm), and (E) high thickness tube (wall thickness ≈ 0.78 mm).  
 
 
 
2.2.5 Multilayer Graft Fabrication Mesh sleeves were taken through a graded 
ethanol/water soak (70%, 50%, 30%, and 0%; 30 minutes each) to ensure hydration and 
penetration of the aqueous hydrogel precursor solutions into the mesh prior to 
polymerization. The pre-wetted meshes were placed in a cylindrical mold with an inner 
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glass mandrel (3 mm OD). Hydrogel solutions were pipetted between the mandrel and 
the hydrated mesh (4 mm ID) and crosslinked as described in Section 2.3, Figure 2.2. 
Given that the inner diameters of the mesh and the multilayer graft (i.e. the hydrogel 
layer) were held constant, the outer diameter of the multilayer graft was dependent on 
the thickness of the electrospun mesh. In these studies, the electrospun mesh thickness 
was modulated from approximately 0.2 to 1.2 mm, resulting in graft wall thickness 
between 0.7 and 1.7 mm and corollary graft outer diameters between 4.4 and 6.4 mm.   
 
 
 
Figure 2.2. Multilayer graft fabrication. (A) Fabrication process of multilayer grafts. (B) 
Multilayer graft.  
 
 
 
2.2.6 Multilayer Graft Structural Stability Following Vacuum Drying To 
analyze the effects of vacuum drying on graft inter-layer cohesion, Carbothane was 
electrospun for 4 hours, and multilayer grafts were fabricated with PEG hydrogels (10 
wt% PEGDA, 3.4kDa). After crosslinking, grafts were cut in half and either dried under 
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vacuum or swelled in phosphate buffered saline (PBS) overnight. Vacuum-dried samples 
were then swollen in PBS. Cross sectional images of both the vacuum dried and 
rehydrated samples and the immediately-swollen controls were obtained with an optical 
zoom microscope (Z-Pix MM-640, Carson Microscopes, 130X) to document 
delamination, or macro-scale physical separation between the hydrogel and electrospun 
mesh. Burst pressure testing of multilayer grafts was carried out as described in Section 
2.7 to determine if mechanical properties were affected by drying.  
2.2.7 Retention of Hydrogel EC Adhesion Following Vacuum Drying and 
Sterilization The effects of vacuum drying and ethylene oxide sterilization on cell 
adhesion were evaluated. PEG-collagen hydrogels (10 wt% PEGDA, 3.4 kDa, 12 mg of 
protein ml
-1
) and PEG hydrogels (10 wt% PEGDA, 3.4 kDa) were fabricated between 
0.75 mm thick spacers. Each of the resulting gels was cut in half, and one segment was 
immediately submerged in PBS while the remaining half was vacuum-dried, ethylene 
oxide sterilized, and rehydrated in PBS. Bovine aortic endothelial cells (BAOECs, Cell 
Applications) were harvested and seeded onto the swollen gels at 10,000 cells cm
-2
. Gels 
were cultured for 3 h at 37 °C/5% CO2, and cell adhesion was evaluated using a Zeiss 
Axiovert microscope in 5 randomly selected fields of view. Cell adhesion was calculated 
by manually counting the cells in each field view, and cell morphology was qualitatively 
assessed to evaluate spreading before and after treatment.  
2.2.8 Multilayer Graft Stability Following Prolonged Exposure to 
Physiological Flow Freshly prepared multilayer grafts were exposed to flow in a 
pulsatile flow bioreactor system for 4 weeks, and resulting delamination between layers 
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and mechanical properties were observed.
156
 BioSpan meshes were electrospun for 8 
hours as described in Section 2.5. Multilayer grafts were prepared with 20 wt% PEGDA 
hydrogels (6 kDa). A peristaltic pump (KrosFlo Research II Pump, Spectrum 
Laboratories, Rancho Dominguez, CA) drew fluid (250 µM Dextran T70 
(Pharmacosmos, Denmark) in PBS with 1% v/v antibiotic-antimycotic solution 
(CellGro, Manassas, VA)) from a stock reservoir at 120 ml min
-1
 with 120 pulses min
-1
. 
Fluid was pumped through six multilayer grafts that were set up in parallel and held in 
place with sutures on each end. After flowing through the grafts, fluid was passed back 
to the reservoir to complete the flow circuit. Prior to beginning the study, the pressure 
profile experienced in each line was monitored  using a pressure transducer (Merit 
Medical, South Jordan, UT) in conjunction with a clinical pressure monitor (DataScope 
3000A). It was verified that the pressure through each graft was consistent and that a 
pulsatile pressure waveform was generated with a mean pressure of ~50 mmHg and a 
peak-to-trough pressure differential of ~20 mmHg, as previously described.
173
 Fluid was 
changed every 4 days during the 4 week flow period.  
The macroscopic interlayer bond integrity was observed with an optical zoom 
microscope (Z-Pix MM-640), and tensile testing was carried out on ring specimens (2-4 
mm long, n=4) before and after the flow study. Rings were mounted onto specialized 
stainless steel grips and strained until failure at a uniaxial strain rate of 6 mm min
-1
 using 
an Instron 3342. Stress and strain were calculated from the force elongation data as 
described in Johnson, et al.
174
 The tangential modulus of elasticity was calculated from 
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the resulting stress-strain data at a stress representative of that in vivo. This physiological 
stress (σ) was approximated with the equation:  
 σ 
PR
H
   [2.1] 
where P is pressure (approximated to be 100 mmHg for physiological conditions), R is 
the inner radius, and H is the wall thickness. The modulus was taken to be the stress 
divided by the strain at this point.
174
   
2.2.9 Multilayer Graft Biomechanical Properties To determine the dependence 
of multilayer graft suture retention strength, burst pressure and compliance on the 
thickness of the electrospun mesh layer, BioSpan was electrospun for 2 to 8 hours to 
form reinforcing meshes with varied thicknesses. Electrospun meshes were then 
combined with 20 wt% PEGDA (6 kDa) hydrogels for testing. Graft suture retention 
strength was determined in accordance with the straight across procedure described in 
the American National Standard Institute- Association for the Advancement of Medical 
Instruments VP20-1994.
175
 Briefly, 18 mm long tubular samples were cut lengthwise to 
obtain rectangular strips (approximately 12 mm wide). A 5.0 commercial PDS II 
monofilament suture (Ethicon, Inc) was inserted 2 mm from the short edge of the 
sample, looped, and tied. The lower end of the sample and the suture loop were secured 
in the grips of a uniaxial load test machine (Instron 3342) and extended at a rate of 100 
mm min
-1
 until the suture pulled through the sample wall. Suture retention strength was 
considered to be the maximum force recorded prior to sample failure.  
For burst pressure and compliance assessment, a nonporous latex tube lining was 
inserted into multilayer grafts (35 mm long). Burst pressure was determined from a 
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method adapted from Sarkar et al.
176
 Deionized water was pumped into the latex tubes at 
a rate of 140 ml min
-1
 using a syringe pump (KDScientific), and the pressure was 
measured using a high pressure gauge (0 to 60 psi pressure range, NoShok) connected 
downstream of the graft. The ends of the grafts were firmly secured and sealed to 
prevent leaking. The maximum pressure prior to construct failure was recorded as the 
burst pressure.  
The static compliance of separate latex-lined grafts was measured as previously 
described.
177
 Briefly, a syringe pump (Harvard Apparatus) was used to subject the 
multilayer grafts to a pressure ramp (0-150 mmHg). Intraluminal pressure was 
monitored using standard in-line strain gauge pressure transducers (Merit Medical, South 
Jordan, UT), and the outer diameter was measured with a He-Ne laser micrometer 
(BenchMike, Lasermike). Compliance (C) was calculated from the recorded pressure, P, 
and diameter, D, according to the following equation: 
   
 D
D0  P
 
D1 0-D80
D80  0
 [2.2] 
 
2.2.10 Multilayer Graft Thromboresistance 
2.2.10.1 Parallel Plate Flow Studies As a first step in evaluating graft 
thromboresistance, the adhesion of platelets exposed to the surface of PEG-Scl2 
hydrogels was evaluated. Glass slides were functionalized with methacrylate groups to 
enable bonding between the PEG-Scl2 hydrogels and the glass.
178
 In brief, glass slides 
were cleaned in a solution of 70% sulfuric acid and 9% hydrogen peroxide (v/v in 
deionized water) for 30 minutes and rinsed thoroughly. After drying, the slides were 
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treated with a 2% v/v solution of 3-(trimethoxysilyl) propyl methacrylate in 95% ethanol 
(pH 5, adjusted with acetic acid) for 5 minutes under nitrogen. They were rinsed with 
deionized water then dried, leaving free methacrylate groups on the glass to react with 
PEGDA during UV exposure. Hydrogels (0.3 mm thick) were formed between an 
acrylated glass slide and a non-acrylated glass slide under sterile conditions. PEG 
hydrogels (10 wt% PEGDA, 3.4 kDa) served as the negative control, and PEG-Scl2-1 
and PEG-Scl2-2 hydrogels (10 wt% PEGDA, 3.4 kDa, 9 mg protein ml
-1
) were tested. 
Tissue-culture polystyrene (TCPS) and collagen-coated TCPS served as positive 
controls. Rat tail collagen type I (BD Biosciences) was coated onto TCPS as per the 
manufacturer’s instructions. Briefly, the collagen solution was diluted with 0.0  M 
acetic acid to 50 µg ml
-1
 and then added to a sterile 6-well TCPS plate at 5 µg cm
-2
. 
After incubation at room temperature for one hour, the remaining solution was aspirated 
off and the coated wells were rinsed with PBS. 
Mepacrine (MP Biomedicals) was added to heparinized whole blood from 
Yucatan miniature pigs at 10 µM to fluorescently label platelets. All studies were 
complete within 8 hours of obtaining blood from the animals. A parallel plate flow 
chamber fitted with a silicon rubber gasket (0.05 in thick; Glycotech) and syringe pump 
(Harvard Apparatus) were used as previously described.
179
 A vacuum source was used to 
secure the flow chamber to each sample surface. Blood was flowed over the samples for 
2 minutes with a shear rate of 2000 s
-1
.
180
  Specimens were run in a random order to 
reduce the effects of time on observed sample-specific platelet activity. Afterwards, the 
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samples were rinsed with PBS and placed into lysis buffer (0.5% v/v TritonX-100 in 
PBS) to lyse adherent platelets or into 2.5% v/v glutaraldehyde solution for fixation.  
Following an hour long incubation at room temperature, the three specimens of 
each surface type that were immersed in lysis buffer were evaluated for lactate 
dehydrogenase (LDH) activity using an LDH assay kit (Roche). The number of platelets 
on each sample was quantified by comparison with the LDH readings of lysed platelet 
suspensions of known concentrations.
180
 The three samples per surface area reserved for 
fixation were exposed to 2.5% glutaraldehyde for 2 hours. After gentle rinsing with PBS, 
the fixed specimens were imaged using fluorescent microscopy (Axiovert 200, Zeiss). 
Three fields of view (200X) were selected at random, and the number of adherent 
platelets in each field was counted.
87
 Parallel brightfield microscopy images taken at 
each field of view were utilized to qualitatively analyze platelet aggregation.
180  
2.2.10.2 Bioreactor Flow Study As a next step in evaluating graft 
thromboresistance, heparinized whole blood was flowed through the lumen of multilayer 
grafts for extended time periods. Reinforcing Carbothane meshes were electrospun for 4 
hours to form multilayer grafts as described in Section 2.5.  PEG hydrogels (20 wt% 
PEGDA, 6 kDa) functioned as a negative control to test the thromboresistance of PEG-
Scl2-1 and PEG-Scl2-2 hydrogels (20 wt% PEGDA, 6 kDa, 15 mg protein ml
-1
). A 6 
mm internal diameter GORE-TEX
®
 vascular graft served as a clinical control (ePTFE, 
Gore Medical, Flagstaff, AZ). The multilayer grafts were fitted onto custom glass 
chambers connected to a peristaltic pump (Masterflex, Cole Parmer). Fresh, heparinized 
Yucatan miniature pig whole blood was incubated with mepacrine (10 µM) for 30 
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minutes prior to testing to fluorescently label platelets. After ensuring that all air bubbles 
were removed from the system, blood was flowed through the samples at a temperature 
of 37°C and a volumetric flow rate of 120 ml min
-1
. As with the parallel plate flow 
studies, the specimens were run in random order to reduce the effects of time on 
observed sample-specific platelet activity. Local pressures were monitored and kept 
constant in all lines during flow. After 6 hours of constant flow, samples were removed, 
gently rinsed with PBS, and fixed in formalin (10% v/v) overnight at 4°C. After fixation, 
grafts were cut longitudinally and imaged (Axiovert 200, Zeiss) to qualitatively analyze 
platelet adhesion. 
2.2.10.3 Activation of Non-Adherent Platelets Given reports that some surfaces 
can activate circulating platelets despite displaying relatively low platelet adhesion, 
activation of non-adherent platelets was investigated in addition to the 
aggregation/activation of surface-adherent platelets.
33,181
 PEG-Scl2-2 (10 wt% PEGDA, 
3.4 kDa, 12 mg protein ml
-1
) and PEG-collagen (10 wt% PEGDA, 3.4 kDa, 4 mg protein 
ml
-1
) hydrogels as well as a 10 wt% PEGDA (3.4 kDa) control were prepared directly in 
24 well plates. Prior to testing, the hydrogels were vacuum dried, ethylene oxide 
sterilized, and swollen in sterile PBS. 
The surface expression of P-selectin (CD62P) and PAC-1 binding associated 
with sample-exposed, non-adherent platelets were analyzed using flow cytometry, as 
previously described.
182
 Briefly, P-selectin expression was determined using an R-
phycoerythrin-conjugated anti-CD62P antibody (BD Pharmingen, San Jose, CA, USA), 
and integrin αIIbβ3 activation was assessed with a fluorescein isothiocyanate (FITC)-
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conjugated PAC-1 antibody (Becton Dickinson, San Jose, CA, USA). Whole blood was 
drawn from five healthy human volunteers, and citrate was added at 0.38% of the final 
volume to prevent clotting. Baseline controls were stored in polypropylene tubes, and 
each hydrogel sample was simultaneously incubated with 1 ml of whole blood for 2 
hours. After incubation, 5 µl of blood from each sample was diluted with 75 µl of 
Tyrodes buffer (139 mM NaCl, 3 mM KCl, 17 mM NaHCO3, 12 mM Glucose, 3 mM 
CaCl2, 1 mM MgCl2 in deionized water) with 1% w/v bovine serum albumin (BSA, 
Calbiochem). For the positive activated control, 5 µl of baseline blood was added to 65 
µl of Tyrodes with 1% BSA followed by the addition of 10 µl of 200 µM adenosine 
diphospate (ADP, Helena). Twenty microliters of antibody (anti-CD62b or PAC-1 
antibody directed against integrin αIIbβ3) was added to each tube. After a 20 minute 
incubation, the mixtures were fixed with 1 ml of 1% v/v paraformaldehyde (Electron 
Microscopy Sciences) in PBS. Samples were vortexed and analyzed with a Coulter Epics 
XL MCL flow cytometer (Beckman Coulter, Miami, FL, USA). Both PAC-1 binding 
and P-selectin expression were expressed as log mean fluorescence intensity (MFI). 
Factor X activity in sample-exposed whole blood was determined using a 
chromogenic assay (Actichrome FX, American Diagnostica Inc, Stamford, CT). After 
the 2 hour incubation, blood was removed from hydrogel laden wells and from the 
baseline polypropylene tube and centrifuged at 1500 X g for 15 minutes at 25°C. Platelet 
poor plasma was harvested for duplicate measures of Factor X activity. Fifty microliters 
of each sample and standards in duplicate were incubated in a 96 well microplate at 
37°  for   minutes. Then, 50 µl each of Russell’s Viper Venom (0.  mg ml-1 deionized 
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water) and 0.1 M calcium chloride were added to each sample. Following a 2 minute 
incubation at 37°C, 50 microliters of 5 mM Spectrozyme FXa were added, and the plate 
was incubated at 37°C for 10 minutes. The reaction was stopped by adding 50 µl of 20% 
acetic acid to each well, and absorbance was measured at 405 nm using a microwell 
plate reader. Percent Factor X activation was determined for samples and the baseline 
control relative to the included standards 
2.2.10.4 In Vivo Acute Thromboresistance All procedures were approved by the 
Institutional Animal Care and Use Committee. Multilayer grafts (3 cm in length, 4 mm 
inner diameter) were implanted in a 6 month old Yucatan miniature pig (30-40 kg) using 
a previously described technique.
183
 Briefly, anesthesia was induced by intramuscular 
injection of Telazol (5 mg/kg) and buprenorphine (0.01-0.05 mg/kg) followed by 
intubation and administration of isoflurane (2-4% MAC) in 100% oxygen for 
maintenance of a surgical plane of general anesthesia. Using sterile technique, an 8-12 
cm incision was made in the ventral midline of the neck. The carotid arteries were 
sequentially exposed and vascular clamps placed at each end of the area of interest on 
the artery to provide temporary vessel occlusion. An end-to-end anastomosis was 
performed using a continuous pattern of 7-0 prolene sutures. A multilayer graft with 
PEG-Scl2-2 (10% 3.4 kDa, 12 mg protein ml
-1
) was implanted on the left side, and a 
PEGDA (10% 3.4 kDa) control graft was implanted on the right side. After confirming 
patency and hemostasis, subcutaneous tissues and skin were closed routinely. Digital 
subtraction and 3-D angiography were performed via the transfemoral technique with 
systemic anticoagulation using heparin after placement of the sheath and maintenance of 
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activated clotting times of 2-3x baseline in order to prevent thromboembolic 
complications related to the procedure itself. After removal of the catheter and sheath, 
the animal was maintained under anesthesia for 5 hours.  The patency and anatomy of 
the grafts were assessed using vascular Doppler and two dimensional ultrasound imaging 
techniques. The study subject was then heparinized and humanely euthanized while still 
under general anesthesia. The carotid arteries were carefully removed for further 
evaluations.  
 
 
2.3 Results and Discussion 
 
2.3.1 Stability of Multilayer Graft Structure and Bioactivity Follow Vacuum 
Drying The stability of the multilayer grafts was evaluated after vacuum drying as a 
preliminary assessment of their potential for long term storage. Vacuum drying and 
reswelling had no visible effects on the interface between the luminal hydrogel layer and 
the reinforcing mesh, Figure 2.3 A-B. Furthermore, graft wall thicknesses were 
unchanged (1.96 ± 0.04 mm before drying versus 1.98 ± 0.05 mm after drying, n=6). 
The burst pressure of dried and rehydrated grafts did not statistically differ from fresh, 
swollen composites, indicating that biomechanical properties were not significantly 
affected by vacuum drying. In future evaluations, graft physical and biomechanical 
properties over time will be measured in response to varied storage conditions (i.e. 
temperature, drying/sterilization processes, time). In addition, BAOEC adhesion on 
PEG-collagen hydrogels was evaluated relative to pure PEG hydrogels after vacuum 
drying and ethylene oxide sterilization as a first step in determining potential effects of 
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the processing measures on bioactivity, Figure 2.3 C-F. There were no significant 
differences in BAOEC adhesion on either the PEG surfaces (51 ± 18 cells mm
-2
 versus 
47 ± 36 cell mm
-2
) or the PEG-collagen surfaces (122 ± 27 cells mm
-2
 versus 113 ± 23 
cell mm
-2
) before or after drying and sterilization. Additionally, qualitative analysis of 
BAOEC spreading revealed similar morphologies on the two surfaces before and after 
treatment; namely, BAOECs bound to the PEG surfaces were generally singular and 
rounded, while BAOECs bound to the PEG-collagen hydrogels were highly spread with 
extended pseudopodia. These results serve as an initial indication that the multilayer 
grafts could be stored dry and re-swollen immediately prior to implantation without 
detriment to their ability to support endothelialization. Future studies will include 
analysis of Scl2-2 degradation and retention in dried and swollen hydrogels over time 
and the corresponding effects on bioactivity and thromboresistance.  
2.3.2 Multilayer Graft Stability Following Prolonged Exposure to 
Physiological Flow Since graft stability under physiological stresses is critical to its 
bioactivity, thromboresistance, and mechanical stability, multilayer grafts were subjected 
to pulsatile flow for a period of 4 weeks. Alterations in graft architecture and/or 
mechanical properties were then examined. The conditioned grafts showed no visible 
signs of delamination between the hydrogel and mesh layers, and measurements of graft 
wall thickness before and after exposure to flow were statistically similar (2.49 ± 0.06 
mm and 2.45 ± 0.14 mm, respectively, n=6). These results indicate that grafts were not 
subject to significant degradation or erosion as a result of pulsatile flow over the selected 
time frame. Specifically, degradation of the luminal hydrogel layer would have resulted 
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in thicker walls, due to associated decreases in crosslink density that would cause 
increases in swelling.
184
 Conversely, physical erosion of the hydrogel layer due to 
pulsatile flow would have decreased the overall wall thickness. The circumferential 
modulus of multilayer constructs at physiological stresses (~190 kPa for the construct 
dimensions assuming an average luminal pressure of 100 mmHg) was statistically 
unchanged after exposure to flow (560 ± 270 kPa before flow vs. 470 ± 110 kPa after 
flow, n=6). The physical and mechanical stability of these multilayer grafts under flow is 
an important aspect in developing a biostable vascular graft, and these results serve as a 
preliminary indication of the potential for long term success of this graft design in the 
body.  
 
 
 
Figure 2.3.  Multilayer graft integrity and maintenance of bioactivity. No visible 
delamination between layers was observed (A) before or (B) after vacuum drying and 
reswelling. Similarly low levels of BAOEC adhesion and spreading were observed on 
pure PEG hydrogel (C) before and (D) after sterilization. BAOEC adhesion and 
spreading on PEG-collagen hydrogel (F) after sterilization is increased relative to pure 
PEG hydrogel, similarly to (E) unprocessed gel, indicating that sterilization process does 
not affect bioactivity. 
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2.3.3 Multilayer Graft Biomechanical Properties A functional small-caliber 
vascular graft must have suture retention strength sufficient for immediate implantation 
as well as requisite long-term burst strength. In addition, graft compliance is not only 
important in matching the physical and bulk mechanical characteristics of native arteries; 
it has a large effect on preventing reocclusion of grafts. Stewart et al. found that a 
compliance mismatch between the graft and host tissue resulted in trapped microspheres 
at the wall near graft connections under pulsatile flow in vitro. Thus, microscopic flow 
separation and stagnant zones in vasculature caused by compliance mismatches may 
contribute to intimal hyperplasia and thrombosis seen in failed synthetic grafts.
185
 Given 
the need for both appropriate compliance and sufficient strength, the ability to employ 
varied electrospinning conditions to tune graft biomechanical properties was 
investigated. By adjusting electrospinning times, the thickness of the reinforcing meshes 
can be altered over a wide range. It was observed that suture retention strength and burst 
pressure increased and compliance decreased as the thickness of the electrospun meshes 
was increased, Table 2.1.  
Over the thickness range investigated (0.21 to 1.19 mm), burst pressure increased 
163%, suture retention strength increased 327%, and compliance decreased 69%. These 
results are in agreement with the known dependence of these various material properties 
on construct dimensions. Namely, all materials have a finite stress limit (f, force/area) 
that they can sustain without failure. As mesh thickness increases, the cross sectional 
area of a sample that is strained during suture retention testing is increased, and the 
maximum force that can be sustained, or suture retention strength in this case, increases. 
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Mesh thickness has a similar effect on burst pressure of vascular grafts. For a thin walled 
tube, the stress limit (σ) of a material is defined as:  
 σ  
PD
 H
   [2.3] 
where D is diameter, H is wall thickness, and P is the maximum pressure that the wall 
can withstand, or burst pressure. Thus, as thickness increases, the burst pressure of a thin 
walled tube should increase. The effects of changing thickness on compliance can be 
determined from the definition of elastic modulus (E):  
 E  
 tress
 train
  
PD
 H
   
D0
 D
 [2.4] 
This equation can be rearranged to relate compliance measurements to elastic modulus:  
    
 D
D0
    P  
D
E
   H  [2.5] 
From this equation, it can be seen that increased mesh thickness causes decreases in 
compliance.
58
  
 
 
Table 2.1. Biomechanical properties of multilayer vascular grafts. Burst pressure, suture 
retention strength, and compliance can be tuned over a wide range by altering 
electrospun mesh thickness.  
 
 
 
The lowest suture retention strengths measured (406 ± 124 gf) exceeded reported 
values of saphenous vein grafts (196 ± 2 gf).
136
 This indicates that the multilayer grafts 
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are suitable for the implantation process. Maximum burst pressure of constructs made 
with a reinforcing BioSpan layer (1.19 ± 0.17 mm thick, n=3) was measured to be 1440 
± 40 mmHg, which approaches reported values of saphenous vein grafts (1680 ± 307 
mmHg).
128
  Finally, maximum graft compliance measured (mesh thickness = 0.21 ± 0.06 
mm) was 5.9 ± 1.4 % radial change per mmHg X 10
-2
. This falls within the previously 
reported range of compliance measured for saphenous vein grafts (4.4 ± 0.8 % per 
mmHg X 10
-2
) and improves on reported compliance values of Dacron vascular grafts 
made from PET (1.9 ± 0.3 % per mmHg X 10
-2
).
186
 These results indicate that the 
reinforcing electrospun mesh can be tuned to provide biomechanical properties 
comparable to saphenous vein grafts and that improve on the properties of current 
synthetic options.   
Although BioSpan meshes displayed properties comparable to saphenous vein 
autografts in these studies, meeting both compliance and burst pressure requirements 
with a single set of electrospinning parameters was not possible by varying mesh 
thickness alone. However, the ability to tune scaffold properties over a large range by 
simply changing mesh thickness is a powerful tool which should aid in fabricating 
improved synthetic vascular grafts. Future studies will investigate the effects of altering 
SPU chemistry to gain further control over biomechanical properties and achieve both 
desired burst pressure and compliance.   
2.3.4 Thromboresistance Assessment 
2.3.4.1 In Vitro Flow Studies To address the possibilities of graft occlusion at the 
site and downstream of the graft, both platelet adhesion and non-adherent platelet 
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activation were analyzed in these studies. The shear rate of blood flow can have 
conflicting effects on the measured blood compatibility of a surface. Increased shear 
rates cause flow separations that increase platelet activity, thereby increasing apparent 
robustness of testing; however, they can also cause dilution of activated clotting factors 
and prevent them from causing clots in vitro, resulting in falsely high blood 
compatibility.
187-188
 The PEG-Scl2-2 surface was tested under both high shear rate flows 
(parallel plate flow study) and venous-like flows (bioreactor flow study). Surface platelet 
adhesion/aggregation was first assessed under relatively short-term flow conditions by 
passing heparinized whole blood over the hydrogel surfaces using a parallel plate flow 
setup. Quantitative values of platelets adhered per square centimeter were found using 
the LDH assay, Figure 2.4A. The levels of platelet adhesion on the PEG, PEG-Scl2-1, 
and PEG-Scl2-2 hydrogels were statistically similar and were each significantly lower 
than the values for the TCPS and collagen-coated TCPS positive controls. Manual 
counting of fluorescently-labeled platelets (data not shown) confirmed these trends. 
These LDH measurements do not distinguish aggregated platelets from those that 
have simply adhered. Therefore, brightfield microscopy was utilized to qualitatively 
analyze platelet morphology and aggregation, Figure 2.4B. Platelets were generally 
singular and rounded on PEG, PEG-Scl2-1 and PEG-Scl2-2 hydrogels, indicating that 
they were unactivated or in the initial stages of activation. In contrast, TCPS and 
collagen-coated TCPS showed large aggregates of non-uniformly shaped platelets, and 
much higher numbers of platelets can be seen in each field view. The combined LDH 
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and microscopy results thus suggest that the positive controls induced not only greater 
platelet adhesion but also greater platelet activation during the two minute flow study. 
 
 
 
Figure 2.4.  Platelet adhesion and aggregation after 2 minutes of whole blood exposure 
in parallel plate flow setup. (A) Platelet levels per square cm of surface determined by 
the LDH assay. No significant differences in platelet adhesion were seen between 
hydrogel samples. All hydrogels had significantly lower adhesion levels than positive 
controls. n=3; mean ± standard deviation displayed; *p<0.05 relative to PEG hydrogel 
control. (B) Hydrogel samples had lower levels of platelet adhesion, spreading, and 
aggregation relative to TCPS and collagen-coated TCPS positive controls. Attached cells 
were fixed with 2.5% glutaraldehyde and imaged by brightfield microscopy.  
 
 
Given the short-term flow results, platelet surface adhesion and aggregation 
under the more complex conditions associated with the composite graft structure, 
physiological pressurization, and longer-term flows was assessed. Macroscopically, the 
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hydrogel-mesh multilayer grafts subjected to flow of heparinized whole blood in a 
pulsatile flow bioreactor withstood flow for the full, 6 hour time period and displayed no 
visible signs of clot formation. In contrast, the ePTFE (GORE-TEX
®
) vascular graft 
used as a clinical control in this study occluded within one hour due to thrombosis. 
These observations were confirmed microscopically, Figure 2.5. PEG, PEG-Scl2-1, and 
PEG-Scl2-2 grafts showed sparsely adhered platelets with regular rounded 
morphologies. These results indicate that PEG-Scl2 hydrogels did not induce significant 
platelet activation after longer periods of flow, further confirming the parallel plate study 
results. High levels of platelet spreading and aggregation were observed on the ePTFE 
clinical graft, suggesting significant activation of adherent platelets. This study implies 
that PEG-Scl2 hydrogels provide a surface with significantly improved 
thromboresistance over current clinical options for synthetic vascular grafts.  
 
 
 
Figure 2.5.  Platelet adhesion after 6 hours of whole blood flow through multilayer 
grafts in a pulsatile flow bioreactor. All grafts with luminal hydrogel layers remained 
patent during the testing time, while the ePTFE (GORE-TEX
®
) vascular graft occluded 
within one hour. Hydrogel samples had lower levels of platelet adhesion, spreading, and 
aggregation relative to ePTFE. Platelets were fluorescently labeled with mepacrine and 
imaged by fluorescent microscopy.  
 
 
 
2.3.4.2 In Vitro Platelet Activation Circulating platelets activated at injury sites 
can promote thrombosis and coagulation. Specifically, activated platelets can initiate an 
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acute inflammatory response through the induction of P-selectin expression in ECs, 
which in turn stimulates leukocyte activity and coagulation.
189-190
 Excessive platelet 
activation resulting in thrombotic emboli and neurologic complications has been 
observed after coronary artery bypass surgeries.
190
 Therefore, minimizing activation of 
surrounding platelets in vascular grafts is critical to their long-term success. To establish 
hemocompatibility of PEG-Scl2-2 hydrogels, it is important to analyze their potential 
effects on surrounding, non-adherent platelets. Platelet activation in whole blood in 
contact with PEG-Scl2 hydrogels for 2 hours was assessed using flow cytometry to 
determine levels of P-selectin (CD62P) surface expression and PAC-1 binding. The 
former is selectively expressed on activated platelets, and the latter measures the active 
conformation of platelet integrin αIIbβ3, which is critical for platelet aggregation. 
Furthermore, Factor Xa generation in plasma after incubation with PEG-Scl2 hydrogels 
was measured.  
Relative to the baseline, none of the hydrogel samples induced significant levels 
of PAC-1 binding or P-selectin expression in exposed blood samples, Figure 2.6A-B. In 
addition, no significant levels of Factor Xa generation were measured in the plasma from 
any hydrogel samples relative to baseline, Figure 2.6C. However, blood samples 
stimulated with 10 µM ADP displayed levels of non-adherent platelet activation 
significantly greater than the baseline. P-selectin is expressed only on the surface of 
activated cells, and its presence has been linked to development of atherosclerosis.
191
  
The PAC-1 antibody selectively binds to the activated form of the platelet glycoprotein 
(gp) IIb/IIIa complex and serves as a competitive binding inhibitor to fibrinogen. Since 
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fibrinogen binding to the activated gp IIb/IIIa complex is required for platelet 
aggregation, levels of PAC-1 binding can be correlated to numbers of activated platelets 
and indicates their potential for aggregation.
192
 Similarly, Factor Xa plays several key 
roles in coagulation.
193
 It is the primary component of the prothrombinase complex, 
which converts large amounts of prothrombin to thrombin. The burst of thrombin 
generation from Factor Xa is responsible for polymerizing fibrin into a thrombus.
193
 
Therefore, the PAC-1, P-selectin, and Factor Xa results indicate that the luminal PEG-
Scl2-2 layer of these vascular grafts will have minimal effects on surrounding, non-
adherent platelets.  When these results are combined with those from the platelet 
adhesion studies, it can be concluded that PEG-Scl2-2 hydrogels provide a 
hemocompatible surface that minimizes platelet adhesion, activation, and thrombus 
formation.   
2.3.4.3 In Vivo Acute Thromboresistance Multilayer grafts were able to hold 
sutures and retained blood flow without rupture. This indicates that their biomechanical 
properties are suitable for in vivo use. Acute (5 h) assessment with intravital imaging 
(carotid digital subtraction angiography) indicated excellent patency with no changes in 
arterial flow or narrowing of the artery. No platelet aggregates were evident in gross 
examination, Figure 2.7. Thus, multilayer grafts based on PEG-Scl2-2 hydrogels are 
resistant to acute in vivo thrombosis, and the initial in vivo characterization corroborates 
the in vitro thromboresistance study results.  
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Figure 2.6. Activation of human platelets after 2 hour incubation with PEG-Scl2 
hydrogels. Mean fluorescence intensity of (A) P-Selectin expression and (B) bound 
PAC-1. No significant increases in platelet activation relative to baseline were measured 
with either antibody for any hydrogel sample. (C) Factor Xa activity. No significant 
differences observed between baseline and samples. n=5; mean ± standard deviation 
displayed; *p<0.05 relative to baseline. 
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Figure 2.7. Multilayer vascular graft implantation. (A) Implantation into porcine carotid 
artery. In vivo acute thromboresistance was established via (B) angiography, (C) gross 
pathology, and (D) micro tomography.  
 
 
  
2.4 Conclusions 
 
 In these studies, multilayered hydrogel-electrospun mesh scaffolds were 
fabricated in which a thromboresistant PEG-Scl2-2 hydrogel layer provides a local 
microenvironment that can be designed to induce rapid endothelialization and an 
electrospun polyurethane mesh provides bulk strength, compliance matching, and suture 
retention. These studies demonstrated that the intimal PEG-Scl2-2 hydrogel does not 
promote platelet adhesion, aggregation, or activation, and thus appears to provide a 
thromboresistant intimal layer. The biomechanical properties of the multilayer graft were 
modulated by varying fabrication parameters of the electrospun polyurethane mesh to 
attain values comparable to saphenous vein autografts. Finally, the bioactivity and 
biomechanical properties of these multilayer grafts remained unchanged after vacuum 
drying and sterilization which shows promise for off-the-shelf applications.  
While these studies provide a broad, initial overview of the potential of these 
multilayer grafts to improve upon current synthetic options, extensive work remains to 
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be completed prior to their use as off-the-shelf vascular grafts. As these grafts are 
intended for long-term implantation, the chemistry of the PEG-based hydrogel must be 
altered to increase biostability, and the long-term biostability of the two layers will be 
evaluated. The potential for rapid endothelialization will be optimized to obtain EC 
adhesion levels more similar to PEG-collagen hydrogels, and alterations in bioactivity of 
PEG-Scl2-2 hydrogels over time will be determined prior to long-term in vivo analysis 
of endothelialization in a porcine animal model.  
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CHAPTER III  
DEVELOPMENT OF A BIOSTABLE REPLACEMENT FOR PEGDA 
HYDROGELS* 
 
3.1 Introduction 
 The overall goal for this work is to develop a vascular graft that is suitable for 
long-term implantation. Thus, the inner hydrogel layer must have long-term biostability. 
Although poly(ethylene glycol) diacrylate (PEGDA) hydrogels are often used as non-
degradable controls in short-term, in vitro studies, it is widely acknowledged that the 
ester linkages introduced upon acrylation of PEG diol are susceptible to slow hydrolytic 
degradation in vivo, on the order of months to years.194-199 Few reports provide 
quantification of the long-term hydrolytic degradation profile of PEGDA hydrogels, and 
most citations refer to a study with tri(ethylene glycol) diacrylate (TEGDA).
200
 The 
majority of PEGDA hydrogels used in biomedical applications are fabricated with pre-
polymers of molecular weight between 2,000 and 10,000 Da.
201-202
 Relative to these 
formulations, low molecular weight (258 Da) TEGDA has a significantly increased ratio 
of ester linkages to backbone ether groups and reduced hydrophilicity. Therefore, it is 
likely that the degradation profiles of TEGDA and PEGDA hydrogels are not 
comparable. Despite their extensive use and characterization, a full investigation of 
PEGDA hydrogel degradation is not readily available in current literature.  
*Reprinted with permission from “Development of a Biostable Replacement for PEGDA 
Hydrogels,” by MB Browning and E Cosgriff-Hernandez, Biomacromolecules 2012, 13 
(3), 779-786. Copyright (2012) American Chemical Society. 
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 Although the exact degradation rate of PEGDA hydrogels is not known, it is 
generally accepted that slow hydrolytic cleavage of the end group ester linkages renders 
it unsuitable for long-term implants. Despite their desirable biocompatibility, tunable 
properties, and unique “non-fouling” surface features, increases in swelling and 
decreases in modulus that occur with degradation would ultimately cause failure of a 
gel-based device.
203-204
 In our vascular graft design, a swelling increase would reduce the 
lumen diameter, and the resulting obstruction in blood flow could initiate thrombosis.
205-
206
 In another example, degradation of a non-fouling hydrogel coating on a glucose 
sensor could initiate a delayed host response to the sensor that would negatively affect in 
vivo sensitivity over time.207 A PEG-based hydrogel system with improved biostability 
that maintains the desirable properties of PEGDA hydrogels would be valuable in 
preventing degradation-related failures of gel-based devices. Previously, Elbert and 
Hubbell synthesized PEG diacrylamide (PEGDAA) to improve the stability of conjugate 
addition reaction bonds between bioactive peptides and PEG hydrogels by replacing the 
hydrolytically-labile esters of PEGDA with more stable amide groups.
208
 We propose 
that PEGDAA could be utilized as a biostable replacement for PEGDA. 
Although hydrolysis of the labile esters has widely been suggested as the 
mechanism PEGDA biodegradation, an alternate or possible secondary mechanism of 
degradation includes oxidation of the ether backbone.
196-197,209-210
 Despite their bioinert 
properties, PEG based devices are susceptible to a degree of non-specific protein 
adsorption after implantation, followed by macrophage recruitment, attachment, and 
activation at the implant site.
20,197
 Activated macrophages secrete cytokines, growth 
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factors, reactive oxygen species, matrix metalloproteinases, and chemotactic factors that 
propagate the foreign body reaction and cause both oxidative and hydrolytic degradation 
of biomaterials.
20,22,211
 Thus, the observed in vivo degradation of PEGDA hydrogels 
could be a result of oxidation, hydrolysis, or some combination of the two. While 
PEGDAA hydrogels do not provide increased resistance to oxidative degradation, they 
can serve as a hydrolytically stable control for in vivo degradation studies with PEGDA 
hydrogels. This provides information about the relative extents of hydrolytic and 
oxidative degradation of PEGDA and serves as a valuable tool in gaining a further 
understanding of the in vivo degradation mechanism of PEGDA hydrogels.   
 In the present study, PEGDAA was synthesized from PEG diamine as a biostable 
replacement for PEGDA. The ability to tune modulus and swelling with alterations in 
macromer molecular weight and concentration was compared between the two hydrogel 
systems. PEGDAA and PEGDA hydrogel cytocompatibility were also compared to 
evaluate their suitability for use in biomedical applications. Additionally, the innate 
resistance to cell adhesion and the ability to incorporate bioactivity into PEGDAA 
hydrogels was assessed.  Finally, degradation of the candidate gels was analyzed in vitro 
under normal and accelerated conditions to confirm the relative biostability of PEGDAA 
to PEGDA and in vivo to determine the mechanism for PEGDA biodegradation. These 
studies serve to fill a gap in the characterization of a widely utilized biomaterial system 
and assess the potential of a novel PEG-based hydrogel system as a biostable 
replacement for PEGDA hydrogels in long-term, in vivo applications. 
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3.2 Materials and Methods 
 
 3.2.1 Materials All chemicals were purchased from Sigma Aldrich (St. Louis, 
MO) and used as received unless otherwise noted.  
3.2.2 Polymer Synthesis PEGDA was synthesized according to a method adapted 
from Hahn, et al., Figure 3.1A.
172
 Briefly, acryloyl chloride (4 molar equivalents) was 
added dropwise to a solution of PEG diol (3.4kDa or 10kDa; 1 molar equivalent) and 
triethylamine (TEA, 2 molar equivalents) in anhydrous dichloromethane (DCM) under 
nitrogen. The reaction was stirred for 24 hours, and the resulting solution was washed 
with 2M potassium bicarbonate (8 molar equivalents). After drying with anhydrous 
sodium sulfate, the product was precipitated in cold diethyl ether, filtered, and dried 
under vacuum. PEGDAA was prepared using a similar method to PEGDA, Figure 3.1B. 
Briefly, acryloyl chloride was added to a solution of PEG diamine (3.4kDa or 10kDa) 
and TEA in anhydrous DCM under nitrogen. The molar equivalent of PEG diamine, 
TEA, and acryloyl chloride was kept at 1:2:4. After reacting for 24 hours, the solution 
was washed with 8 molar equivalents of 2M potassium bicarbonate and dried with 
anhydrous sodium sulfate. The product was precipitated in cold diethyl ether, filtered, 
and dried under vacuum to obtain the final product.  
Fourier transform infrared (FTIR) spectroscopy and proton nuclear magnetic 
resonance (
1
H-NMR) spectroscopy were used to confirm functionalization of PEGDA 
and PEGDAA. Control and acrylated polymers were solution cast directly onto KBr 
pellets to acquire transmission FTIR spectra using a Bruker TENSOR 27 spectrometer. 
Successful acrylation of PEG diol was indicated by an ester peak at 1730 cm
-1
 in the 
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spectra. The presence of amide peaks at 1640 cm
-1
 and 1675 cm
-1
 signified successful 
acrylamidation of PEG diamine. Proton NMR spectra of control and functionalized 
polymers were recorded on Mercury 300 MHz spectrometer using a TMS/solvent signal 
as an internal reference. PEGDA:  
1
H-NMR (CDCl3): 3.6 ppm (m, -OCH2CH2-), 4.3 
ppm (t, -CH2OCO-), 6.1 ppm (dd, -CH=CH2), 5.8 and 6.4 ppm (dd, -CH=CH2). 
PEGDAA:  
1
H-NMR (CDCl3): 3.6 ppm (m, -OCH2CH2-); 6.5 ppm (s, -CH2-NH-); 6.4 
ppm (m, -CH=CH2); 5.6 and 6.1 ppm (m, -CH=CH2). 
 
 
 
Figure 3.1. PEGDA and PEGDAA synthesis routes. Synthesis of (A) PEGDA and (B) 
PEGDAA with an amide group in place of the ester linkage in PEGDA. 
 
 
 
3.2.3 Hydrogel Characterization 
3.2.3.1 Hydrogel Preparation Hydrogels were prepared by dissolving PEGDA or 
PEGDAA in deionized water. A photointiator solution (1 mg Irgacure 2959 per 0.01 ml 
70% ethanol) was added at 1 vol% of precursor solution. Solutions were pipetted 
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between 1.5 mm spaced plates and crosslinked by 6 min exposure to long wave UV light 
(Intelli Ray Shuttered UV Flood Light, Integrated Dispensing Solutions, Inc., 365 nm, 4 
mW/cm
2
).   
3.2.3.2 Hydrogel Modulus Hydrogels were swollen in deionized water for 24 
hours prior to compressive modulus measurements. Six 8-mm diameter discs were 
punched from swollen hydrogel sheets and subjected to mechanical testing using a 
dynamic mechanical analyzer (RSAIII, TA Instruments) equipped with a parallel-plate 
compression clamp. Testing was performed under unconstrained compression at room 
temperature. Dynamic strain sweeps were used to determine the linear viscoelastic range 
for each hydrogel formulation. Then, a strain within the upper end of the linear 
viscoelastic range was used in a constant strain frequency sweep. Tests were conducted 
between 0.79 and 79 Hz, and the compressive storage modulus was taken at 1.25 Hz.  
3.2.3.3 Hydrogel Swelling Ratio Six 8-mm diameter discs were punched from 
each sheet directly after polymerization and weighed (Wi). The hydrogel discs were 
swollen in deionized water for 24 hours and weighed to determine the equilibrium 
swelling mass (Ws). Then, samples were dried under vacuum for 24 hours and weighed 
to assess dry (polymer) mass (Wd). The equilibrium volumetric swelling ratio, Q, was 
calculated from the equilibrium mass swelling ratio:  
    
 s
 d
   [3.1] 
3.2.4 Cell Studies 
3.2.4.1 Cell Culture NIH/3T3 Swiss mouse fibroblasts (ATCC-CCL92) were 
used for cell culture. Cells were cultured in vitro at 37°C/5% CO2 with Dulbecco’s 
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Modified Eagle Medium (DMEM, high glucose GlutaMAX
TM
) supplemented with 10% 
heat-inactivated fetal bovine serum (FBS) and 1% Penicillin-Strepotomycin solution 
(Gibco). Cells were used between passages 6 and 8 after 3 days of culture for all studies. 
3.2.4.2 Cytocompatibility To evaluate hydrogel cytocompatibility, an indirect 
contact method was adapted from Trudel et al.
212
 Briefly, hydrogel solutions (10 wt%, 
10kDa) were first sterile filtered with cellulose acetate syringe filters (0.2 µm pore size, 
VWR), and then 75 µl was pipetted into Transwell
©
 inserts (Costar Corporation, 6.5 
mm, 3 µm pore size poly(carbonate) membrane filter) and crosslinked in a laminar flow 
hood as described in Section 2.3.1. Sterile phosphate buffered saline (PBS) was added to 
lower wells, and hydrogels were swollen in the plate overnight at 37°C/5% CO2. Wells 
with empty inserts served as controls. After swelling, the PBS was removed, and 
fibroblasts were seeded with 235 µl of culture media in the lower tissue culture 
poly(styrene) (TCPS) wells at 5,000 cells cm
-1
 using the pipette tip access ports of the 
Transwell
©
 plate. After 24 and 72 hours of incubation, cell viability was determined 
using a Live/Dead Viability/Cytotoxicity Kit (Molecular Probes). Stained samples were 
examined at 10X magnification via fluorescence microscopy (Nikon Eclipse TE2000-S) 
to visualize viable (fluorescein filter set) and non-viable (rhodamine filter set) cells. Five 
field views were randomly assessed per specimen, with 3 specimens per sample. Percent 
cell viability was reported as the ratio of live cells to total cells in each field view.  
3.2.4.3 Cell Adhesion and Spreading To evaluate the ability to incorporate 
bioactivity into PEGDAA hydrogels, PEG-collagen gels were fabricated and seeded with 
cells. Rat tail collagen type I was functionalized with photoreactive crosslink sites 
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through the established NHS-lysine Ɛ-amino group reaction according to a protocol 
adapted from Sebra et al.
171
 Briefly, the protein was reacted with acrylate-PEG-N-
hydroxysuccinimide (Acr-PEG-NHS, MW 3500, Jenkem Technologies USA, Allen, 
TX) in 50 mM sodium bicarbonate buffer (pH 8.5). The molar ratio of Acr-PEG-
NHS:NH2 was 2:1, and the reaction was allowed to proceed with stirring for 24 hours at 
room temperature. Dialysis against 0.1M hydrochloric acid for 24 hours was used to 
neutralize the basic reaction solution, and excess Acr-PEG-NHS and other reaction 
byproducts were removed via dialysis against deionized water for 24 hours (Thermo-
Fisher Scientific, Slide-A-Lyzer dialysis cassettes, 20,000 MWCO). Functionalization of 
the modified proteins was confirmed with FTIR spectroscopy. FTIR absorbance peaks 
assigned to the protein (C=O of amide) at 1650 cm
-1
 and to PEG (C-O-C of ether) at 
1110 cm
-1
 were present in the purified product, indicating successful functionalization of 
collagen. 
Functionalized collagen was dissolved at 3 mg protein ml
-1
 in 10 wt% PEGDA 
and PEGDAA (10kDa) solutions, and hydrogels were crosslinked between 0.75 mm 
spaced plates as described in Section 2.3.1. Control hydrogels were prepared without 
functionalized collagen. After swelling in sterile PBS overnight, four 12 mm diameter 
punches were taken from each hydrogel, and fibroblasts were seeded onto specimens at 
5000 cell cm
-1
. After a 4 hour incubation at 37°C/5% CO2, cells were fixed with 3.7% 
glutaraldehyde (Invitrogen) and stained with rhodamine phalloidin (F-actin/cytoplasm, 
Invitrogen) and SYBRGreen (DNA/nucleus, Invitrogen). Representative images were 
obtained with a Nikon Eclipse TE2000-S with 5 field views per specimen and 3 
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specimens per hydrogel formulation. The number of cell nuclei per image was used as a 
quantitative assessment of cell adhesion on each test surface and was counted using the 
SYBRGreen stained images. Average cell spreading, or cell area, was quantified by 
applying the Photoshop “magic wand” tool to the image background of the rhodamine 
phalloidin stained images and adjusting the tool tolerance so that all extracellular regions 
were selected. The histogram function was then utilized to evaluate the extracellular 
pixels (PEx). The average pixels per cell (Acell) for that image was then quantified as 
follows:  
 Acell  
PT- PEx
 
  [3.2] 
where PT represents total image pixels and N is total cell nuclei. Pixels were then 
converted to microns using known objective scaling. 
3.2.5 Hydrogel In Vitro Degradation To compare the degradation profile of 
PEGDAA to PEGDA, twelve 8 mm diameter punches were taken from each hydrogel 
formulation and incubated in either PB  (pH≈7.5), 0.1M sodium hydroxide (NaOH, 
pH≈13.0), or 20% hydrogen peroxide (H2O2) with 0.1M cobalt chloride (CoCl2) with 
shaking at 37°C. For degradation analysis in PBS, masses of swollen hydrogel punches 
were measured weekly and solutions were changed twice a week for 6 weeks. Hydrogels 
were incubated in 0.1M NaOH to evaluate degradation under accelerated hydrolytic 
conditions. PEGDA hydrogel punches were weighed every 3 hours and the 0.1M NaOH 
solution was changed every 6 hours until total dissolution occurred. PEGDAA hydrogels 
were weighed daily for the first week with solution changes each day, then weighed 
weekly with bi-weekly solution changes for an additional 5 weeks. Accelerated 
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oxidative degradation was carried out in 20% H2O2 with 0.1M CoCl2, during which 
samples were weighed daily until complete dissolution occurred. For all degradation 
studies, swelling ratio was calculated at each time point relative to initial dry (polymer) 
mass to evaluate decreases in crosslink density that occurred with degradation. 
Measurements were normalized to the swelling ratio at time 0. 
3.2.6 Hydrogel In Vivo Degradation All procedures were approved by the 
Institutional Animal Care and Use Committee. Hydrogels (10%, 10 kDa) were 
crosslinked under sterile conditions between 1.5 mm spaced plates. Specimens (2 mm by 
12 mm) were cut and enclosed in cylindrical stainless steel mesh cages (1.5 mm length, 
3 mm diameter). Three month old female Sprague Dawley rats were anesthetized before 
and during the procedure with 2% isoflurane. Their sides were shaved, and incision sites 
were scrubbed with chlorhexidine. Incisions (approximate 1 cm long) were made on the 
side of the rats, and blunt dissection was used to prepare implant pockets (2 per side). 
Specimens were introduced through the incision and positioned within the pocket away 
from the incision site. The incisions were then closed with stainless steel surgical wound 
clips. Clips were removed 7 days post-implantation. After 28 days, rats were euthanized 
with carbon dioxide inhalation. A subsequent bilateral thoracotomy was performed to 
ensure death. Implants were removed, and hydrogel specimens were removed from the 
stainless steel cages. Swelling ratio and modulus of explants was measured as a 
determination of the extent of degradation.  
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3.2.7 Statistical Analysis All the data were expressed as the mean ± standard 
derivation of the mean. Statistical analysis was performed by one-way analysis of 
variance and Tukey’s post hoc test.  tatistical significance was accepted at p<0.05. 
 
 
3.3 Results and Discussion 
3.3.1 Polymer Synthesis and Gel Formation Similar acrylation procedures were 
employed to generate PEGDA from PEG diol and PEGDAA from PEG diamine. 
Following purification, polymer structures were confirmed with FTIR and 
1
H NMR 
spectroscopy. The presence of ester peaks at 1730 cm
-1
 in the FTIR spectra of PEGDA 
indicated successful acrylation of PEG diol. Similarly, new amide peaks at 1640 cm
-1
 
and 1675 cm
-1
 verified acrylamidation of PEG diamine, Figure 3.2. The absence of ester 
peaks in the PEGDAA spectra confirmed that there were no hydrolytically-labile esters 
in the amide-based formulations. The integration ratio of acryloyl protons to backbone 
methyl protons in the 
1
H NMR spectra confirmed the structures of PEGDA and 
PEGDAA as polyethers with acrylate and acrylamide endgroups, respectively, Figure 
3.3. Greater than 90% conversions of hydroxyl to acrylate endgroups and amine to 
acrylamide endgroups were observed for all candidate macromers. Following 
characterization, PEGDA and PEGDAA were crosslinked into a hydrogel network using 
the same photoinitiator type and concentration (0.1 wt% of Irgacure 2959) and UV light 
intensity and exposure time (6 min of 4 mW/cm
2
). This indicates that PEGDAA 
hydrogels could potentially be polymerized in situ in direct contact with cells or as cell 
carriers in a similar manner to PEGDA hydrogels that are currently in use.
209,213-216  
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Figure 3.2. FTIR spectra of PEG(10K) DA synthesized from PEG(10K) diol and 
PEG(10K) DAA synthesized from PEG(10K) diamine.  
 
 
 
 
 
Figure 3.3. NMR spectra of (A) PEGDA and (B) PEGDAA. 
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3.3.2 Hydrogel Characterization Modulus and swelling ratios of PEGDAA and 
PEGDA hydrogels were measured for varied macromer molecular weights (3.4kDa and 
10kDa) and concentrations (10 and 20 wt%) to evaluate the ability to tune scaffold 
properties. PEGDAA and PEGDA hydrogels exhibited similar changes in gel properties 
with compositional changes, Figure 3.4. Specifically, a decrease in molecular weight 
from 10kDa to 3.4kDa resulted in modulus increases for both PEGDAA and PEGDA 
gels (approximately 45% increases for 10% gels and 80% increases for 20% gels). An 
increase in polymer concentration from 10 to 20 wt%, resulted in a 65% increase in 
modulus of PEG(3.4k) hydrogels and 20% increase in modulus of PEG(10k) hydrogels. 
Hydrogel swelling ratios were also tuned over a wide range with changes in macromer 
molecular weight and concentration. PEGDAA and PEGDA hydrogels at 10% 
concentration exhibited swelling decreases of approximately 25% in response to a 
molecular weight decrease from 10 kDa to 3.4 kDa. Similarly, 20% PEGDAA and 
PEGDA hydrogels had roughly 30% decreases in swelling with decreased molecular 
weight. An increase in concentration from 10 to 20% caused a 20% decrease in swelling 
for both PEG(3.4k)DAA and PEG(3.4k)DA hydrogels and a 25% swelling decrease for 
PEG(10k)DAA and PEG(10k)DA hydrogels. 
The tunability of PEG hydrogel modulus and swelling over a wide range with 
simple formulation changes is critical to their utility in a wide array of 
applications.
195,209,217-218
 PEGDAA hydrogel properties can be tuned over a similar range 
and to comparable degrees as PEGDA hydrogels. This suggests the potential to 
rationally design PEGDAA hydrogels to meet specific application needs by utilizing the 
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properties of PEGDA hydrogel systems established in the literature.
166,219-220
 Thus, 
translation from PEGDA to the more biostable PEGDAA hydrogel formulation can be 
carried out without the need for significant design changes.  
 
 
Figure 3.4. Characterization of hydrogel compressive modulus and swelling ratios. (A) 
Compressive modulus and (B) swelling ratio of PEGDA and PEGDAA hydrogels. Both 
modulus and swelling ratio of PEGDAA hydrogels can be tuned similarly to PEGDA 
hydrogels by altering macromer weight (3.4k or 10k) or concentration (10 wt% or 20 
wt%). (n=6, mean ± standard deviation, *p<0.05 relative to 10% 10k gel, ¤p<0.05 
relative to 20% 10k gel, 
‡
p<0.05 relative to 10% 3.4k gel)  
 
 
 
3.3.3 Cell Studies The biocompatibility of PEGDA hydrogels is essential to their 
use in biomedical applications and any replacement system for PEGDA must retain a 
similar biocompatibility profile.
221-224
 As a first measure, a Live/Dead 
Viability/Cytotoxicity assay was performed to confirm that PEGDAA retained the 
favorable cytocompatibility of PEGDA. The low levels of protein adsorption and cell 
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adhesion on unmodified PEG hydrogels make direct cytocompatibility studies difficult 
to perform. Therefore, a Transwell system was used to investigate viability of 3T3 
mouse fibroblasts after indirect exposure to candidate hydrogels suspended in cell 
media. Both PEGDAA and PEGDA hydrogel systems had high levels of cell viability 
similar to the empty poly(carbonate) (PC) insert control after 24 and 72 hours 
(PEGDAA: 98 ± 3% and 97 ± 4%; PEGDA: 98 ± 5% and 97 ± 3%; PC: 99 ± 2% and 96 
± 4%, respectively), Figure 3.5. This serves as an initial measure of the suitability of 
PEGDAA hydrogel use in biomedical applications that currently employ PEGDA 
hydrogels.
207,225
  Additionally, Constant et al. reported that PEGDAA-based implants 
induced less inflammation and reduced fibrous encapsulation after implantation in 
rabbits for 4 weeks compared to poly(ethylene) specimens.
226
 Although these PEGDAA-
based implants were prepared using a different method and formulation, the results from 
these studies further indicate the potential suitability of PEGDAA for in vivo 
applications.   
Intrinsic resistance to protein adsorption and cell adhesion is a valuable aspect of 
PEG-based hydrogels. Not only does it provide a non-fouling surface in vivo, it also 
permits controlled introduction of bioactivity with the addition of peptides and proteins 
into the hydrogel network.
165,227
 A biostable replacement for PEGDA hydrogels must 
provide a similarly bioinert surface that can be altered with the introduction of bioactive 
factors to allow for cell adhesion. To this end, fibroblasts were seeded on PEG hydrogels 
and on PEG-collagen hydrogels in the presence of serum proteins to assess cell adhesion 
and spreading, Figure 3.6.  
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Figure 3.5. Hydrogel cytocompatibility. (A) Live/Dead staining of 3T3 fibroblasts 
adhered to TCPS after 24 hours of indirect contact with hydrogels. (B) PEGDA and 
PEGDAA samples displayed similarly high percent viability as compared to the 
poly(carbonate) (PC) control at both 24 and 72 hours. (n=3, mean ± standard deviation, 
p>0.05 for all samples at both time points) 
 
 
PEGDAA hydrogels had low levels of cell adhesion and spreading comparable to 
PEGDA hydrogels, indicating that PEGDAA could be used as a non-fouling surface in 
place of PEGDA.
165,228-229
 Acrylate-functionalized collagen was successfully crosslinked 
into PEGDAA hydrogels, resulting in a three-fold increase in cell adhesion and two-fold 
increase in spreading relative to pure PEGDAA hydrogels after three hours of culture. 
Similar increases in cell adhesion and spreading were observed on PEGDA-collagen 
hydrogels relative to PEGDA hydrogels. These studies demonstrate the ability to 
incorporate bioactivity into PEGDAA hydrogels as indicated by increased cell adhesion 
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and spreading with comparable results to those seen with PEGDA. This further validates 
the capacity to transition from PEGDA to PEGDAA with minimal changes in material 
design.
145,198,230-231
  
 
 
Figure 3.6. Cell adhesion to hydrogels. (A) Rhodamine phalloidin and SYBRGreen 
stained 3T3 fibroblast adhesion on hydrogels after a 3 hour incubation period. Increases 
in (B) adhesion and (C) spreading were seen in PEG-collagen hydrogels relative to 
controls, indicating that bioactivity can be incorporated into PEGDAA hydrogels 
similarly to PEGDA hydrogels. (n=3, mean ± standard deviation, *p<0.05 compared to 
PEGDA and PEGDAA) 
 
 
3.3.4 Hydrogel In Vitro Degradation  
3.3.4.1 Hydrolytic Degradation To verify the increased hydrolytic stability of 
PEGDAA relative to PEGDA, in vitro hydrolytic degradation was analyzed over a six 
week time frame. It was hypothesized that hydrolytic cleavage of ester linkages in 
PEGDA hydrogels results in decreased crosslink density, which can be monitored with 
corresponding increases in swelling ratio.
195
 For degradation in PBS at 37°C, no 
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significant increases in swelling were observed in either hydrogel system (PEGDAA or 
PEGDA), Figure 3.7A.  
 
 
 
Figure 3.7. Hydrogel in vitro degradation in PBS and 0.1M NaOH. Changes in hydrogel 
swelling ratio as a function of incubation time in (A) PBS and (B) 0.1M NaOH at 37°C. 
No significant changes in swelling ratio were observed in PBS for the given time period 
(p>0.05 between all time points for each sample in PBS). In 0.1M NaOH, PEG(3.4k)DA 
hydrogels completely dissolved within 72 to 80 hours, and PEG(10k)DA hydrogels 
completely dissolved within 30 to 36 hours. PEGDAA hydrogels remained stable in 
0.1M NaOH over 6 weeks (data beyond week 1 not shown) with minimal increases in 
swelling. (n=6, mean ± standard deviation, p<0.05 between all time points of PEGDA 
gels in 0.1M NaOH, p>0.05 between all time points shown of PEGDAA gels in 0.1M 
NaOH). 
 
 
This was expected, based on previous in vitro degradation studies in which 
PEGDA hydrogels served as biostable controls.
201
 Although the small increases in 
swelling that occurred in this study were not statistically significant, a linear regression 
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analysis of the measurements reveals a general increase in swelling over time for both 
PEGDA hydrogel formulations (0.38 mg and 0.78 mg increases in swollen mass per 
week for 3.4k and 10k hydrogels, respectively). In contrast, the same analysis of the 
PEGDAA measurements reveals minimal variations in swelling, equivalent to 0.00 mg 
and 0.03 mg respective increases in swollen mass of 3.4k and 10k hydrogels each week. 
These trends suggest that the PEGDA hydrogels were undergoing a slow rate of 
hydrolytic degradation during the time frame of the study whereas the PEGDAA 
hydrogels displayed no evidence of degradation.  
 An accelerated degradation study was carried out in 0.1M NaOH at 37°C to 
substantiate these results and predict longer implantation times, Figure 3.7B. Under 
accelerated hydrolytic conditions, PEG(3.4k)DA hydrogels experienced a loss in 
mechanical integrity in 50 to 56 hours and underwent complete dissolution in 72 to 80 
hours. As expected, given the lower crosslink density, PEG(10k)DA hydrogels degraded 
at a faster rate with a loss in integrity in 15 to 18 hours and full dissolution in 30-36 
hours. In contrast, both molecular weights of PEGDAA remained intact with no 
significant changes in swelling for one week. This confirms the significantly increased 
hydrolytic stability of PEGDAA relative to PEGDA due to elimination of ester linkages 
in the endgroups.
232
 To further characterize the PEGDAA hydrogels, accelerated 
degradation was carried out to six weeks, during which they continued to remain stable 
with small increases in swelling. Thus, the amide-based PEGDAA hydrogels have 
significantly improved hydrolytic stability relative to PEGDA hydrogels.  
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3.3.4.2 Oxidative Degradation The utility of in vitro accelerated degradation 
testing to predict long-term in vivo behavior is contingent on identifying all potential 
mechanisms of biodegradation. Thus, accelerated oxidative degradation was carried out 
in vitro using a solution of 20% H2O2/0.1M CoCl2 to compare susceptibility to oxidation 
of PEGDA and PEGDAA. Both systems had similar degradation profiles in the 
accelerated solution, indicating that PEGDAA undergoes oxidation similarly to PEGDA, 
Figure 3.8. This was expected, as oxidation affects the ether backbone of PEG, which is 
constant between the two systems. Additionally, the 3.4 kDa gels had higher oxidative 
stability relative to the 10 kDa gels, similarly to the PEGDA gels in the accelerated 
hydrolytic study.  
 
 
Figure 3.8. Accelerated oxidative degradation in 20% H2O2/0.1M CoCl2 of 20% 
PEG(3.4k) and PEG(10k) DA and DAA gels at 37C. PEG(3.4k) gels underwent 
complete dissolution within 13 days, while PEG(10k) gels underwent complete 
dissolution within 84 hours. (n=6, mean ± standard deviation, p<0.05 between all time 
points). 
 
 
 
3.3.4.3 In Vivo Degradation Upon confirmation that PEGDAA gels have 
enhanced hydrolytic stability and similar susceptibility to oxidation as PEGDA gels, the 
two systems were utilized in an in vivo degradation study. After four weeks of 
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subcutaneous implantation enclosed in stainless steel mesh cages, samples were 
explanted. Swelling ratio and compressive modulus of explanted samples were measured 
and compared to their initial properties and to those of samples that had been incubated 
in PBS at 37C for four weeks, Figure 3.9. PEGDA gels had significant increases in 
swelling and decreases in modulus after both in vitro and in vivo incubation, while 
PEGDAA gels had no changes in either swelling or modulus in vitro or in vivo. Slightly 
higher changes in PEGDA swelling and modulus indicated increased degradation in vivo 
and can be attributed to accelerated degradation that occurs with the in vivo host 
response. It has previously been shown that PEG hydrogels promote macrophage 
attachment and activation both in vitro and in vivo.197 Upon activation, macrophages 
secrete degradative agents, including acids, cytokines, growth factors, reactive oxygen 
species, matrix metalloproteinases, and chemotactic factors.
20,22,211
  The reactive oxygen 
species can accelerate oxidative degradation, whereas a reduced pH from lysosomal 
acids can accelerate hydrolytic degradation.
211
 The results from this study serve as an 
initial indication that hydrolysis of endgroup esters has a greater effect on PEGDA 
hydrogel in vivo degradation than oxidation of backbone ethers, as the oxidatively-labile 
PEGDAA hydrogels remained stable. Future studies will evaluate these systems over 12 
weeks to obtain a better indication of the relative extents of PEGDA hydrolytic and 
oxidative degradation in vivo. This work represents the first use of a suitable control for 
determination of the mechanism of PEGDA hydrogel degradation in vivo and the first 
indication of hydrolysis having a greater effect than oxidation in the short term. 
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Figure 3.9. Hydrogel in vivo degradation. Swelling ratio and modulus measurements of 
10% PEG(10k)DA and DAA gels after 4 weeks in PBS at 37C and after 4 weeks in vivo 
enclosed in stainless steel mesh cages implanted subcutaneously into rats. PEGDA gels 
had significant increases in swelling and significant decreases in modulus over 4 weeks 
in vitro and in vivo. PEGDAA gels remained stable both in vitro and in vivo with no 
changes in modulus or swelling. (n=10, mean ± standard deviation, *p<0.05 relative to 
control). 
 
 
 
3.4 Conclusions 
 
 The aim of this study was to develop a biostable replacement for traditional 
PEGDA hydrogels by synthesizing amide-based PEGDAA and to utilize PEGDAA to 
determine the relative extents of PEGDA hydrolytic and oxidative degradation in vivo. 
The range of PEGDAA hydrogel modulus and swelling that resulted from changes in 
macromer molecular weight or concentration was similar to that of PEGDA hydrogels. 
Therefore, the established properties of PEGDA hydrogel systems can be readily 
transferred to the design of replacement PEGDAA hydrogels. Results also indicated that 
PEGDAA hydrogels were cytocompatible and retained the low cell adhesion of PEGDA 
hydrogels. The ability to impart bioactivity as indicated by increased cell adhesion and 
spreading was demonstrated by conjugating collagen into the PEGDAA matrix. 
Accelerated hydrolytic degradation studies revealed significantly increased hydrolytic 
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stability of PEGDAA relative to PEGDA, and provided a well-defined in vitro 
degradation profile for PEGDA hydrogels. Accelerated oxidative degradation studies 
confirmed that the two systems have comparable susceptibility to oxidation, whereas in 
vivo degradation studies indicated that PEGDAA has increased biostability. Thus, it is 
likely that PEGDA hydrogels are more susceptible to hydrolytic degradation in vivo. 
These results indicate that PEGDAA could be used as a biostable replacement for 
PEGDA with minimal design changes to provide a gel-based device with similar 
properties and cell-material interactions. As such, PEGDAA has the potential to reduce 
degradation-related failure in long-term in vivo applications, such as is required for our 
vascular graft.  
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CHAPTER IV  
MANIPULATION OF PROTEIN AND NETWORK VARIABLES TO ENHANCE 
INITIAL AND SUSTAINED EC ADHESION* 
 
4.1 Introduction 
Although PEG-Scl2-2 hydrogels appear to provide immediate thromboresistance, 
longer-term hemocompatibility will depend on the establishment of a confluent 
endothelial cell (EC) layer on the graft luminal surface. Many graft designs successfully 
grow confluent EC monolayers in vitro, but much of this layer can be lost upon exposure 
to physiological shear stresses.
127
  Thus, the potential for a vascular graft to rapidly form 
a stable endothelium in vivo is important in preventing thrombosis and improving on 
current options. In short, PEG-Scl2-2 hydrogels must be able to promote EC adhesion, 
spreading, and migration. We have previously demonstrated the capability of PEG-Scl2-
2 hydrogels to promote EC adhesion and spreading; however, PEG-collagen hydrogels 
consistently provide enhanced EC adhesion and spreading relative to PEG-Scl2-2 
hydrogels.
164
 Thus, the focus of this work is on utilizing the exceptional tunability of 
PEG-Scl2-2 hydrogels to further improve EC interactions through the use of the protein 
functionalization process.  
While many methods exist for incorporation of bioactive agents into hydrogels, 
*Reprinted with permission from “Bioactive hydrogels with enhanced initial and 
sustained cell interactions,” by MB Browning, B Russell, J Rivera, M Höök, and E 
Cosgriff-Hernandez, Biomacromolecules. 2013, Accepted. Copyright (2013) American 
Chemical Society. 
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covalent attachment generally provides greater stability and control over biomolecule 
presentation and release.
233-234
 Many growth factors and proteins contain lysines in their 
backbones that provide a primary amine for functionalization, including both collagen 
and Scl2-2. Thus, the NHS-lysine Ɛ-amino group reaction can be utilized to 
functionalize a wide range of bioactive agents with crosslinkable acrylate groups using 
Acr-PEG-NHS.
171,221,235
 Following functionalization, Scl2-2 can be immobilized in PEG 
hydrogels during photopolymerization without detriment to bioactivity.
164
 This method 
has been successfully utilized in a number of applications to provide scaffolds that 
deliver specific bioactive cues for tissue regeneration and healing.
164,231,236-237
  
Functionalization of therapeutic proteins with PEG linkers can also be used in drug 
delivery systems to increase circulation times.
238
  
The PEG linkers on functionalized proteins serve to covalently stabilize them 
into synthetic networks; however, they can also introduce steric hindrance around 
integrin binding sites on proteins and interfere with cell-protein interactions, Figure 
4.1.
239-240
 In proteins and growth factors with multiple amine functionalization sites, the 
density of Acr-PEG-NHS can be easily varied in the traditional functionalization scheme 
to provide bioactive factors with a range of functionalization densities. A protein that is 
functionalized with fewer linkers could potentially have improved cell interactions 
through allowing increased access to integrin binding sites, Figure 4.1. However, Van 
Den Bulcke et al. demonstrated that gelatin hydrogels with lower functionalization levels 
had decreased moduli compared to those with higher functionalization levels. This 
indicates that a reduction in crosslinking occurs as protein functionalization density is 
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decreased due to reduced crosslinking sites on the protein.
241
 From these findings, one 
can also assume that lowering the functionalization density would decrease initial 
incorporation and retention of proteins in a bioactive hydrogel network. Thus, there is an 
evident trade-off between reduced steric interactions that promote enhanced initial cell 
interactions and sufficient protein retention to support sustained cell interactions. These 
are both critical factors in the development of our vascular graft, as in vivo 
endothelialization can occur very slowly, and sustained bioactivity is desired throughout 
this process. However, the effect of functionalization density on both initial cell 
interactions and protein retention over time is poorly characterized in current literature.  
 
 
Figure 4.1. Schematic representation of hypothesized effects of protein functionalization 
density on integrin binding. A decreased number of PEG linkers on the protein backbone 
(low functionalization density) could reduce steric blocking and improve integrin 
binding to functionalized proteins. 
 
 
 In the present studies, we investigated the impact of reducing Acr-PEG-NHS 
functionalization density on EC adhesion and protein maintenance over time in both 
PEG-collagen and PEG-Scl2-2 hydrogel systems. Additionally, hydrolytic stability of 
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the PEG matrix and the protein linker was enhanced in an effort to improve protein 
retention, Figure 4.2. The resulting protein levels in the hydrogel matrix and the 
corollary effects on bioactivity were analyzed over a swelling time frame of 6 weeks to 
determine a functionalization scheme that increases initial and sustained cell-material 
interactions.
242
  
 
 
Figure 4.2. Comparison of network macromers and PEG functionalization linkers used 
to tune retention of collagen and Scl2-2. Ester linkages in PEGDA and Acr-PEG-NHS 
(red) were replaced with amides in PEGDAA and Aam-PEG-I (blue) to increase 
hydrolytic stability.  
 
 
4.2 Materials and Methods 
4.2.1 Materials All chemicals and materials were purchased from Sigma Aldrich 
(St. Louis, MO) and used as received unless otherwise noted. Acr-PEG-NHS (3.5 kDa) 
and PEG diamine (3.4 kDa) were purchased from Jenkem Technology USA (Allen, TX).  
4.2.2 Synthesis of PEGDA and PEGDAA Poly(ethylene glycol) diacrylate 
(PEGDA) was synthesized as previously described.
172
 Briefly, acryloyl chloride was 
added dropwise to a solution of PEG (3.4 kDa) diol and triethylamine (TEA) in 
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anhydrous dichloromethane (DCM) under nitrogen. The molar ratios of PEG diol, TEA, 
and acryloyl chloride were 1:2:4, respectively. After 24 hours of stirring, the reaction 
solution was washed with 8 molar equivalents of 2M potassium bicarbonate and dried 
with anhydrous sodium sulfate. The final product was precipitated in cold diethyl ether, 
filtered, and dried under vacuum.  
PEG diacrylamide (PEGDAA) was prepared as previously described in a similar 
method to PEGDA.
242
 Briefly, acryloyl chloride (4 molar equivalents) was added 
dropwise to a solution of PEG (3.4 kDa) diamine (1 molar equivalent) and TEA (2 molar 
equivalents) in anhydrous DCM under nitrogen. The reaction was allowed to proceed for 
24 hours, and then it was washed with 2M potassium bicarbonate (8 molar equivalents). 
Following drying with anhydrous sodium sulfate, the product was precipitated in cold 
diethyl ether, filtered, and dried under vacuum.  
Successful synthesis of PEGDA and PEGDAA was confirmed with Fourier 
transform infrared (FTIR) and proton nuclear magnetic resonance (
1
H-NMR) 
spectroscopy. A Bruker TENSOR 27 spectrometer was used to obtain transmission FTIR 
spectra of control and functionalized polymers that were solution cast onto KBr pellets. 
Successful acrylation of PEG diol was indicated by the introduction of an ester peak at 
1730 cm
-1
 and loss of the hydroxyl peak at 3300 cm
-1
. The introduction of amide peaks 
at 1640 cm
-1
 and 1675 cm
-1
 indicated successful acrylamidation of PEG diamine. A 
Mercury 300 MHz spectrometer with a TMS/solvent signal as an internal reference was 
utilized to obtain 
1
H-NMR spectra of control and functionalized polymers. Greater than 
90% conversions of hydroxyl to acrylate endgroups and amine to acrylamide endgroups 
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were observed for all candidate macromers. PEGDA:  
1
H-NMR (CDCl3): 3.6 ppm (m, -
OCH2CH2-), 4.3 ppm (t, -CH2OCO-), 6.1 ppm (dd, -CH=CH2), 5.8 and 6.4 ppm (dd, -
CH=CH2). PEGDAA:  
1
H-NMR (CDCl3): 3.6 ppm (m, -OCH2CH2-); 6.5 ppm (s, -CH2-
NH-); 6.4 ppm (m, -CH=CH2); 5.6 and 6.1 ppm (m, -CH=CH2). 
4.2.3 Protein Functionalization with Acrylate-PEG-N-Hydroxysuccinimide The 
Scl2.28 sequence was amplified and purified as previously described.
161
 Scl2-2 was 
modified from Scl2-1 through the introduction of the GFPGER sequence during site 
directed mutagenesis as previously described.
161
 Scl2-2 and non-gelling rat tail collagen 
type I were functionalized with photoreactive crosslink sites according to a previously 
described protocol.
171
 The backbones of both Scl2-2 and collagen type I contain ~33 
lysines that can be utilized in the established NHS-lysine Ɛ-amino group reaction to 
allow for bioconjugation. The proteins were reacted with Acr-PEG-NHS (MW 3500) in 
50 mM sodium bicarbonate buffer (pH 8.5) for 24 hours at room temperature. The molar 
ratio of Acr-PEG-NHS:NH2 was varied from 0.1:1 to 1:1 to provide proteins with varied 
functionalization densities (0.1X, 0.5X, and 1X). Dialysis against 0.1M hydrochloric 
acid was carried out for 24 hours to remove basic byproducts, and additional purification 
was completed by dialysis against reverse osmosis (RO) water for 24 hours (MWCO = 
20,000 Da). Following lyophilization of purified products, FTIR spectroscopy was 
utilized as described above to confirm functionalization of modified proteins with varied 
PEG-linker densities.  
4.2.4 Synthesis of Acrylamide-PEG-Isocyanate Linker A solution of PEG (3.4 
kDa) diamine in anhydrous DCM was added dropwise to hexane diisocyanate under 
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nitrogen at a 1:2 molar equivalent to synthesize PEG diisocyanate (PEGDI). The 
reaction was allowed to proceed with stirring for 2 hours. Upon completion of the 
PEGDI synthesis, a solution with 1 molar equivalent of aminoethyl acrylamide 
(Enamine, Kiev, Ukraine) in dimethyl sulfoxide was added dropwise to the reaction 
solution while stirring under nitrogen. After 2 hours, the final product was precipitated in 
cold diethyl ether, filtered, and dried under vacuum. Successful synthesis of PEGDI and 
Aam-PEG-I was confirmed with FTIR spectroscopy in a method like that described 
above. Aam-PEG-I structure was confirmed with 
1
H-NMR spectroscopy as described 
above. Aam-PEG-I:  
1
H-NMR (CDCl3): 3.6 ppm (m, -OCH2CH2-), 3.3 ppm (m, -
NHCH2CH2NH-), 1.4 and 3.1 ppm (m, -NH[CH2]6N-), 5.1-5.4 and 7.3 ppm (s, -NH-), 
6.1 ppm (dd, -CH=CH2), 5.8 and 6.2 ppm (dd, -CH=CH2). 
4.2.5 Protein Functionalization with Acrylamide-PEG-Isocyanate Scl2-2 and 
rat tail collagen type I were functionalized with Aam-PEG-I in a method that was 
modified from that described above. Briefly, Aam-PEG-I was dissolved in anhydrous 
dimethylformamide and added dropwise to protein solutions in phosphate buffered 
saline (PBS) at room temperature. The molar ratio of Aam-PEG-I:NH2 was either 0.1:1 
or 1:1 to provide proteins with low and high functionalization densities, respectively. 
After 2 hours of stirring, dialysis against RO water for 24 hours (MWCO = 20,000 Da) 
was used to purify functionalized proteins. FTIR spectroscopy confirmed 
functionalization of proteins with low and high Aam-PEG-I densities. 
4.2.6 Preparation and Characterization of Bioactive PEG Hydrogels PEG, 
PEG-Scl2-2, and PEG-collagen hydrogels were prepared by dissolving PEG (3.4 kDa) 
 87 
 
DA or PEG (3.4 kDa) DAA (10 wt%) and functionalized Scl2-2 or collagen (4 mg ml
-1
) 
in 20 mM acetic acid. A photoinitiator solution (1 mg Irgacure 2959 per 0.01 ml 70% 
ethanol) was added at 1 vol% of precursor solution. Solutions were pipetted between 
0.5-1.5 mm spaced plates or into microcentrifuge tubes and crosslinked by 6 min 
exposure to long wave UV light (Intelli Ray Shuttered UV Flood Light, Integrated 
Dispensing Solutions, Inc., 365 nm, 4 mW/cm
2
).   
To measure compressive modulus, six 8-mm diameter discs were punched from 
hydrogel sheets (1.5 mm thick) and swollen in RO water overnight. Samples were 
subjected to mechanical testing using a dynamic mechanical analyzer (RSAIII, TA 
Instruments) equipped with a parallel-plate compression clamp. Testing was performed 
under unconstrained compression at room temperature. Dynamic strain sweeps were 
used to determine the linear viscoelastic range for each hydrogel formulation. A strain 
within the upper region of the linear viscoelastic range was used in a constant strain 
frequency sweep. Tests were conducted between 0.79 and 79 Hz, and the compressive 
storage modulus was taken at 1.25 Hz.  
For swelling assessments, six 8-mm diameter discs were punched from hydrogel 
sheets (1.5 mm thick) directly after polymerization. The hydrogel discs were swollen in 
RO water overnight and weighed to determine the equilibrium swelling mass (Ws). 
Then, samples were dried under vacuum overnight and weighed to assess dry (polymer) 
mass (Wd). The equilibrium volumetric swelling ratio, Q, was calculated from the 
equilibrium mass swelling ratio:  
    
  
  
   [4.1] 
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4.2.7 Protein Retention in Bioactive PEGDA Hydrogels PEGDA-collagen and 
PEGDA-Scl2-2 gels were crosslinked directly into microcentrifuge tubes and swelled in 
phosphate buffered saline (PBS) at 37C with weekly solution changes. After a swelling 
time period of 1 day to 6 weeks, gels were dried under vacuum then incubated in a 
specified volume of 0.5M sodium hydroxide (NaOH) at 37C for approximately 3 hours, 
or until complete hydrolysis occurred. Protein concentration in the hydrolyzed gel 
solutions was determined with a 3-(4-carboxy-benzoyl)-2-quinoline-carboxaldehyde 
(CBQCA) protein quantification kit (Molecular Probes, Life Technologies, Grand 
Island, NY), as specified by the manufacturer. Briefly, 10 µl aliquots of each sample 
were diluted in 125 µl of 0.1M sodium borate buffer. Then, 5 µl of 5 mM potassium 
cyanide (KCN) were added to each sample, followed by an addition of 10 µl of 5 mM 
CBQCA (dissolved to 40 mM in DMSO, then diluted to 5 mM in 0.1M sodium borate 
buffer). Each sample was tested in triplicate and run against a standard of the same 
protein type and functionalization density to prevent any errors that could occur due to 
different numbers of free amines on the varied functionalization densities and/or on the 
two protein types. After 1 to 3 hours of incubation in a black 96 well plate at room 
temperature with shaking, fluorescence was read using an Infinite M200 Pro plate reader 
(Tecan Group, Inc.; emission = 550 nm, excitation = 465 nm). Standard curves of 
fluorescence versus protein concentration were generated for each protein formulation, 
and the protein concentration (C, mg/ml) in the hydrolyzed gels was determined by 
inserting the measured fluorescence into a best-fit linear equation for corresponding 
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standard curves. Protein retention in PEGDA gels at each time point (PRDA, mg/ml) was 
then calculated to be:  
PRDA      
V a H
V0
   [4.2] 
where VNaOH is the volume of the hydrolysis solution and V0 is the original gel volume 
in milliliters. Initial protein incorporation (I) was defined as the percentage of protein 
retained relative to the initial concentration (C0) after 1 day of swelling in PBS: 
 I  
PRDA
 0
   100    [4.3] 
Percent protein retention over time (% PR) was measured as the percent difference 
between the protein retained at each time point (PRn) relative to the initial protein 
incorporation concentration taken after 1 day of swelling in PBS (PR1): 
   PR  
PR1- PRn
PR1
   100  [4.4] 
4.2.8 Protein Retention in Bioactive PEGDAA Hydrogels PEGDAA-collagen 
and PEGDAA-Scl2-2 gels were prepared similarly to PEGDA gels and swelled in PBS 
at 37C for up to 6 weeks. Due to the hydrolytic stability of PEGDAA gels, protein loss 
was measured to determine protein retention. It was confirmed that the two methods 
provided similar initial protein incorporation measurements (less than 10% difference) in 
PEGDA gels. Briefly, swelling solutions were retained throughout the specified time 
period, frozen at -80C, and lyophilized to obtain the gel leachables. The lyophilized 
powders were dissolved in a known volume of PBS, and protein concentration of the 
resulting solution was determined with a CBQCA protein quantitation kit as described 
above. All samples were tested in triplicate against a standard of the same protein type 
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and functionalization density. The concentration of lost protein (CL, mg/ml) in the 
hydrolyzed gels was determined by inserting the measured fluorescence into a best-fit 
linear equation for corresponding standard curves. Protein retention (PRDAA, mg/ml) was 
then calculated as:  
PRDAA  
 0 V0-  L VPB 
V0
 [4.5] 
where C0 and V0 are the original protein concentration (mg/ml) and gel volume (ml), 
respectively, and VPBS is the volume of PBS used to dissolved the lyophilized leachables 
(ml). Initial protein incorporation (I) was measured from PRDAA according to Equation 
4.3, and percent protein retention was measured relative to the initial protein 
incorporation concentration according to Equation 4.4. 
4.2.9 Endothelial Cell Adhesion and Spreading Bovine aortic endothelial cells 
(BAOECs) were used for all cell studies. Cells were cultured in vitro at 37°C/5% CO2 
with Dulbecco’s Modified Eagle Medium (DMEM, high glucose GlutaMAXTM, 
Invitrogen) supplemented with 10% heat-inactivated fetal bovine serum (FBS, 
Invitrogen) and 1% Penicillin-Strepotomycin solution (Gibco). Cells were used between 
passages 7 and 10 after 10-14 days of culture for all studies. 
Bioactive hydrogels were crosslinked between 0.5 mm spaced plates as described 
above and swelled for 3 hours in 70% ethanol. Subsequently, gels were swelled in sterile 
PBS for approximately 6 hours with solution changes every 2 hours to remove residual 
ethanol. Then, 6 mm diameter punches were taken from each hydrogel formulation and 
discs were swelled in PBS at 37C for a specified time period (1 day to 6 weeks) with 
regular solution changes. Only bioactive hydrogel formulations with greater than 10% 
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protein retention at 6 weeks were used in 6 week bioactivity retention studies. Following 
the desired time period, BAOECs were seeded onto specimens at 10,000 cells cm
-1
 for 3 
hours at 37°C/5% CO2. Cells were then fixed with 3.7% glutaraldehyde and stained with 
rhodamine phalloidin (F-actin/cytoplasm, Invitrogen) and SYBRGreen (DNA/nucleus, 
Invitrogen). Representative images were obtained with a Nikon Eclipse TE2000-S with 
3 field views per specimen and 4 specimens per hydrogel formulation. The number 
of cell nuclei per image was used as a quantitative assessment of cell adhesion on each 
test surface and was counted using the SYBRGreen stained images. Average cell 
spreading, or cell area, was quantified by applying the Photoshop “magic wand” tool to 
the image background of the rhodamine phalloidin stained images and adjusting the tool 
tolerance so that all extracellular regions were selected. The histogram function was 
utilized to evaluate the extracellular pixels (PEx). The average pixels per cell (Acell) for 
that image was quantified as:  
Acell  
PT  PEx
 
  [4.6] 
where PT represents total image pixels and N is total number of cell nuclei. Pixels were 
then converted to microns using known objective scaling. 
4.2.10 Statistical Analysis All modulus, swelling, and protein retention data were 
expressed as the mean ± standard derivation of the mean. All cell adhesion and 
spreading data were expressed as the mean ± standard error of the mean. Statistical 
analysis was performed by an unpaired two-tailed student’s t-test. Statistical significance 
was accepted at p<0.05. 
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4.3 Results and Discussion 
 
4.3.1 Protein Functionalization with Acr-PEG-NHS Fourier transform infrared 
(FTIR) spectroscopy was utilized to confirm functionalization of collagen and Scl2-2 
with a range of Acr-PEG-NHS densities, Figure 4.3. IR absorbance peaks assigned to 
the amide of the protein (C=O) at 1650 cm
-1
 and the ether backbone of the Acr-PEG-
NHS (C-O-C) at 1110 cm
-1
 were present in the purified products. As the reaction ratios 
of Acr-PEG-NHS-to-lysine were increased from 0.1:1 to 1:1, a corollary increase in the 
relative peak height ratios of ether-to-amide was also observed. This confirmed that 
proteins with a range of functionalization levels were synthesized. Additionally, relative 
peak ratios of different batches of functionalized proteins remained constant, indicating 
that similar functionalization levels were achieved between batches. For these studies, 
collagen and Scl2-2 were functionalized with 0.1:1, 0.5:1, and 1:1 molar ratios of Acr-
PEG-NHS-to-lysine to yield 0.1X, 0.5X, and 1X functionalization densities, 
respectively.   
4.3.2 Protein Functionalization with Acrylamide-PEG-Isocyanate Linker 
Acrylamide-PEG-isocyanate (Aam-PEG-I) was synthesized in which the hydrolyzable 
acrylate group of Acr-PEG-NHS was replaced with a biostable acrylamide group, 
Figure 4.1. FTIR spectroscopy was used to confirm key structural features during the 
two-step reaction of Aam-PEG-I, Figure 4.4A. First, isocyanate endcapping of PEG 
diamine was indicated by the introduction of an isocyanate peak at 2250 cm
-1
 and urea 
peaks at 1560 and 1650 cm
-1
. In the second step, relative decreases in the isocyanate 
peak and increases in the urea peaks confirmed successful formation of the Aam-PEG-I 
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linker. The integration ratio of acryloyl protons to backbone methyl protons and 
presence of HDI methyl protons in the 
1
H NMR spectra confirmed the structure and final 
average molecular weight of Aam-PEG-I, Figure 4.4B. Endgroup conversion ratios of 
greater than 80% and final molecular weights between 3800 and 4200 Da were observed 
for all candidate linkers, indicating that minimal coupling occurred during the synthesis.  
 
 
Figure 4.3.  Transmission FTIR spectra of functionalized proteins. (A) Collagen and (B) 
Scl2-2. Ratio of 1110 cm
-1
 (ether of PEG) to 1650 cm
-1
 (amide of protein) peaks 
decreases with decreasing functionalization density. 
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Figure 4.4. Confirmation of acrylamide-PEG-isocyanate synthesis and functionalization. 
(A) Transmission FTIR spectra of PEG (3.4 kDa) diisocyanate (PEGDI) synthesized 
from PEG (3.4 kDa) diamine and acrylamide-PEG (3.4 kDa)-isocyanate (Aam-PEG-I) 
synthesized from the resulting PEGDI. (B) 
1
H NMR spectra of Aam-PEG-I. (C) 
Transmission FTIR spectra of Aam-PEG-I-functionalized collagen and Scl2-2. Ratio of 
1110 cm
-1
 (ether) to 1650 cm
-1
 (amide) peaks decreases with decreasing 
functionalization density. 
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The final product was utilized to functionalize collagen and Scl2-2 with low 
(0.1X) and high (1X) functionalization densities. IR absorbance peak ratios of the ether 
of the Aam-PEG-I (1110 cm
-1
) were decreased relative to the amide of the proteins 
(1650 cm
-1
) as functionalization density was decreased, Figure 4.4C. Relative peak 
ratios were constant between different batches of Aam-PEG-I functionalized proteins, 
indicating that consistent levels of functionalization were achieved.  This data confirmed 
that Aam-PEG-I can be used to functionalize proteins with varied functionalization 
densities similarly to the traditional Acr-PEG-NHS linker.  
4.3.3 Bioactive Hydrogel Modulus and Swelling Ratio To confirm that protein 
functionalization density and linker type do not alter bulk network properties, 10% PEG 
(3.4 kDa) DAA gels were prepared with Acr-PEG-NHS- and Aam-PEG-I-functionalized 
collagen at high (1X) and low (0.1X) functionalization densities, and compressive 
modulus and swelling ratio were measured relative to 10% PEG (3.4 kDa) DAA gel 
controls. No significant differences in modulus or swelling were observed for any of the 
tested formulations, Figure 4.5. This was expected, as the protein component comprises 
less than 1% of the network, and properties should be dominated by the synthetic PEG 
matrix. Our previous studies have demonstrated similarly negligible effects from adding 
functionalized Scl2-2 into PEG-based hydrogel scaffolds.
164
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Figure 4.5. Bioactive hydrogel compressive modulus and swelling ratio. 10% PEG (3.4 
kDa) DAA gels with no protein (Control), Acr-PEG-NHS-functionalized collagen at 
high (1X Acr) and low (0.1X Acr) functionalization densities, and Aam-PEG-I-
functionalized collagen at high (1X Aam) and low (0.1X Aam) functionalization 
densities. No significant differences in either modulus or swelling ratio were measured 
between any of the tested groups (p>0.05). n=6.   
 
 
 
4.3.4 Initial Protein Incorporation and Bioactivity PEGDA was crosslinked 
with each of the Acr-PEG-NHS-functionalized collagen and Scl2-2 proteins at an initial 
concentration of 4 mg protein ml
-1
. After swelling the gels in PBS for 24 hours to 
remove uncrosslinked proteins, they were hydrolyzed in 0.5M NaOH. CBQCA was run 
on the resulting solutions relative to non-swollen controls to quantify the concentration 
of proteins remaining in the gels and determine the initial protein incorporation during 
crosslinking for each functionalization density, Figure 4.6A. As functionalization 
density is decreased, the initial incorporation of both collagen and Scl2-2 was reduced 
from ~80% to ~60%. This was expected given that the lower functionalization density 
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proteins have fewer available crosslinking sites. Despite having a reduced protein 
concentration after 1 day of swelling, gels with lower functionalization density proteins 
demonstrated significantly increased levels of BAOEC adhesion after 3 hours of 
incubation, Figure 4.6B and C. While spreading on PEG-Collagen gels was not 
significantly affected by functionalization density, spreading on PEG-Scl2-2 gels was 
significantly increased (p<0.05) by reducing functionalization from 1X to 0.1X (from 
643 ± 285 to 1088 ± 332 mm
2
/cell). Given that cell interactions with the bioactive PEG 
hydrogel are limited to the functionalized proteins, these results suggest that the PEG 
linkers could block integrin binding to functionalized proteins and reduce bioactivity. 
While similar effects have been observed with PEGylated drugs, this has not been 
documented with bioactive hydrogels.
240
 Monfardini et al. reported that branched PEG 
linkers reduce bioactivity relative to linear linkers.
243
 While linear PEG was used here, 
subsequent crosslinking into a PEG network may provide a similar effect. It can be 
concluded from these findings that reducing protein functionalization density is a facile 
method for improving cell-material interactions with bioactive hydrogels by reducing the 
steric hindrance around integrin binding sites.   
It should be noted that BAOEC interactions with PEG-Scl2-2 hydrogels were 
consistently lower than those on PEG-Collagen hydrogels. This is to be expected, as 
collagen contains three α1β1 and α2β1 integrin binding sites whereas Scl2-2 only contains 
one.
3
 However, reducing Scl2-2 functionalization density to 0.1X provided comparable 
EC adhesion and spreading to PEG-Collagen 1X and 0.5X gels. While similar effects 
could likely be achieved by increasing Scl2-2 concentration, the use of larger amounts of 
 98 
 
protein increases scaffold cost.
227,231,244
 Additionally, concentration increases can be 
limited by solubility of large molecules such as growth factors and proteins.
245
 Thus, 
reducing functionalization density provides an alternate route for increasing cell 
interactions that is facile, adaptable, and cost effective.  
 
 
Figure 4.6. Initial protein incorporation and bioactivity of PEG-collagen and PEG-Scl2-
2 hydrogels in response to functionalization density. (A) Initial protein incorporation in 
PEGDA-Scl2-2 and PEGDA-collagen hydrogels after 1 day of swelling in PBS at 37C 
decreases with decreasing functionalization density. n=3; mean ± standard deviation; 
p<0.05 for each decrease in functionalization density. (B) General increases in BAOEC 
adhesion were seen with decreases in protein functionalization density. n=4 samples, 3 
images per sample for a total of 12 images; mean ± standard error; *p<0.05 vs. all 
samples, †p<0.05 vs. Scl2-2 0.5X and Scl2-  1X, ‡p<0.05 vs. Scl2-2 1X. (C) 
Rhodamine phalloidin and SYBR Green stained BAOECs adhered to PEG-collagen and 
PEG-Scl2-2 hydrogels after a 3 hour incubation period. Scale bar applies to all images.  
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4.3.5 Protein and Bioactivity Retention: Acr-PEG-NHS Although reduced 
functionalization density enhanced cell interactions, it was hypothesized that it may also 
reduce protein retention within the hydrogel over time. Indeed, following 6 weeks of 
swelling in PBS at 37C, both collagen and Scl2-2 levels in PEGDA hydrogels were 
reduced by 91 to 100%, Figure 4.7A. These large protein losses were attributed to 
hydrolysis of the PEGDA network. While PEGDA hydrogels are typically considered 
biostable, the acrylate esters are susceptible to hydrolytic degradation that results in 
alterations of both scaffold properties and protein levels over time.
194-197
 PEGDA is 
suitable for relatively long-term bioactive factor delivery applications on the order of 
months, but it cannot be used in applications that require several years of bioactivity. To 
address this, PEG diacrylamide (PEGDAA), a PEG-based hydrogel system that is 
comparable to traditional PEGDA hydrogels but with improved hydrolytic stability was 
utilized, Figure 4.1.
242
 PEGDAA was previously employed by Elbert et al. to improve 
conjugate addition reaction bond stability between bioactive peptides and PEG 
hydrogels.
208
 In the current study, increasing network stability with PEGDAA hydrogels 
resulted in significantly increased protein retention compared to PEGDA hydrogels 
(from 0-9% to 14-67%) after 6 weeks of swelling in PBS at 37C, Figure 4.7B. Thus, 
PEGDAA enhanced sustained network protein levels and may provide a tool for better 
controlling long-term delivery of drugs and presentation of bioactive agents. It should be 
noted that the ether linkages in PEG hydrogels are also susceptible to oxidative 
degradation, which has been proposed as an alternate in vivo degradation mechanism.197 
It is likely that in vivo degradation of PEGDA hydrogels is due to some combination of 
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both hydrolytic and oxidative degradation; therefore, PEGDAA should enhance overall 
in vivo stability compared to PEGDA even if oxidation does occur.196,200,242  
The effect of the observed protein loss over time on cell adhesion and spreading 
was investigated on bioactive hydrogel formulations that retained at least 10% of their 
protein at 6 weeks. Thus, none of the PEGDA-Acr-PEG-NHS systems were tested in 
bioactivity retention studies. Analysis of 3 hour BAOEC adhesion and spreading on 
PEGDAA hydrogels with Acr-PEG-NHS-functionalized collagen and Scl2-2 after 
swelling in PBS at 37C for up to 6 weeks revealed that comparable adhesion and 
spreading levels were maintained for high functionalization density proteins (1X), 
Figure 4.7C. However, gels with low functionalization density proteins (collagen 0.1X; 
Scl2-2 0.5X and 0.1X) had significantly reduced BAOEC adhesion and spreading 
relative to controls (swollen in PBS at 37C for 1 day). This corresponded to the large 
decreases in protein concentrations in low functionalization density gels, and could be 
expected due to decreased cell adhesion that typically occurs with decreased bioactive 
factor concentration.
198,227,244
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Figure 4.7. Protein and bioactivity retention over 6 weeks in PEGDA and PEGDAA 
gels. Protein retention in (A) PEGDA and (B) PEGDAA hydrogels over 6 weeks of 
swelling in PBS at 37C. n=3; mean ± standard deviation; *p<0.05 relative to previous 
time point. (C) BAOEC adhesion and spreading on bioactive PEGDAA hydrogels after 6 
weeks of swelling in PBS at 37C. Measurements normalized to 1X samples at 1 day of 
swelling. n=4 samples, 3 images per sample for a total of 12 images; mean ± standard 
error; *p<0.05 relative to 1 day sample. 
  
 
 
4.3.6 Protein and Bioactivity Retention: Aam-PEG-I Although the PEGDAA 
network provided increased stability that enhanced protein retention, there was still a 
significant reduction in protein concentration over time that corresponded with loss of 
bioactivity, especially at low functionalization densities. It was hypothesized that 
hydrolysis of the acrylate esters of the Acr-PEG-NHS linkers could also contribute to the 
observed protein losses. To test this hypothesis, Aam-PEG-I, a PEG linker with 
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improved hydrolytic stability, was utilized to investigate the effects of linker stability on 
long-term protein and bioactivity retention in bioactive PEG hydrogels, Figure 4.1. It 
was found that increasing linker stability with Aam-PEG-I resulted in significantly 
improved protein retention in both PEGDA and PEGDAA gels over 6 weeks of swelling 
compared with Acr-PEG-NHS functionalized proteins, Figure 4.8A. Thus, increasing 
functionalization linker stability with Aam-PEG-I appears to have an even greater effect 
on long-term protein retention than increasing network stability with PEGDAA when 
compared with the traditional Acr-PEG-NHS/PEGDA system. The functionalization 
linker developed here demonstrates strong potential for use as a protein, drug, or peptide 
functionalization linker in a wide range of systems to provide a sustained presence of 
bioactive factors.  
BAOEC adhesion and spreading on PEGDAA hydrogels with collagen- and 
Scl2-2-Aam at 3 hours revealed that reducing the functionalization density with Aam-
PEG-I produces similar increases in initial cell-material interactions as the traditional 
Acr-PEG-NHS system for both collagen and Scl2-2. Both protein systems had 
significant increases in BAOEC adhesion and spreading (40-70% and 10-40%, 
respectively) with reduction of functionalization density from 1X to 0.1X, and all 
analogous gel systems had statistically similar BAOEC interactions for the two linker 
types. Upon confirmation of similar initial bioactivity with the two linker systems, 
PEGDA and PEGDAA gels with collagen- and Scl2-2-Aam were swollen in PBS for 6 
weeks at 37C to evaluate bioactivity retention in the new system.  
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Figure 4.8. Aam-PEG-I functionalized collagen and Scl2-2 protein retention and 
bioactivity retention. (A) Aam-PEG-I-functionalized protein retention in PEGDA and 
PEGDAA hydrogels after 6 weeks of swelling in PBS at 37C. n=6; mean ± standard 
deviation; *p<0.05 relative to 1 day time point. (B) 3 hour BAOEC adhesion on 
bioactive PEG hydrogels with Aam-PEG-I-functionalized proteins after swelling gels in 
PBS for 6 weeks at 37C. Measurements normalized to 1X samples at 1 day of swelling. 
n=4 samples, 3 images per sample for a total of 12 images; mean ± standard error; 
*p<0.05 relative to 1 day time point. 
 
 
 
In all PEGDAA gels with Aam-PEG-I, no significant alterations in BAOEC 
adhesion were measured after swelling gels for 6 weeks at 37C, and gels with low 
functionalization density proteins maintained their enhanced BAOEC adhesion 
compared to high functionalization density protein gels, Figure 4.8B. Thus, the use of 
Aam-PEG-I allows for reduced functionalization density to increase bioactivity without 
losses over time. Similarly, bioactivity of PEGDA gels with Aam-PEG-I-functionalized 
proteins at low functionalization densities was similarly or better retained than analogous 
PEGDAA gels with Acr-PEG-NHS-functionalized proteins. No significant changes in 
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BAOEC spreading were measured for any of the Aam-PEG-I systems after 6 weeks of 
swelling. These results indicate that the use of a biostable linker and network 
significantly increases protein and bioactivity retention compared to the traditional 
PEGDA/Acr-PEG-NHS system. Additionally, the significant improvements in both 
protein and bioactivity retention with Aam-PEG-I-functionalized proteins in PEGDA 
hydrogels indicate that this linker could be utilized in degradable matrices to provide 
control over bioactive factor delivery independently of linker hydrolysis. 
Aam-PEG-I allows for use of low functionalization densities for enhanced initial 
cell interactions while maintaining long term protein levels within the gel to sustain 
desired cell interactions. This linker in combination with a PEGDAA network would be 
valuable in long-term implantable devices in which prolonged cell-material interactions 
are desired, such as our off-the-shelf vascular graft. As in vivo endothelialization that 
occurs via migration from the anastomoses can be a slow process (on the order of 0.2 
mm per day), retention of bioactive factors over longer time frames is required, and 
alterations in swelling or modulus and/or physical breakage that occur with gel 
degradation could disrupt this process.
203,206
 Additionally, the combination of linkers, 
networks, and functionalization schemes presented here provides the means to tune 
protein and drug delivery with enhanced precision. For example, a drug delivery device 
could be designed to address the different stages of wound healing with temporally-
controlled release of multiple bioactive agents by functionalization with linkers of varied 
biostability.
246
 A similarly designed scaffold could be used to regulate stem cell 
differentiation in vitro or in vivo with controlled release of multiple cues.247  
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4.4 Conclusions 
The ability to tune the mechanical, chemical, and biological properties of PEG-
based hydrogels is highly valuable in the development of improved biomaterials for 
regenerative medicine and drug delivery. Functionalization of bioactive factors and 
subsequent incorporation into PEG hydrogels provides controllable bioactivity; however, 
PEG linkers used to functionalize proteins can also sterically hinder integrin binding 
sites and impair cell-material interactions. Reducing the density of PEG linkers during 
functionalization provides a facile method to significantly improve initial cell adhesion 
and spreading with many advantages over altering bioactive factor concentration, but 
this also reduces protein retention over time as a result of network and/or PEG linker 
hydrolysis. These studies demonstrate that this protein loss is substantial with almost 
total loss of protein observed after 6 weeks in low functionalization density systems. The 
novel Aam-PEG-I linker synthesized here presents a PEG linker option with 
significantly enhanced hydrolytic stability relative to the traditional Acr-PEG-NHS 
linker. When used at a low functionalization density in combination with PEGDAA, this 
system provides a hydrogel with significantly improved initial bioactivity that can be 
sustained over long swelling times. This will allow for a controlled investigation of 
longer-term cell interactions in future studies without concerns over effects of protein 
loss over time. Although these findings were focused on the characterization of bioactive 
hydrogels for use in a vascular graft, the common use of PEGylation to enhance 
circulation time of bioactive factors makes these findings highly relevant in drug 
delivery as well.   
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CHAPTER V  
EFFECTS OF SUBSTRATE MODULUS AND PROTEIN CONCENTRATION ON 
EC INTERACTIONS 
 
5.1 Introduction  
Utilization of a synthetic hydrogel matrix in the fabrication of the intimal layer of 
our vascular graft not only provides a material with thromboresistance and controlled 
introduction of bioactivity, it also allows for independent exploration of effects of 
protein and matrix variables on cell-material interactions. It is extensively acknowledged 
in current literature that increasing bioactive factor concentration provides a means to 
increase cell adhesion and spreading.
227,231,244
 This presents an additional variable for 
alteration of endothelial cell (EC) interactions with PEG-Scl2-2 hydrogels to achieve a 
vascular graft material that is capable of endothelialization. While protein parameters 
can be valuable in altering cell-material interactions, PEG hydrogels in particular 
provide matrix variables as well.  
One of the most widely utilized properties of PEG hydrogels is the ability to alter 
their swelling and mechanical properties over wide ranges with simple changes in PEG 
molecular weight and/or concentration.
248
 Multiple reports have demonstrated that 
substrate modulus affects cell-material interactions with various cell types.
151,167-168,249-252
 
Previous work with ECs has demonstrated that shear stresses on their apical side caused 
by hemodynamic forces affect cell function and structure and induce changes throughout 
the cell interior.
253
 More recently, studies have focused on evaluating the interactions 
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between the extracellular matrix and the basal EC side for promotion of angiogenesis. In 
general, stiffer collagen and fibrin gels reduce vascular network formation.
254-255
 
However, ECs have been found to have increased spreading on stiffer gels due to the 
ability of the cells to generate traction forces on their matrix.
256
 These spreading 
increases may be more valuable in generation of an off-the-shelf vascular graft than 
findings concerning angiogenesis. Previous studies have primarily been performed using 
natural polymer hydrogels, wherein substrate modulus can only be altered by changing 
overall protein concentration. Thus, little information is available on the effects of 
synthetic hydrogel matrix variables on EC interactions or on the effects of substrate 
modulus independent of protein concentration. PEG-Scl2-2 hydrogels provide a means 
to vary substrate modulus independently of bioactive factor concentration to evaluate its 
effects on EC adhesion and spreading.  
Here, a full study of the effects of protein concentration with varied 
functionalization densities on EC adhesion and spreading over one week was performed 
to determine effects of Scl2-2 concentrations on initial and prolonged cell interactions. 
Additionally, two compositions of PEG-Scl2-2 and PEG-collagen gels (1X 
functionalization density, 1 mg protein/ml; 0.1X functionalization density, 8 mg 
protein/ml) were fabricated with two different substrate moduli by increasing PEG 
molecular weight from 3.4 kDa to 10 kDa to investigate effects of substrate modulus on 
the high and low end of bioactivity levels in our hydrogel formulations. Finally, EC 
migration was measured as a function of protein concentration to determine the ability to 
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tune migration rates on PEG-Scl2-2 hydrogels and as an initial evaluation of their 
potential for in situ endothelialization from the vascular graft anastomoses. 
 
 
5.2 Materials and Methods 
5.2.1 Materials All chemicals and materials were purchased from Sigma Aldrich 
(St. Louis, MO) and used as received unless otherwise noted. Acr-PEG-NHS (3.5 kDa) 
and PEG diamine (3.4 kDa) were purchased from Jenkem Technology USA (Allen, TX).  
5.2.2 Synthesis of PEGDA and PEGDAA Poly(ethylene glycol) diacrylate 
(PEGDA) was synthesized as previously described.
172
 Briefly, 4 molar equivalents of 
acryloyl chloride were added dropwise to a solution of PEG (3.4 kDa or 10 kDa) diol 
and 2 molar equivalents of triethylamine (TEA) in anhydrous dichloromethane (DCM) 
under nitrogen and allowed to react for 24 hours. Then, the reaction solution was washed 
with 8 molar equivalents of 2M potassium bicarbonate and dried with anhydrous sodium 
sulfate. The final product was precipitated in cold diethyl ether, filtered, and dried under 
vacuum.  
PEG diacrylamide (PEGDAA) was prepared as previously described in a similar 
method to PEGDA.
242
 Briefly, acryloyl chloride (4 molar equivalents) was added 
dropwise to a solution of PEG (3.4 kDa) diamine (1 molar equivalent) and TEA (2 molar 
equivalents) in anhydrous DCM under nitrogen. The reaction was allowed to proceed for 
24 hours prior to being washed with 2M potassium bicarbonate (8 molar equivalents). 
Following drying with anhydrous sodium sulfate, the product was precipitated in cold 
diethyl ether, filtered, and dried under vacuum.  
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Successful synthesis of PEGDA and PEGDAA was confirmed with Fourier 
transform infrared (FTIR) and proton nuclear magnetic resonance (
1
H-NMR) 
spectroscopy. Control and functionalized polymers were solution cast onto KBr pellets 
and FTIR spectra were obtained using a Bruker TENSOR 27 spectrometer. The 
introduction of an ester peak at 1730 cm
-1
 and loss of the hydroxyl peak at 3300 cm
-1
 
indicated successful acrylation of PEG diol, and the introduction of amide peaks at 1640 
cm
-1
 and 1675 cm
-1
 indicated successful acrylamidation of PEG diamine. A Mercury 300 
MHz spectrometer with a TMS/solvent signal as an internal reference was utilized to 
obtain 
1
H-NMR spectra of control and functionalized polymers. Greater than 90% 
conversions of hydroxyl to acrylate endgroups and amine to acrylamide endgroups were 
observed for all candidate macromers. PEGDA:  
1
H-NMR (CDCl3): 3.6 ppm (m, -
OCH2CH2-), 4.3 ppm (t, -CH2OCO-), 6.1 ppm (dd, -CH=CH2), 5.8 and 6.4 ppm (dd, -
CH=CH2). PEGDAA:  
1
H-NMR (CDCl3): 3.6 ppm (m, -OCH2CH2-); 6.5 ppm (s, -CH2-
NH-); 6.4 ppm (m, -CH=CH2); 5.6 and 6.1 ppm (m, -CH=CH2). 
5.2.3 Synthesis of Acrylamide-PEG-Isocyanate Linker One molar equivalent of 
PEG (3.4 kDa) diamine dissolved in anhydrous DCM was added dropwise to 2 molar 
equivalents of hexane diisocyanate under nitrogen to synthesize PEG diisocyanate 
(PEGDI). After 2 hours of stirring, a solution with 1 molar equivalent of aminoethyl 
acrylamide (Enamine, Kiev, Ukraine) in dimethyl sulfoxide was added dropwise to the 
reaction solution while stirring under nitrogen. The reaction was allowed to proceed for 
2 hours, and then the final product was precipitated in cold diethyl ether, filtered, and 
dried under vacuum. Successful synthesis of PEGDI and Aam-PEG-I was confirmed 
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with FTIR spectroscopy in a method like that described above. The introduction of an 
isocyanate peak at 2250 cm
-1
 and urea peaks at 1560 and 1650 cm
-1
 confirmed 
isocyanate endcapping of PEG diamine, and relative decreases in the isocyanate peak 
and increases in the urea peaks confirmed successful formation of the Aam-PEG-I 
linker.  Aam-PEG-I structure was confirmed with 
1
H-NMR spectroscopy as described 
above. Aam-PEG-I:  
1
H-NMR (CDCl3): 3.6 ppm (m, -OCH2CH2-), 3.3 ppm (m, -
NHCH2CH2NH-), 1.4 and 3.1 ppm (m, -NH[CH2]6N-), 5.1-5.4 and 7.3 ppm (s, -NH-), 
6.1 ppm (dd, -CH=CH2), 5.8 and 6.2 ppm (dd, -CH=CH2). 
5.2.4 Protein Functionalization The Scl2.28 sequence was amplified and 
purified as previously described.
161
 Scl2-2 was modified from Scl2-1 through the 
introduction of the GFPGER sequence during site directed mutagenesis as previously 
described.
161
 Scl2-2 and a rat tail collagen type I control were functionalized with Aam-
PEG-I. Briefly, Aam-PEG-I was dissolved in anhydrous dimethylformamide and added 
dropwise to protein solutions in phosphate buffered saline (PBS) at room temperature. 
The molar ratio of Aam-PEG-I:NH2 was 0.1:1, 0.5:1, or 1:1 to provide proteins with 
low, medium, and high functionalization densities, respectively. After 2 hours of stirring, 
functionalized proteins were purified using dialysis against reverse osmosis (RO) water 
for 24 hours (MWCO = 20,000 Da). FTIR spectroscopy confirmed functionalization of 
proteins with varied Aam-PEG-I densities. The presence of both ether peaks from the 
PEG linker at 1110 cm
-1
 and amide peaks from the proteins at 1560 cm
-1
 confirmed 
functionalization, and relative decreases in absorbance peak ratios of the ether of the 
Aam-PEG-I to the amide of the proteins confirmed variation in functionalization density. 
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5.2.5 Preparation and Characterization of Bioactive PEG Hydrogels PEG, 
PEG-Scl2-2, and PEG-collagen hydrogels were prepared by dissolving PEG (3.4 kDa) 
DA or PEG (3.4 kDa or 10 kDa) DAA (10 wt%) and functionalized Scl2-2 or collagen 
(1, 4, or 8 mg ml
-1
) in 20 mM acetic acid. A photoinitiator solution (1 mg Irgacure 2959 
per 0.01 ml 70% ethanol) was added at 1 vol% of precursor solution. Solutions were 
pipetted between 0.5-1.5 mm spaced plates or into microcentrifuge tubes and crosslinked 
by 6 min exposure to long wave UV light (Intelli Ray Shuttered UV Flood Light, 
Integrated Dispensing Solutions, Inc., 365 nm, 4 mW/cm
2
).   
To measure compressive modulus, six 8-mm diameter discs were punched from 
hydrogel sheets (1.5 mm thick) and swollen in RO water overnight. Samples were 
subjected to mechanical testing under unconstrained compression at room temperature 
using a dynamic mechanical analyzer (RSAIII, TA Instruments) equipped with a 
parallel-plate compression clamp. The linear viscoelastic range for each hydrogel 
formulation was determine using dynamic strain sweeps. A strain within the upper 
region of the linear viscoelastic range was used in a constant strain frequency sweep 
from 0.79 and 79 Hz. The compressive storage modulus was taken at 1.25 Hz.  
For swelling assessments, six 8-mm diameter discs were punched from hydrogel 
sheets (1.5 mm thick) directly after polymerization. The hydrogel discs were swollen in 
RO water overnight and weighed to determine the equilibrium swelling mass (Ws). 
Then, samples were dried under vacuum overnight and weighed to assess dry (polymer) 
mass (Wd). The equilibrium volumetric swelling ratio, Q, was calculated from the 
equilibrium mass swelling ratio:  
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   [5.1] 
5.2.6 Initial Protein Incorporation PEGDAA-collagen and PEGDAA-Scl2-2 
gels were crosslinked directly into microcentrifuge tubes and swelled in PBS at 37C for 
24 hours. The swelling solutions were then removed from the tubes, frozen at -80C, and 
lyophilized to obtain the gel leachables. The lyophilized powders were dissolved in a 
known volume of phosphate buffered saline (PBS), and protein concentration of the 
resulting solution was determined with a 3-(4-carboxy-benzoyl)-2-quinoline-
carboxaldehyde (CBQCA) protein quantification kit (Molecular Probes, Life 
Technologies, Grand Island, NY), as specified by the manufacturer. Briefly, 10 µl 
aliquots of each sample were diluted in 125 µl of 0.1M sodium borate buffer. Then, 5 µl 
of 5 mM potassium cyanide (KCN) were added to each sample, followed by an addition 
of 10 µl of 5 mM CBQCA (dissolved to 40 mM in DMSO, then diluted to 5 mM in 
0.1M sodium borate buffer). Each sample was tested in triplicate and run against a 
standard of the same protein type and functionalization density. After 1 to 3 hours of 
incubation in a black 96 well plate at room temperature with shaking, fluorescence was 
read using an Infinite M200 Pro plate reader (Tecan Group, Inc.; emission = 550 nm, 
excitation = 465 nm). The concentration of lost protein (CL, mg/ml) in the hydrolyzed 
gels was determined by inserting the measured fluorescence into a best-fit linear 
equation for corresponding standard curves. Protein retention at 24 hours (PR, mg/ml) 
was then calculated as:  
     
 0 V0-  L VPB 
V0
   [5.2] 
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where C0 and V0 are the original protein concentration (mg/ml) and gel volume (ml), 
respectively, and VPBS is the volume of PBS used to dissolved the lyophilized leachables 
(ml). Initial protein incorporation (I) was measured from PR as: 
 I  
PRDA
 0
   100     [5.3] 
5.2.7 Endothelial Cell Adhesion and Spreading Bovine aortic endothelial cells 
(BAOECs) were used for all cell studies. In vitro culture was carried out at 37°C/5% 
CO2 with Dulbecco’s Modified Eagle Medium (DMEM, high glucose GlutaMAX
TM
, 
Invitrogen) supplemented with 10% heat-inactivated fetal bovine serum (FBS, 
Invitrogen) and 1% Penicillin-Strepotomycin solution (Gibco). Cells were used between 
passages 2 and 5 after 7-10 days of culture for all studies. 
Bioactive hydrogels were crosslinked between 0.5 mm spaced plates as described 
above and swelled for 3 hours in 70% ethanol. Subsequently, gels were taken through an 
ethanol swelling ramp (15 minutes each in 50%, 25%, and 0% ethanol in water) to 
remove residual ethanol. Then, 6 mm diameter punches were taken from each hydrogel 
formulation and swelled in PBS for 1-3 hours to ensure full hydration. BAOECs were 
seeded onto specimens at 10,000 cells cm
-1
 and cultured at 37°C/5% CO2 for 3 hours, 72 
hours, or 1 week. Media was changed at 3 hours and then every 48 hours. Following the 
desired culture time, cells were fixed with 3.7% glutaraldehyde and stained with 
rhodamine phalloidin (F-actin/cytoplasm, Invitrogen) and SYBRGreen (DNA/nucleus, 
Invitrogen). Representative images were obtained with a Nikon Eclipse TE2000-S with 
3 field views per specimen and 4 specimens per hydrogel formulation. Fluorescent 
images (3 images per specimen, 4 specimens per sample) of SYBRGreen- and 
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rhodamine phalloidin-stained cells were utilized to quantify the extent of cell spreading. 
Average cell spreading, or cell area, was quantified by applying the Photoshop “magic 
wand” tool to the image background and adjusting the tool tolerance so that all 
extracellular regions were selected. The histogram function was then utilized to evaluate 
the extracellular pixels (PEx). The average pixels per cell (Acell) for that image was then 
quantified as follows:  
       
  -    
 
   [5.4] 
where PT represents total image pixels and N is total number of cell nuclei. Pixels were 
then converted to microns using known objective scaling. 
5.2.8 Endothelial Cell Migration For PEG-Scl2 hydrogels to support graft 
endothelialization, they must support both EC adhesion and migration. To analyze EC 
migration on PEG-Scl2 hydrogels, sterile filtered PEG-Scl2-2 (10 wt% PEG(3.4 kDa) 
DA, 6 or 12 mg protein/ml) and PEG-collagen (10 wt% PEG(3.4 kDa) DA, 2 or 4 mg 
protein/ml) hydrogels were prepared between glass plates separated by 0.5 mm spacers. 
The resulting hydrogels were immersed in PBS for 24 h, after which a set of 2.54 cm 
punches were collected from the swollen gels. 
BAOECs were harvested and seeded onto the hydrogels at 10,000 cells cm
-2
. 
Gels were cultured for 24 h at 37 °C/5% CO2 to allow for cell adhesion and equilibrium 
cell spreading. EC migration was monitored for 1 h at 5 min intervals in at least three 
randomly selected locations of each hydrogel formulation using a Zeiss Axiovert 
microscope. For determination of single cell migration parameters, only cells that 
remained in isolation (>100 µm from other cells) were measured. Cell centroid position 
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at each 5 minute time increment was determined based on cell outlines using Photoshop. 
These centroids were then used to calculate the mean-square displacement (MSD, <D
2
>) 
for a range of time intervals. In brief,  
       
 
 
   
 
     [5.5] 
where N is the total number of 5 minute time increments in the time interval under 
consideration, and di is the square of cell displacement during time increment i.
257
 The 
speed, S, and direction persistence time (P) were determined by fitting the MSD (<D
2
>) 
and the time interval, t, to the persistent random walk equation using nonlinear least 
squares regression analysis:
152
  
            -   - - 
 
 
    [5.6] 
 
5.3 Results and Discussion 
5.3.1 Effects of Protein Concentration on EC Adhesion and Spreading BAOEC 
adhesion and spreading on PEG-Scl2-2 and PEG-collagen gels over one week was 
analyzed as a function of protein concentration (1, 4, and 8 mg protein ml
-1
 hydrogel 
solution) with three different functionalization densities for each protein (1X, 0.5X, and 
0.1X), Figure 5.1. In general, increases in protein concentration resulted in increases in 
EC adhesion at 3 hours for all functionalization densities of both protein types, and 
lower functionalization densities (0.1X) supported greater BAOEC adhesion than high 
functionalization densities (1X). The observed concentration effects were expected, 
based on the multitude of reports in literature demonstrating that increasing bioactive 
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factor concentration can be used to increase cell interactions.
198,227,244
 Additionally, the 
effects of functionalization density correlate with our previous results. 
 
 
 
Figure 5.1. Effects of protein concentration on BAOEC adhesion over 1 week. All Scl2-
2 samples had significant increases in adhesion from 3 hours to 1 week except for 0.1X 1 
and 4 mg/ml samples, whereas no collagen samples exhibited significant increases in 
adhesion from 3 hours to 1 week. n=4 samples, 3 images per sample for a total of 12 
images; mean ± standard error;*p<0.05 relative to corollary 4 mg/ml sample, ƚp<0.05 
relative to corollary 8 mg/ml sample, ǂp<0.05 relative to corollary 1X sample. 
 
 
PEG-Scl2-2 hydrogels exhibited BAOEC proliferation between 3 hours and 1 
week to provide significant increases in EC adhesion for all samples except for the 1 and 
4 mg/ml samples for the 0.1X functionalization density. This is the first time that we 
have confirmed the ability of Scl2-2 to support significant BAOEC proliferation. 
Although PEG-collagen hydrogels had greater initial adhesion than corollary Scl2-2 
samples, no significant increases in EC adhesion occurred between 3 hours and 1 week. 
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This resulted in greater BAOEC adhesion on PEG-Scl2-2 gels at 1 week than on PEG-
collagen gels, especially with higher concentration samples. It has previously been 
shown that α1β1 is the only collagen receptor that can activate the Shc-mediated growth 
pathway.
258
 Shc-linked integrin mediated adhesion promotes cell survival and 
progression through the Gap 1 phase of the cell cycle in which eukaryotic cell division 
takes place, whereas adhesion mediated by other types of integrins can cause exit from 
the cell cycle and, in some cases, cell death.
259-260
 Thus, it is possible that the controlled 
presence of only α1β1 and α2β1 integrin binding sites in Scl2-2 provides more direct cell 
signaling to promote EC proliferation, whereas the multitude of integrin binding sites in 
collagen results in contradictory signaling that reduces proliferation.  
It can be seen that for the most part, concentration effects on BAOEC adhesion to 
PEG-Scl2-2 hydrogels are enhanced over one week, while functionalization density 
effects are reduced. It was hypothesized that this could be due to the reduced initial 
protein incorporation that occurs with reducing functionalization density, as the effects 
of decreased concentration and increased access to integrin binding sites are conflicting. 
Although we have shown that this does not affect initial adhesion levels, it is possible 
that the concentration differences between high and low functionalization densities have 
a greater effect over time. Initial protein incorporation for each of these gel systems was 
measured to obtain an indication of these potential effects, Table 5.1.  As expected, 
lower functionalization densities had reduced initial incorporations than higher 
functionalization densities. Thus, it is possible that normalizing initial concentrations for 
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each functionalization density would provide enhanced functionalization density effects 
in the long term similarly to short term effects.  
 
 
Table 5.1. Initial protein incorporation of Aam-PEG-I-functionalized collagen and Scl2-
2 in PEGDAA hydrogels.  
 
 
 
5.3.2 Effects of Protein Concentration on EC Migration EC migration from the 
anastomoses will be a significant mechanism in the endothelialization of the multilayer 
grafts. Thus, as an initial evaluation of the potential for rapid endothelialization, BAOEC 
migration on PEG-Scl2-2 hydrogels (1X functionalization density) with varied 
concentrations (6 and 12 mg protein/ml) was tracked over 1 hour and compared to that 
on PEG-collagen hydrogels, Figure 5.2. BAOEC migration rates on the hydrogels were 
affected by both type and concentration of protein, Figure 5.3. Specifically, an increase 
in the concentration of Scl2-2 from 6 to 12 mg of protein ml
-1
 of hydrogel solution 
resulted in a 3 fold increase in BAOEC migration rates from 4.2 ± 2.2 µm min
-1
 to 13.2 
± 4.2 µm min
-1
. A corresponding increase in collagen concentration (2 to 4 mg of protein 
per ml, based on an equivalent number of binding sites relative to 6 and 12 mg of Scl2-2 
per mL), did not cause a significant increase in migration rates. Additionally, migration 
speeds on PEG-Scl2-2 hydrogels were increased relative to those on equivalent PEG-
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collagen hydrogels. It has been previously shown that cell adhesion strength generally 
increases to a saturation point with an increase in ligand density and affinity, but cell 
migration rate responds in a biphasic manner to increases in these variables.
168
 
Specifically, there is a maximum ligand density/affinity to which migration is increased 
and beyond which migration speed is reduced due to the increased adhesion strength.
261
 
Thus, it is likely that the reduced migration speed on PEG-collagen hydrogels would 
correlate with increased adhesion strengths.  
 
 
 
Figure 5.2. Micrographs used to track BAOEC centroid position to determine migration 
rates on (A) PEG-Scl2-2 hydrogels and (B) PEG-Collagen hydrogels. The scale bar 
applies to all images, and images are shown at 10 minute intervals. 
 
 
 
These studies demonstrated that Scl2-2 concentration can be used to control EC 
migration rates, and PEG-Scl2-2 hydrogels have the potential to improve upon the rate 
of EC migration relative to collagen-based systems. Future studies will analyze EC 
migration rate and adhesion strength as a function of each of the protein and network 
variables tested in the 1 week adhesion studies. Elucidation of these interactions is 
essential in developing off-the-shelf grafts that promote rapid in vivo formation of the 
stable, endothelial linings.  
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Figure 5.3. BAOEC migration. EC migration rates increased ~3 fold with increased 
concentration of Scl2-2, and average migration speeds on Scl2-2 gels were ~10 fold 
greater than those observed on equivalent PEG-collagen gels. n=6; mean ± standard 
error of mean displayed; *p>0.05 relative to lower concentration sample. 
 
 
5.3.3 Effects of Substrate Modulus on EC Adhesion and Spreading The ability 
to tune PEG hydrogel properties over a wide range with simple alterations in molecular 
weight and concentration while maintaining a constant protein concentration enables 
facile investigation of the effects of scaffold properties on bioactivity. To evaluate this, 
Scl2-2 and collagen were crosslinked at either 1 mg/ml (1X functionalization density) or 
8 mg/ml (0.1X functionalization density) into 10% PEG(3.4 kDa or 10 kDa) DAA 
solutions. The reduction of PEG molecular weight from 3.4 kDa to 10 kDa resulted in a 
modulus reduction and swelling ratio increase of approximately 60%, Figure 5.4. 
BAOEC adhesion and spreading was measured at 3 hours to obtain an initial indication 
of effects of substrate modulus, Figure 5.5. It was found that for all four formulations, 
there were decreases in BAOEC adhesion with reduced substrate modulus, with 
significant decreases for Scl2-2 samples. No significant trends in BAOEC spreading 
were measured in relation to substrate modulus. Although current literature does not 
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contain much information on the effects of substrate modulus on EC adhesion, these 
results do correlate with numerous reports that have shown that increasing substrate 
modulus increases cell adhesion.
167
 Additionally, the decreases in spreading that have 
been shown with decreased natural polymer scaffold modulus were on scaffolds with 
much lower modulus values than the 10% PEG(10k) gels in this study.
256
 Although 
protein concentrations are the same in the gel systems here, the 10% PEG(10k) gels have 
higher swelling ratios than the 10% PEG(3.4k) gels. Thus, it is possible that this increase 
in swelling results in larger distances between integrin binding sites in the gel, which 
would result in the reduced adhesion shown in these studies. In our previous work, we 
utilized a 4-arm PEG crosslinker to create local increases in crosslink density to increase 
modulus with minimal effects on mesh size.
248
 In future investigations, compositions 
with similar swelling ratios and different modulus values could be utilized to decouple 
the effects of swelling from the effects of modulus on EC adhesion. This would provide 
definitive information on the effects of substrate modulus in our system; however, we 
have shown that modulus can be utilized as an additional tool to alter bioactivity of 
PEG-Scl2-2 hydrogels.  
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Figure 5.4. Effects of PEG molecular weight on compressive modulus and volumetric 
swelling ratio. Reducing molecular weight from 3.4 kDa to 10 kDa provided a reduction 
in modulus and increase in swelling of approximately 60%. 
 
 
 
 
Figure 5.5. Effects of substrate modulus on 3 hour BAOEC adhesion. Significant 
increases in adhesion occurred with reducing functionalization density and increasing 
concentration. General decreases in adhesion occurred with reduced modulus. n=4 
samples, 3 images per sample for a total of 12 images; mean ± standard error; *p<0.05 
relative to corollary 10% 10k sample.  
 
 
 
5.4 Conclusions  
PEG-Scl2-2 hydrogels are an ideal system for the independent investigation of a 
wide range of protein and network variables on bioactivity. Here, we showed that 
increases in protein concentration can be used to increase both EC adhesion and 
migration. Additionally, PEG-Scl2-2 hydrogels promote significant EC proliferation 
over one week, resulting in adhesion levels that are greater than corollary PEG-collagen 
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gels. This is most likely due to the clarity in signaling that occurs with Scl2-2 relative to 
collagen, as it only contains integrin binding sites for α1β1 and α2β1 integrins whereas 
collagen contains numerous integrin binding sites. Substrate modulus can be easily 
decreased by reducing PEG molecular weight, which results in decreased EC adhesion. 
In future studies, the effects of each of these variables (functionalization density, protein 
concentration, and substrate modulus) on EC migration and adhesion strength will be 
evaluated. The formulation that promotes the highest EC migration rates under flow with 
adhesion strengths that are higher than of high shear thrombosis (70-100 dynes/cm
2
) will 
be chosen for in vivo studies in our porcine carotid artery model to assess 
endothelialization and long-term (30 and 90 day) thromboresistance. 
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CHAPTER VI  
CONCLUSIONS 
 
6.1 Summary  
In this work, multilayer vascular grafts were developed for use in small-diameter 
bypass applications. To progress beyond current clinically available synthetic options, 
cell-material interactions must be improved to provide both thromboresistance and 
potential for in situ endothelialization without the need for expensive cell harvesting or 
pre-culture. Additionally, compliance mismatch with native vasculature must be reduced 
while maintaining sufficient burst pressures to prevent flow alteration-induced intimal 
hyperplasia. PEG-Scl2-2 hydrogels proved to be thromboresistant in a series of whole 
blood studies in vitro as well as in a porcine carotid artery in vivo. Electrospun 
polyurethane mesh biomechanical properties were altered over a wide range with simple 
changes in mesh thickness to achieve comparable burst pressures and compliance values 
to autologous vascular grafts. Inter-layer integrity was confirmed following vacuum 
drying and re-swelling and after exposure to 4 weeks of pulsatile flow. PEGDAA 
hydrogels were fabricated and found to be similar to PEGDA hydrogels with enhanced 
biostability in vitro and in vivo. These studies indicate the potential of this design for 
long-term implantation with reduced risk of thrombosis and intimal hyperplasia.  
To enhance EC adhesion to PEG-Scl2-2 hydrogels, protein functionalization 
density was reduced. With the use of acrylamide-PEG-isocyanate as a biostable 
functionalization linker, reduced functionalization densities were utilized that had 
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enhanced initial and sustained EC interactions, potentially suitable for long-term 
implantation and in situ endothelialization. EC adhesion was further increased by 
increasing Scl2-2 concentration and increasing substrate modulus. Initial studies show 
that EC migration speed can also be altered by increasing Scl2-2 concentration. 
Additionally, PEG-Scl2-2 hydrogels promoted significantly greater EC proliferation 
over one week than PEG-collagen hydrogels. In short, we have demonstrated the 
exceptional tunability of PEG-Scl2-2 hydrogels in efforts to determine a formulation that 
is capable of rapid endothelialization.  
 
6.2 Significance of Work 
Scl2 proteins are a valuable biomaterial system with many advantages over 
traditional proteins or peptides. However, prior to this work, the use of these proteins 
was severely limited due to their inability to form stable, 3D matrices. The methodology 
to functionalize Scl2 proteins with photocrosslinkable linkers without detriment to their 
other properties significantly broadens their potential for use. The Scl2 system could 
potentially be utilized to target a number of different integrins or enzyme-labile sites, 
and the use of them in this vascular graft design could serve as a catalyst to altering these 
strategies for a wide range of regenerative medicine applications. In general, these 
studies have given an initial indication of their great potential and served to characterize 
basic cell-material interactions with Scl2-based systems in response to a number of 
variables. This serves to provide a platform of information for use in future Scl2 protein-
based applications.   
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In Chapter 3, we presented the first full characterization of PEGDA hydrogel 
degradation in current literature. Additionally, the use of PEGDAA provides a potential 
replacement for PEGDA hydrogels in long term in vivo applications with minimal 
design changes required for translation between systems. The ability to use PEGDAA in 
an in vivo degradation studies allows for controlled elucidation of the mechanisms of 
PEGDA hydrogel in vivo degradation for the first time. Both the in vitro and in vivo 
work serves to fill a gap in the understanding of this widely utilized biomaterial system. 
In Chapter 4, the ability to use functionalization density as a means to control 
bioactivity was evaluated. This facile method allows for enhanced bioactivity to be 
achieved while potentially reducing the amount of protein needed and/or allowing use of 
different proteins, such as Scl2-2, that lower cell adhesion but have benefits over 
traditionally used proteins. Furthermore, the development of acrylamide-PEG-isocyanate 
(Aam-PEG-I) as a biostable functionalization linker has many potential uses beyond this 
work. It could be utilized in combination with degradable linkers in a number of 
applications that require temporally-controlled release of varied bioactive factors. The 
use of Aam-PEG-I and PEGDAA also allows for a controlled investigation of long-term 
cell-material interactions without concerns over effects of protein loss over time. Thus, 
this system has many potential wide-ranging uses in both regenerative medicine and 
drug delivery.  
PEG-Scl2-2 hydrogels have many advantages over other systems that have been 
studied for use in vascular grafts. Notably, the thromboresistance provides a significant 
benefit over collagen, and the bioactivity capabilities are greater than those of peptides. 
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Scl2-2 allows for an in-depth investigation of how scaffold micro-environment affects 
EC adhesion through independent tuning of protein and network variables. The 
information gained in the presented studies can be used in future EC migration, adhesion 
strength, and phenotype evaluations to determine a formulation that has the best 
potential for in situ endothelialization and to gain a better understanding of EC 
interactions with their surroundings.  
 
6.3 Challenges and Future Directions 
Although this work presents many advances in the development of this vascular 
graft design, a significant amount of work is required prior to their successful 
employment. With the inner layer, a full study of EC static and dynamic migration, 
adhesion strength, and phenotype in response to the presented protein and matrix 
variables (functionalization density, protein concentration, substrate modulus) will be 
carried out. The final formulation must first provide adhesion strengths sufficient for 
high shear thrombosis (70-100 dynes/cm
2
). From these, the formulations that promote 
EC proliferation and quiescent will be taken, and the one of these with the highest 
migration speed will be chosen for future studies. Upon determination of the PEG-Scl2-2 
hydrogel with the most suitable EC interactions, thromboresistance will be confirmed in 
vitro after 6 hours of whole porcine blood flow with the bioreactor system presented in 
Chapter 2. In vivo host response will be evaluated in a rat model, and then this gel 
formulation will be incorporated into a multilayer graft and implanted into a porcine 
carotid artery model. In vivo thromboresistance and endothelialization will be evaluated 
at 30 and 90 days.  
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In previous in vivo studies, significant issues with suturing through the two 
layers have come about. Specifically, small pieces of hydrogel break off as the suture 
goes through the graft that can then travel downstream and cause occlusions in smaller 
vessels. This was a possible cause for seizures in a previous in vivo study and must be 
addressed prior to future in vivo work. One potential solution is to make the hydrogel 
layer thinner. This could be done by simply soaking or dipping the meshes in a hydrogel 
solution that is then crosslinked rather than crosslinking a full layer of gel between the 
mesh and a glass mandrel. This could also potentially reduce the overall host response to 
the vascular graft with the addition of a PEG coating on both the inside and outside 
surfaces. All previous in vivo studies were performed with 10% PEG(3.4 kDa) gels, 
which are relatively brittle. By increasing the molecular weight, hydrogel elasticity 
would be increased. These two methods would be easy to implement and could be used 
independently in combination with one another to improve graft suturability. Another 
option would be to alter the hydrogel network chemistry. Previously, researchers have 
developed hydrogels with very high toughness through the creation of semi-
interpenetrating networks of covalently and physically crosslinked polymers.
262
 In other 
work in our lab, PEG-based segmented polyureas have been synthesized. These could be 
used in the vascular graft project to form a physical network that could then be swelled 
in a PEGDAA solution that can be covalently crosslinked. This double network hydrogel 
should retain the favorable properties of PEG hydrogels, and could potentially have 
improved mechanical properties. Upon making any of these changes in formulation, 
 129 
 
effects EC interactions and thrombogenicity would have to be assessed, but they could 
potentially improve the overall graft design and utility.  
This design requires long-term biostability so that the vascular graft can remain 
in the patient throughout their lifetime. The electrospun mesh chemistry has already been 
altered to utilize a poly(carbonate urethane) that is resistant to both hydrolytic and 
oxidative degradation. While PEGDAA hydrogels have shown initially that they have 
improved biostability relative to PEGDA hydrogels, current in vivo studies are 
underway for 12 weeks to gain a better idea of the degradation profile of both systems. It 
is likely that PEGDA hydrogels are susceptible to some combination of both oxidative 
and hydrolytic degradation and that therefore PEGDAA hydrogels will degrade 
oxidatively over long time frames. While the inner layer of the vascular graft would 
likely be protected from the host response, degradative species could diffuse through the 
outer graft layer and cause degradation. If significant degradation is noted during the 12 
week in vivo study, we could incorporate an antioxidant, such as retinol or ascorbic acid, 
into the electrospun mesh. Currently, we are investigating the use of a semi-
interpenetrating network of the segmented polyurethane (physical network) and 
methacrylated poly(dimethyl sulfoxide) (covalent network). The hydroxyl groups on 
either of these antioxidants could be reacted with acryloyl chloride to create a 
photocrosslinkable acrylate group. This would allow for covalent incorporation of an 
antioxidant to prevent oxidation of the inner hydrogel layer over longer time frames.  
Many design changes have been made in the hydrogel formulation since 
performing initial thrombosis studies, most notably the network and linker chemistries 
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presented in Chapter 4. While we do not expect thromboresistance to be affected by 
either change in chemistry, alternatives must be considered beforehand in the event that 
the new formulation has increased platelet interactions. The most likely cause would be 
the increased hydrophobicity introduced into the Aam-PEG-I linker with the use of 
hexane diisocyanate. Diisocyanobutane could be used instead with minimal protocol 
changes to produce a linker with fewer hydrophobic methanes. Another option would be 
to obtain custom synthesized acrylamide-PEG-NHS from the company that currently 
makes the Acr-PEG-NHS that we use (JenKem Technologies). If the acrylamide 
linkages in PEGDAA induce thrombosis, vinyl endgroups could be explored instead as 
an alternative photocrosslinkable system.  
Although it has previously been demonstrated that Scl2-1 proteins are non-
immunogenic, no in vivo studies have been performed to assess the host response to 
PEG-Scl2-2 hydrogels. PEG hydrogels have previously been shown to induce a minimal 
host response, but Scl2-2 is a bacterial protein that could potentially have an adverse 
response. To address this, current work in the Höök laboratory is focusing on replacing 
potentially immunogenic portions of  cl  proteins with a “murinized” and “humanized” 
version of those amino acid sequences. It is expected that these alterations would 
minimize any potential concerns over the host response to PEG-Scl2-2 hydrogels.  
While many steps are required between the current state of this work and 
implementation in the clinic, this design has the potential to present an off-the-shelf 
vascular graft that improves on current synthetic grafts. The future investigations on this 
project will allow for continued expansion on the knowledge of synthetic matrix 
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formation and characterization, endothelialization processes, and prevention of long-
term implant degradation.   
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APPENDIX A  
COMPOSITIONAL CONTROL OF PEG HYDROGEL MODULUS INDEPENDENT 
OF MESH SIZE* 
 
A.1 Introduction 
Poly(ethylene glycol) (PEG) hydrogels are currently being investigated in a wide 
range of tissue engineering applications due to their established biocompatibility, high 
permeability, and tunable properties.
137,214,263-266
 Aqueous solutions of acrylate-
derivatized PEG (PEGDA) can be rapidly crosslinked under mild conditions, permitting 
in situ polymerization in direct contact with cells and tissues.214-215 This feature enables 
ready fabrication of cell-laden PEGDA scaffolds with complex geometries.
195,213,216
 
Perhaps the most widely studied aspect of these versatile hydrogels is the ability to 
spatially and systematically tune their biochemical and biomechanical properties by 
varying the properties and conditions of the polymerization process.
166,195,201,209,219,267
 
However, the interdependence of hydrogel modulus and mesh size hampers our ability to 
correlate specific cell responses to independent scaffold properties.
268-269
 Given that both 
substrate modulus and mesh size are known to impact a wide range of cellular responses, 
the inability to independently tune these effects limits the rational selection of scaffold 
parameters to achieve desired cell behaviors.
209,219,269-272
 
*Reprinted with permission from “Compositional Control of PEG Hydrogel Modulus 
Independent of Mesh Size,” by MB Browning, T Wilems, M. Hahn, and E. Cosgriff-
Hernandez, Journal of Biomedical Materials Research, Part A. 2011, 98 (2), 268-273. 
Copyright (2011) Wiley Periodicals, Inc. 
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The mechanical properties and network architecture of PEG hydrogels can be 
controlled by varying the compositional properties and polymerization conditions of the 
hydrogel.
166
 Traditionally, the crosslink density of the polymer network has been 
modulated by altering the molecular weight and/or concentration of PEGDA to these 
purposes. For linear homopolymers, the molecular weight of the polymer is one of the 
most accessible compositional variables that can be used to control the properties of the 
hydrogel network.
220
 Lower molecular weight PEG hydrogels have a decreased chain 
length between crosslinks, which translates to an increased crosslink density. An 
increase in crosslink density results in increases in modulus of these polymer networks. 
Thus, decreases in PEG molecular weight can be used to dramatically increase the 
modulus of hydrogels.
220
 Modulation of PEGDA concentration is also used to control 
hydrogel properties. Bryant et. al. found that by doubling the concentration of PEG in 
hydrogels, the crosslink density was tripled due to an increase in the number of 
interchain reactions that occurred during polymerization.
219
 This increase in crosslink 
density resulted in statistically significant increases in modulus.
219
 However, increases in 
modulus that result from increased crosslink density are coupled with decreases in mesh 
size that can have undesirable effects on diffusivity and swelling of the network.
166
 Thus, 
to increase the relatively low mechanical properties of PEG hydrogels, the mesh size 
must be reduced and hydrogel permeability sacrificed.
273
  
We propose to develop a methodology that circumvents this limitation such that 
hydrogel modulus can be tuned independently of mesh size. Prior research has typically 
used linear PEGDA to form hydrogel networks. We hypothesize that adding a low 
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concentration of 4-arm PEG cross-linker will create local increases in crosslink density 
that substantially increase the modulus while minimally perturbing bulk average mesh 
size, Figure A.1. In addition to decoupling the mesh size and modulus, adding a 4-arm 
PEG cross-linker is expected to increase the range of mechanical properties achievable 
by PEG hydrogel systems and allow for finer tuning of the gel modulus. 
 
  
 
Figure A.1. Schematic representation of PEG hydrogel network formation with and 
without 4-arm PEG-acrylate illustrating the hypothesized local increase in cross-link 
density with minimal change in hydrogel mesh size. 
 
 
 
A.2. Materials and Methods 
A.2.1. Materials All chemicals were used as received. 4-arm poly(ethylene 
glycol) (2 kDa) (4-arm PEG) was purchased from JenKem Technology (Allen, Texas). 
All other chemicals were purchased from Sigma Aldrich (St. Louis, MO). 
A.2.2. Polymer Synthesis PEGDA was synthesized according to a method 
adapted from Hahn, et al.
172 
Briefly, acryloyl chloride was added dropwise to a solution 
of PEG (3.4, 6, or 10 kDa) and triethylamine in anhydrous dichloromethane (DCM) 
under nitrogen. The molar ratio of PEG, acryloyl chloride, and triethylamine was 1:2:4, 
 159 
 
respectively. After the addition of acryloyl chloride, the reaction was stirred for an 
additional 24 hours at room temperature. The resulting solution was then washed with 8 
molar equivalents of 2M potassium bicarbonate to remove acidic byproducts and dried 
with anhydrous sodium sulfate. The product was precipitated in cold diethyl ether, 
filtered, and dried under vacuum.  
4-arm PEG-acrylate (4-arm PEG-Acr) was prepared using a method similar to 
PEGDA. Briefly, acryloyl chloride was added dropwise to a solution of 4-arm PEG and 
triethylamine in anhydrous DCM under nitrogen. The molar ratio of 4-arm PEG, 
acryloyl chloride, and triethylamine was 1:4:8, respectively, so that the ratios of the 
reactant and catalyst were kept constant relative to the hydroxyl end groups of the PEG. 
After the addition of acryloyl chloride, the reaction was stirred for an additional 24 
hours. The resulting solution was then washed with 16 molar equivalents of 2 M 
potassium bicarbonate to remove acidic byproducts, washed with brine to remove 
residual water, and dried with anhydrous sodium sulfate. The organic solvents were then 
removed with rotary evaporation (Buchi, R-210) and the product was dried under 
vacuum. 
Functionalization of linear PEG and 4-arm PEG was confirmed using Fourier 
transform infrared (FTIR) spectroscopy and proton nuclear magnetic resonance (
1
H-
NMR) spectroscopy. Transmission FTIR spectra of control and functionalized polymers 
were acquired on a Bruker TENSOR 27 spectrometer by solution casting directly onto 
KBr pellets. The presence of ester peaks at 1730 cm
-1
 and loss of hydroxyl peaks at 3300 
cm
-1
 in the IR spectra indicated successful acrylation, Figure A.2. Proton NMR spectra 
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of control and functionalized polymers were recorded on a Mercury 300 MHz 
spectrometer using a TMS/solvent signal as an internal reference. Percent conversions of 
hydroxyl to acrylate endgroups of greater than 85% were observed for all candidate 
polymers. 
1
H-NMR (CDCl3):  3.6 ppm (m, -OCH2CH2-), 4.3 ppm (t, -CH2OCO-) 5.8 
ppm (dd, -CH=CH2), 6.1 and 6.4 ppm (dd, -CH=CH2).   
 
 
 
Figure A.2.  Transmission FTIR spectra of PEGDA and 4-arm PEG acrylate. (A) 
PEG(6K)DA compared to PEG(6K); (B) 4-arm PEG acrylate relative to 4-arm PEG.  
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A.2.3. Hydrogel Preparation Variations of PEG molecular weight (3.4, 6, or 10 
kDa), linear PEGDA concentration (10, 20, or 30 wt%), and 4-arm PEG-Acr 
concentration (0, 10, or 20 wt%) were combined to create 27 distinct hydrogel 
formulations to be characterized. Precursor solutions were prepared by dissolving 
PEGDA and 4-arm PEG-Acr in phosphate buffered saline (PBS). The solutions were 
mixed, and photointiator solution (1 mg Irgacure 2959 per 10 µl 70% ethanol) was 
added at 1% volume of precursor solution. Solutions were pipetted into an appropriate 
mold and polymerized by 10 min exposure to long wave UV light (Ultraviolet Products 
High Performance UV Transilluminator, 365 nm, 1 mW/cm
2
).  
A.2.4. Hydrogel Mechanical Properties To characterize hydrogel mechanical 
properties, both tensile and compressive tests were conducted on the selected PEGDA 
formulations. To avoid slippage artifacts associated with the tensile testing of 
rectangular hydrogel segments, tensile specimens were prepared by polymerizing 
hydrogel solutions in cylindrical molds (OD = 5 mm, ID = 3 mm) and swelling in PBS 
for 24 hours prior to mechanical testing. Six ring specimens (2-4 mm long) were cut 
from each tubular hydrogel and strained until fracture at a uniaxial strain rate of 6 
mm/min using an Instron 3342. The secant modulus of elasticity was calculated from the 
resulting stress-strain data. The range of strains within 30% of blood pressure 
(approximately 9 to 17 kPa) and the corresponding stresses were used to determine the 
secant modulus in this study. Specimens for compressive modulus assessment were 
prepared by polymerizing hydrogel solutions into 1.5 mm sheets and swelling in PBS for 
24 hours prior to testing. Six 8-mm discs were punched from each formulation and 
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subjected to mechanical testing under unconstrained compression at room temperature 
using a dynamic mechanical analyzer (RSAIII, TA Instruments) equipped with a 
parallel-plate compression clamp. Dynamic strain sweeps were performed to determine 
the linear viscoelastic range for each hydrogel formulation. Then, a strain within the 
upper end of the linear viscoelastic range was used in a constant strain frequency sweep. 
The test was conducted between 0.79 and 79 Hz, and the storage modulus of each 
hydrogel was taken at 1.25 Hz.  
A.2.5. Hydrogel Swelling Ratios Hydrogels were polymerized in 0.75 mm thick 
sheets to assess the effects of compositional variables on swelling behavior. Eight 8-mm 
discs were punched from each sheet directly after polymerization and weighed (Wi). 
Each disc was swelled in deionized water for 24 hours and weighed to determine the 
equilibrium swelling mass (Ws). Then, the hydrogel discs were dried under vacuum for 
24 hours and weighed to determine dry (polymer) mass (Wd). The equilibrium 
volumetric swelling ratio, Q, was calculated from the equilibrium mass swelling ratio:  
   
  
  
    [A.1] 
A.2.6. Hydrogel Mesh Size Hydrogel mesh size was characterized using a series 
of Dextran diffusion experiments as described by Liao et al.
274 
Briefly, hydrogels were 
polymerized into 0.75 mm thick sheets and swelled for 24 hours in PBS to constant 
dimensions. Discs 8-mm in diameter were punched from each hydrogel formulation. 
Fluorescently labeled dextrans (4, 20, 40 and 70 kDa) were dissolved at 0.05 mg ml
-1
 in 
PBS and added at 0.5 ml per hydrogel disc (four discs per dextran molecular weight). 
Dextran solutions were allowed to diffuse into the hydrogels for 24 hours, after which 
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each disc was dipped in PBS, gently blotted, and transferred to 0.5 ml of fresh PBS. 
Dextran that had diffused into the hydrogels was then allowed to diffuse out into the 
surrounding solution for 24 hours. Two 200 µl aliquots were taken from each PBS 
solution surrounding the discs, and their fluorescence was measured at ex/em 480/520. 
Standard curves of each dextran molecular weight were used to convert the fluorescence 
signals to concentrations.  
For the 30% PEG(6 kDa) hydrogel formulation, the fluorescence readings fell to 
background levels for dextran molecular weight exceeding 20 kDa (data not shown). The 
hydrodynamic diameter of the 20 kDa dextran is approximately 6.5 nm, and the 
hydrodynamic diameter of the next largest dextran used in the investigation (40 kDa) is 
approximately 9.6 nm. Therefore, the mesh size of the 30% PEG(6 kDa) hydrogel was 
approximated to be the average of these two diameters, or 8.0 nm. Then, the mesh sizes 
of the remaining hydrogel formulations were calculated relative to that of the 30% 
PEG(6 kDa) hydrogel. For all hydrogel formulations, the measured concentrations for 
each dextran molecular weight were plotted versus the dextran hydrodynamic diameter. 
The area under the resulting curve was used as a quantitative indicator of hydrogel 
permissivity over the assigned range of hydrodynamic diameters. For a given hydrogel 
(x), the mesh size (ξ) was then calculated according to the following equation:  
    
  
          
      [A.2] 
A.2.7. Statistical Analysis All of the data were expressed as the mean ± standard 
derivation of the mean. Statistical analysis was performed by an unpaired two-tailed 
student’s t-test. Statistical significance was accepted at p<0.05 
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A.3. Results and Discussion 
The ability to independently tune hydrogel modulus and mesh size is important 
in advancing our understanding of how scaffold properties impact cellular behavior. In 
this study, small amounts of 4-arm PEG-Acr were incorporated into PEGDA polymer 
networks to create local increases in crosslink density with minimal effects on gel mesh 
size. We hypothesized that this methodology would provide the means to decouple PEG 
hydrogel modulus and mesh size and provide finer control over cell-microenvironment 
interactions. To this end, we investigated the effect of each compositional variable (PEG 
molecular weight, PEGDA concentration, and 4-arm PEG-Acr concentration) on 
compressive modulus, tensile modulus, and gel mesh size.  
A.3.1 Hydrogel Mechanical Properties Tensile testing was used to examine the 
effect of compositional variables on hydrogel mechanical properties, Figure A.3A. As 
expected, increases in hydrogel modulus were associated with decreased PEG molecular 
weight and increased PEGDA concentration. Statistically significant increases in secant 
modulus were also observed with increased 4-arm PEG-Acr concentrations. Without the 
addition of the 4-arm PEG cross-linker, a decrease in PEG molecular weight from 10k to 
3.4k resulted in an average increase in secant modulus of 153%, and an increase in 
PEGDA concentration from 10% to 30% induced an average increase in secant modulus 
of 128%. The addition of the 4-arm PEG-Acr resulted in more moderate increases in 
secant modulus with a mean of 25%. Furthermore, the overall range of moduli was 
broadened by adding this third compositional variable. Relative to the 10% PEG 
hydrogels, the 30% PEG hydrogels with 20% 4-arm PEG-Acr were associated with 
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increases in moduli (e.g. PEG(10k) DA: 78 kPa versus 412 kPa) that were ~1.7X greater 
than the increases seen with only linear PEGDA (e.g. PEG(10k) DA: 78 kPa versus 257 
kPa). Similarly, compression testing resulted in the expected trends, with higher storage 
moduli observed with decreasing PEG molecular weight and increasing PEGDA 
concentration, Figure A.3B. The addition of 4-arm PEG-Acr into the polymer networks 
also resulted in statistically significant increases in storage modulus for all hydrogel 
systems and a broader range of available moduli.  
A.3.2 Hydrogel Mesh Size and Equilibrium Swelling It is difficult to visualize 
PEG hydrogel mesh size using traditional methods, such as standard scanning electron 
microscopy.
275
 Thus, in this study, a series of dextran diffusion experiments were used to 
give a quantitative indicator of scaffold mesh size. The resulting mesh sizes relative to 
that of the 30% 6kDa hydrogels are shown in Figure A.3C. As expected, mesh size 
decreased with decreasing PEG molecular weight and increasing PEGDA concentration 
due to the corresponding increases in crosslink densities that occur with these changes in 
composition. Decreasing the molecular weight of PEG resulted in an average decrease in 
mesh size of 112%, and increasing the concentration of PEGDA reduced the mesh size 
by an average of 85%. In contrast, the addition of 4-arm PEG-Acr to the hydrogel 
networks induced a mean decrease in mesh size of only 9%. It was hypothesized that 
small concentrations of 4-arm PEG cross-linker would have local, limited effects on 
crosslink density and therefore would minimally disrupt bulk average mesh size. 
Although adding 4-arm PEG-Acr did result in decreased mesh size, contrary to 
hypothesis, these changes were moderate-to-minimal, and in many cases, below 
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statistical significance. Equilibrium swelling ratios, Figure A.4, supported these mesh 
size trends. Specifically, the addition of the 4-arm PEG-Acr resulted in more moderate 
decreases in swelling than a commensurate addition of linear PEGDA and, in several 
instances, was associated with no statistically significant change in swelling.  
 
 
 
Figure A.3. Hydrogel material properties. (A) Tensile modulus of hydrogel ring 
specimens (n = 6; average ± standard deviation). Statistically significant increases in 
moduli were observed for all increases in 4-arm PEG-Acr concentration (p<0.05). (B) 
Compressive modulus of hydrogel disc specimens from constant viscoelastic strain at a 
frequency of 1.25 Hz (n = 6; average ± standard deviation). Statistically significant 
increases in modulus were observed for all increases in 4-arm PEG-Acr concentration 
(p<0.05). (C) Hydrogel mesh size (n=4; average ± standard deviation, * p < 0.05). 
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 Cumulatively, these results demonstrate that substantial increases in modulus can 
be induced by the local alterations in hydrogel crosslink density introduced by 4-arm 
PEG-Acr and that hydrogel formulations can be identified in which these modifications 
in local crosslink density minimally disrupt bulk gel mesh size. Indeed, there are several 
sets of gels that can be chosen throughout the range of hydrogels that were tested that 
have either statistically indistinguishable bulk mesh sizes but distinct moduli or similar 
moduli and significantly different mesh sizes. Figure A.5 displays a scatter plot of 
tensile modulus versus mesh size with regions circled that show the ability to tune these 
two properties independent of each other. Specific examples of this are highlighted in 
Table A.1. The present methodology represents a powerful tool in tissue engineering 
design by enabling the independent investigation of scaffold material properties on cell 
behavior and response. For example, desired modulus increases were typically obtained 
by decreasing PEGDA molecular weight or increasing PEGDA concentration. These 
changes resulted in a corollary decrease in mesh size. Nuttleman et. al. reported 
decreased diffusivity with decreased hydrogel mesh size which negatively affected cell 
viability.
222
 Thus, researchers were challenged to obtain desired mechanical properties 
while maintaining mesh sizes that enabled prolonged viability of encapsulated cells. This 
study demonstrates compositional control of hydrogel properties with the potential 
ability to increase the modulus of relatively weak PEG hydrogels without adversely 
affecting cell viability by decreasing diffusivity.   
 
 168 
 
Figure A.4. Hydrogel equilibrium volumetric swelling ratio. Statistically significant 
decreases in swelling ratios were observed for all increases in 4-arm PEG-Acr 
concentration (n = 8; average ± standard deviation, p < 0.05). 
 
 
 
  
Figure A.5. Scatter plot of tensile modulus versus mesh size. The circled regions display 
the ability to use 4-arm PEG cross-linker to vary the modulus independent of  mesh size 
(upper circle) or vary the mesh size independent of modulus (lower circle).  
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Table A.1. Demonstration of successful decoupling of PEG hydrogel modulus and mesh 
size. In the first group, tensile modulus is significantly different for the three hydrogels 
(p < 0.05) whereas mesh size is statistically the same (p > 0.05).  In the second group, 
mesh size is significantly different for the three hydrogels (p < 0.05) while modulus is 
statistically the same (p > 0.05). 
 
 
 
 
 
A.4. Conclusions 
 The aim of this study was to develop a new approach for tuning PEG hydrogel 
modulus independent of mesh size such that the modulus of PEG hydrogels could be 
increased without adverse effects on gel mesh size. The incorporation of 4-arm PEG-Acr 
into PEG hydrogels resulted in significant increases in modulus with minimal effects on 
the mesh size. It also demonstrated the ability to alter mesh size while maintaining 
modulus. Furthermore, the 4-arm PEG cross-linker provides an additional compositional 
variable that can be modulated to broaden the range of available mechanical properties 
and more finely tune the modulus of PEG hydrogel systems. This new methodology 
expands the compositional control over these properties and provides new tools to probe 
the individual and combined effects of modulus and mesh size on cell behavior.  
  
 
